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ABSTRACT

Terrill-Usery, Shana., Ph.D., University of Missouri-St. Louis, August 2014.
Understanding Mechanistic Details of Neuroinflammatory Pathways Stimulated by the
Alzheimer’s Disease Amyloid-Beta Protein. Major Professor: Michael. R. Nichols.

Alzheimer’s disease (AD) is characterized by neuroinflammation. Senile plaques
composed of aggregated amyloid-β protein (Aβ) are found in AD patients’ brains. The
Aβ is formed by the proteolytic cleavage of the amyloid precursor protein (APP)
resulting in Aβ fragments that are 39-42 amino acids in length. The two most common
peptides are Aβ(1-40) and Aβ(1-42), which differ by two amino acids, isoleucine and
alanine. Within the brain of AD patients, Aβ monomer self-assembles to form several
aggregate morphologies, including oligomers, protofibrils, and fibrils. Activated
microglial cells and associated secreted proinflammatory cytokines surround these
plaques producing a localized inflammatory environment in the brain. Several innateimmune pathways, including Toll-like receptors (TLRs) and the NLRP3 inflammasome,
have been implicated in AD inflammation. Aβ plays a primary role in activating these
pathways likely contributing to the progressive neurodegeneration in AD. In order to
better understand the complexities of this interaction, I investigated the inflammatory
response of microglia to Aβ(1-42) and Aβ(1-42)/Aβ(1-40) protofibrils, along with
additional biophysical properties. Increased understanding of these pathological events
will expand the current model of Aβ neuroinflammatory pathways and help identify new
therapeutic targets for AD.
My research has demonstrated that the Aβ(1-42) protofibrils triggered a time- and
TLR/MyD88-dependent process that produced inflammatory cytokines tumor necrosis
factor alpha (TNFα) and interleukin-1β (IL-1β) mRNA and intracellular pro and mature
forms of IL-1β protein. Despite previous reports suggesting that NLRP3 activation
requires two signals from two distinct molecules, my research indicated that Aβ(1-42)
protofibrils alone could efficiently prime (TLR-dependent pro-IL-1β production) and
activate (cleavage of pro-IL-1β to mature-IL-1β) the NLRP3 inflammasome. However,
the increased intracellular mature-IL-1β did not translate into greater IL-1β secretion.
Instead, we found that Aβ was able to elicit a very rapid, unsustainable, yet re-inducible
quantized burst of secreted IL-1β, which occurred prior to Aβ priming of the microglia.
These findings suggested a basal level of either pro- or mature-IL-1β in the cultured
primary microglia yet revealed multiple sites of IL-1β regulation by Aβ(1-42)
protofibrils. These sites, which are potential therapeutic targets, include TLR/MyD88mediated priming, NLRP3 inflammasome activation, and modulation of the IL-1β
secretory process.
xiii

Different ratios of Aβ(1-42)/Aβ(1-40) were used in studies aimed at exploring the
effect of Aβ(1-40) on Aβ(1-42) aggregation. Reconstitution of dry Aβ(1-42)/Aβ(1-40)
peptide mixtures at different ratios resulted in immediate protofibril formation. However,
size exclusion chromatography (SEC)-purification of the mixed solutions indicated that
as the ratio of Aβ(1-42)/Aβ(1-40) decreased, the amount of SEC-isolated protofibrils
decreased and the monomer increased. Subsequent SEC studies showed that if the Aβ(142) concentration was held constant while increasing the Aβ(1-40) concentration, there
was no change in the amount of SEC-isolated protofibrils formed, while monomer
increased. An Aβ C-terminal-selective ELISA was employed to directly measure the
Aβ(1-42)/Aβ(1-40) ratio of protofibrils and monomers after SEC-separation. The
combination of these two strategies as well as other biological and biophysical studies
suggested that Aβ(1-40) may not significantly interact with Aβ(1-42) during protofibril
formation.
Separate collaborative studies with the Stine and Demchenko laboratories in the
UMSL Department of Chemistry and Biochemistry were also conducted in order to study
the biocompatibility of BV-2 microglial cells on different gold substrates and the
antagonistic properties of Lipid A analogs in LPS-induced THP-1 macrophages,
respectively. The gold surface biocompatibility studies (Stine collaboration) showed that
all four surfaces (glass, UF-Au, UT np-Au, and np-Au) tested were metabolically nontoxic, non-disruptive to the cellular membranes and compatible with microglia functional
assays, while all but one (np-Au) supported microglia growth and proliferation. The
LPS-induced antagonist studies (Demchenko collaboration) analyzed the antagonistic or
inhibitory effect of six different Lipid A analogs, while also observing each compounds
toxicity and agonistic or stimulatory activity. The results determined one compound that
inhibited the LPS-induced TNFα response with the lowest IC50, while remaining nontoxic and producing no agonistic activity.
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THE INFLUENCE OF GOLD SURFACE TEXTURE ON MICROGLIA MORPHOLOGY
ACTIVATION

Yih Horng Tan, Shana E. Terrill, Geeta S. Paranjape, Keith J. Stine and Michael R. Nichols

This publication was due to the collaborative efforts of the Nichols and Stine laboratories.
The gold surface biocompatibility studies showed that most of the gold substrates tested were
metabolically non-toxic, non-disruptive to the cellular membranes and compatible with microglia
functional assays, while one (np-Au) was unable supported microglia growth and proliferation.
All imaging within this publication was performed by Dr. Y.H. Tan, who also produced all
surfaces necessary. My role in this publication was to perform all cellular plating and further
biocompatibility studies. Further descriptions of this publications and my experimental work is
found in Chapter 5.
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The inﬂuence of gold surface texture on microglia
morphology and activation†

Published on 23 September 2013. Downloaded on 10/01/2014 20:46:55.

Yih Horng Tan,‡ Shana E. Terrill,‡ Geeta S. Paranjape, Keith J. Stine and
Michael R. Nichols*
Microglial cells play a critical role in the propagation of neuroinﬂammation in the central nervous system.
Microglia sense and respond to environmental signals including chemical, physical and biological cues
from the surrounding cell/tissue components. In this project, our goal was to examine the eﬀects of
surface texture on BV-2 microglia morphology and function by comparing ﬂat and nanoporous gold
(np-Au) surfaces to the more conventional glass. The biocompatibility of np-Au with microglia was evaluated using functional cell assays and high resolution imaging with scanning electron microscopy (SEM).
Microglia seeded on glass, ultra-ﬂat gold (UF-Au), ultra-thin (UT) np-Au and np-Au monolith were adherent to all surfaces and their viability was not compromised as assessed by multiple toxicity assays. SEM
revealed detailed morphological characteristics of adherent microglia and indicated few dramatic
changes as a result of the diﬀerent surfaces. Microglia proliferation was hampered by np-Au monolith but
less by UT np-Au and not at all on UF-Au or glass. Microglial activation, measured by tumor necrosis
factor α (TNFα) production, was fully functional (and equivalent) on all gold surfaces compared to glass.
The present ﬁndings should help further the understanding of basic microglia biology on textured surReceived 11th April 2013,
Accepted 11th September 2013

faces and more fully evaluate np-Au as a multi-functional biocompatible material. The knowledge

DOI: 10.1039/c3bm60096c

obtained and technology developed will have a signiﬁcant impact in the fabrication of nanoelectronic
devices, chemical sensor development, porous nanostructured materials for BioMEMs/NEMs integration,

www.rsc.org/biomaterialsscience

and functional biomaterial coatings for drug delivery.

Introduction
Over the past few decades, significant eﬀorts have focused on
the development of new intelligent biomaterials or biomembrane-mimicking substrates/interfaces. These materials have
the ability to monitor, investigate, and modulate biological
behavior. The development of this capability will improve,
and perhaps revolutionize therapeutics such as the repair
of damaged tissues due to trauma, disease, or congenital
abnormalities. However, such novel biomimetic interfaces
must continually be evaluated for biocompatibility properties
including in vivo stability, stimulation of the host immune
response, and interaction with living cells.1 Gold has been
investigated for many years as a potential biomaterial, both for
application in biomedical devices and for use as a cell culture

Department of Chemistry and Biochemistry and Center for Nanoscience, University of
Missouri-St. Louis, One University Boulevard, St. Louis, Missouri 63121, USA.
E-mail: nicholsmic@umsl.edu; Fax: +1 (314) 516-5342; Tel: +1 (314) 516-7345
† Electronic supplementary information (ESI) available. See DOI:
10.1039/c3bm60096c
‡ These two authors contributed equally to this work.

110 | Biomater. Sci., 2014, 2, 110–120

substrate. Many of these studies have investigated the eﬀect of
gold nanoscale topography or chemical modification of the
gold surface on cellular response.2–5 The advantages of gold
stem from its chemical stability, high conductivity6 and the
advances in gold-thiol chemistry for presenting ligands or
immobilized proteins for cell adhesion studies.4,7–9 Numerous
examples of cell culture on gold or chemically-modified gold
substrates have been reported and these studies demonstrate
that cell adhesion is influenced by the size and geometric
shape of the gold surface, the chemical and protein composition on the substrate surface or the mechanical properties of
the substrate.10,11 In addition to bulk gold substrates, subnanometer size colloidal Au clusters or nanoparticles have
attracted interest for potential applications for drug delivery or
use as imaging contrast agents.12–14 Recently, it was demonstrated that microglial uptake of gold nanoparticles and subsequent microglial activation was influenced by the shape of
the nanoparticles.15
Nanoporous gold is a member of a new class of mesoporous
metals that possess pores and ligaments ranging from tens to
hundreds of nanometers in scale. These features are of
increasing interest due to their potential applications in
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biosensors,6,16 catalysis,17 and cell culture platforms.5 The
naturally occurring rough surface features of nanoporous gold
are ideal for decreasing surface impedance and enhancing
electrical potential stability in an implantable biomedical
device.18,19 The resistance of nanoporous gold to corrosion
and oxidation combined with its porosity makes it a unique
material with significant feasibility as a potential platform for
adherent cell culture and drug delivery.5 Numerous compatibility studies between mammalian cells and metallic surfaces,
particularly gold, have been conducted recently reflecting the
increased interest in this area. These studies have utilized
both neurons and immune cells and have investigated a
variety of interactions including internalization of gold nanoparticles, microglial activation by metal surfaces, diﬀerential
cell adherence to electrodes, and gold surface eﬀects on astrocyte morphology.5,15,20 Despite these important advances there
are still numerous questions surrounding cell–gold surface
interactions and it is important to demonstrate the eﬀects of
new types of substrates on cell adherence, viability, morphology, and function within the same study.
In the current study, gold substrates with diﬀerent porosities, including ultra-thin nanoporous gold, were evaluated for
their ability to support microglial survival, growth, and functional cytokine production upon stimulation. Scanning electron microscopy (SEM) was used in conjunction with cellular
assays to evaluate, at high resolution, whether microglia morphology and function is perturbed by varied surfaces. The
knowledge obtained in the present study may have implications for the fabrication of nanoelectronic devices and the
design or improvement of microelectrode arrays for chronic
deep-brain microstimulation and recording.21

Materials and methods
Preparation of nanoporous gold (np-Au) monoliths
Preparation of np-Au plates (monoliths) was performed as previously described,6,8,22 with a few modifications. Briefly, 10
carat yellow gold sheets (4.0 inch × 2.0 inch × 0.0098 inch, L ×
W × H, respectively) were purchased from Hoover and Strong
(Richmond, Virginia, USA). The stated atomic composition of
this commercial alloy is 41.7% Au, 20.3% Ag, and 38% Cu.
Depending on the experiment protocols, the 10 carat sheet was
cut into pieces of size of 8.0 mm × 8.0 mm × 0.25 mm, L × W × H,
respectively, and placed in a concentrated nitric acid bath
for 48 hours (the acid solution was refreshed at the 24 hour
time point). Trace metal grade nitric acid was purchased from
Fisher Scientific (Pittsburgh, USA). After the nitric acid dealloying treatment, samples were rinsed thoroughly with MilliQ water (18.2 MΩ cm resistivity at 25 °C, Millipore Corporation, Boston, USA) to neutral pH, followed by rinsing with
HPLC grade ethanol (Sigma Aldrich, St. Louis, Missouri, USA).
The microstructure of np-Au was characterized using scanning
electron microscopy using a JEOL JSM-6320F field emission
SEM (JEOL USA, Inc., California, USA).
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Fabrication of ultra-thin nanoporous gold (UT np-Au) and
ultra-flat gold (UF-Au)
UT np-Au was prepared from commercially available gold/
silver leaf (used as received, Sepp Leaf Products, Inc.
New York, NY, USA) which was cut into a 2.0 inch × 2.0 inch
dimension and floated on a concentrated nitric acid bath for
4 hours. After the nitric acid de-alloying treatment, the acid
solution was carefully exchanged with Milli-Q water to neutral
pH. The free floating np-Au leaf was then removed by dipping
a circular coverslip (1.0 cm diameter), previously coated with
polydimethylsiloxane (PDMS) (Dow Corning, USA), underneath
the porous gold leaf. As the glass slide was removed, the freefloating leaf adhered smoothly onto the surface of the coverslip. After curing the PDMS pre-polymer in an oven for
3 hours, the sample was rinsed and kept in deionized water.
For UF-Au preparation, freshly cleaved ruby muscovite mica
was coated with a gold film, 200 nm thick, and glued onto a
glass coverslip.16 The UF-Au is acceptable for cell seeding after
stripping oﬀ from the mica sheet.
Scanning electron microscopy analysis
Surface morphology and general structure of np-Au monolith,
UF-Au, UT np-Au and glass were studied by SEM using a JEOL
JSM-6320F field emission instrument. Microglia plated on substrate surfaces were fixed with 3.5% glutaraldehyde followed by
4% osmium tetroxide. Fixed cell samples were sputter-coated
with 50 nm gold using an Anatech LTD instrument and
imaged.
Energy dispersive X-ray analysis (EDS)
The presence of gold in the acid dealloy substrates was determined with EDS by examination of the spectrum for peaks
near 2.13 and 9.71 keV (gold); 2.98 keV (silver); and 0.93 and
8.04 keV (copper). No special preparation of the samples was
required for EDS analysis. Five EDS spectra were captured and
analyzed from diﬀerent regions of each type of gold substrate.
For comparison, the EDS spectrum was obtained for 10 carat
yellow gold sheet and gold/silver leaf prior to acid treatment
(ESI, Fig. S1†). All EDS spectra were captured using a Link
Pentafet 6886 Model accessory (Oxford Microanalysis Group, UK).
Cell culture and stimulation
BV-2 murine microglial cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, 4.5 g L−1 glucose)
(Hyclone, Thermo Fisher Scientific, Pennsylvania, USA) containing 50 U mL−1 penicillin, 50 μg mL−1 streptomycin, 50 μM
β-mercaptoethanol, and 5% fetal bovine serum (FBS,
Hyclone).23 For cellular studies, microglia were removed from
culture flasks with 0.25% trypsin and seeded at a density of
5 × 105 cells mL−1 onto prepared glass or gold substrates situated in individual wells of a sterile 24-well cell culture plate
in growth medium. Prior to cell treatment, medium was
replaced with fresh serum-free medium followed by stimulation with ultra-pure lipopolysaccharide (LPS) from E. coli K12
(InvivoGen, San Diego, CA, USA) at a final concentration of
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10 ng mL−1 (or otherwise stated). The cells were incubated at
37 °C for 24, 48, or 72 h in 5% CO2 and the medium was collected and stored at −20 °C for subsequent analysis by
enzyme-linked immunosorbent assay (ELISA) or for counting
of the cells in the medium. The background cellular response
was assessed with the same volume of sterile water used as the
vehicle for LPS.

a 2 : 1 ratio of LDH reaction cocktail and XTT/PMS resulting in
final concentrations of 1 mM NAD+, 25 mM lactate and 95 mM
CAPS buﬀer pH 10.0 (all from Sigma Aldrich, St. Louis, MO,
USA), 0.33 mg mL−1 XTT and 8.3 μM PMS. The extent of
LDH released (LDH activity) was measured by the change in
absorbance of reduced XTT at 467 nm over a linear time
course of 5 minutes.

ELISA analysis

Cell adhesion and growth

Measurement of microglia-secreted TNFα levels in the
medium was determined by ELISA as previously detailed.23
Briefly, 96-well plates were coated overnight with monoclonal
anti-mouse TNFα capture antibody, washed with phosphatebuﬀered saline (PBS) containing 0.05% Tween-20 and blocked
with PBS containing 1% BSA, 5% sucrose and 0.05% NaN3 followed by a wash step. Successive treatments with washing in
between were done with samples and standards, biotinylated
polyclonal anti-mouse TNFα detection antibody in 20 mM Tris
with 150 mM NaCl and 0.1% BSA, streptavidin-horseradish
peroxidase (HRP) conjugate, and equal volumes of HRP substrates 3,3′,5,5′-tetramethylbenzidine and hydrogen peroxide.
The reaction was stopped by the addition of 1% H2SO4 solution. The optical density of each sample was analyzed at
450 nm with a reference reading at 630 nm using a SpectraMax
340 absorbance plate reader (Molecular Devices, Union City,
CA, USA). The concentration of TNFα in the experimental
samples was calculated from a mouse TNFα standard curve of
15–2000 pg mL−1. When necessary, samples were diluted to
fall within the standard curve.

BV-2 microglia were plated overnight and stimulated as
described above. After 24 hours of treatment, the medium was
removed and the cells in the medium were counted using a
Cellometer Auto T4 Plus SK-150 cell counter (Nexcelom Bioscience LLC, Lawrence, MA, USA). The number of cells recovered in the medium was divided by the total number of cells
plated to determine the percentage of detached cells, and
indirectly, the percentage of cells attached to the glass and
gold substrates. The extent of microglia proliferation was
determined by direct counting of the adherent cells over time.
At each time point, the medium was removed and the adherent cells were detached with 0.25% trypsin and counted as
described above.

XTT cell viability assay
Viability of BV-2 microglia was determined by using an XTT
[2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] assay as previously described.23 Cellular metabolic
activity was monitored by mitochondria-mediated reduction of
XTT (Sigma Aldrich, St. Louis, MO, USA). XTT assay was also
used in a cell-free manner to rule out the possibility of any bacterial contamination or contribution of the glass or gold substrates to XTT reduction. In the cellular XTT assay, control
cells or cells exposed to LPS for 24 h were further incubated
with 0.33 mg mL−1 XTT and 8.3 μM phenazine methosulfate
(PMS) (Acros, Morris Plains, NJ, USA) in RPMI medium
without phenol red for 2 h at 37 °C. The extent of XTT
reduction was determined from the absorbance of the reduced
form of XTT at 467 nm.
LDH release assay
The viability of the BV-2 microglia was also measured by the
release of intracellular lactate dehydrogenase (LDH) into the
cell medium. The LDH activity assay which involves LDHmediated reduction of nicotinamide adenine dinucleotide
(NAD+), was coupled to XTT reduction to increase sensitivity,
in a procedure modified from Korzeniewski et al.24 Briefly, following cell incubation for 24 h in the absence or presence of
LPS, the medium was removed and centrifuged to remove any
detached microglia. 25 μL conditioned medium was added to
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Results
Characterization of gold substrate surfaces
Four substrates, including glass, ultra-flat gold (UF-Au), ultrathin nanoporous gold (UT np-Au) and nanoporous gold monolith (np-Au), were characterized by SEM. UF-Au substrate was
generated using a well-recognized gold deposition technique
which produces a 200 nm thick layer of gold on mica that can
be subsequently glued to a glass coverslip.16 Stripping oﬀ the
mica sheet leaves templated gold on glass. For comparison, a
glass coverslip was used as a control in this study. Since glass
is a poor conductor, approximately 10 nm of gold was sputtered on one side of the glass coverslip in order to enable SEM
characterization. SEM images revealed relatively flat and
smooth surfaces for the glass and the UF-Au substrate (Fig. 1A
and B). In contrast, the corrugated morphology of the np-Au
substrate was prepared as previously described.6,8,16 The
porous metals, UT np-Au and np-Au, were formed by de-alloying and exhibited a completely irregular morphology for both
the metallic gold ligaments and pore channels (Fig. 1C and D).
The irregular structure made it diﬃcult to quantitate diﬀerences between the gold substrates. However, randomized
manual measurements were made using the images in Fig. 1C
and D which are representative of numerous samples. These
measurements revealed an average ± standard error pore diameter and ligament thickness for UT np-Au of 52.8 ± 2.0 nm
(n = 157 measurements) and 51.7 ± 1.5 nm (n = 185 measurements), respectively. Values for the np-Au monolith plate
average pore diameter and ligament thickness were 25.1 ±
0.9 nm (n = 228 measurements) and 40.5 ± 1.2 nm (n =
210 measurements), respectively. In addition to the notable
pore diameter diﬀerence between the two nanoporous gold
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Fig. 1 Scanning electron microscopy images of BV-2 murine microglial cells seeded on diﬀerent substrate surfaces. (A–D) 2.4 μm × 1.8 μm SEM
images of blank glass coverslip, UF-Au, UT np-Au and np-Au monolith plates. (E–H) 24.0 μm × 18.0 μm (or 5000× magniﬁcation) SEM images of
BV-2 microglia adhered on the respective substrate surfaces in the top panel. (I–L) SEM images at 30 000× magniﬁcation showing major and minor
processes of microglia interacting with the substrate surfaces. The red boxes in panels E–H indicate areas that are shown at higher magniﬁcation in
panels I–L. Presented images are representative of n = 12 images for each condition at each time point over four separate experiments.

substrates, another physical diﬀerence of these substrates was
their thickness (z dimension). From our analysis, the UT npAu substrate was about 125 nm thick after transfer onto a glass
coverslip, while SEM cross-section imaging indicated that the
thickness of the np-Au monolith plate was approximately
250 μm.
Qualitative X-ray analysis of substrate specimens
The nanoporous gold substrates were prepared by acid dealloying to remove the less noble metals. However, residual
amounts of these metals may form metal oxides that could
directly aﬀect microglia by impeding their proliferation or viability. The cellular toxicity may occur via interference with the
cell’s normal metabolic process or metal-induced production
of reactive oxygen species causing oxidative stress in cells.25,26
To rule out the presence of high amounts of residual metals
remaining after the acid de-alloying process, energy dispersive
X-ray spectroscopy (EDS) analysis was conducted to determine
the composition of metals (such as, gold, copper and silver) on
the gold substrates. This approach is simple and promising
because (1) each element has a unique set of peaks in its X-ray
spectrum and (2) energy dispersive X-ray analysis, also known
as EDX or XEDS, has detection limits of approximately 0.1% in
bulk materials.8 Gold is known to be biocompatible but the
presence of other metals may yield metal oxides that can
damage and kill cells.25,26 If the residual content of the copper
or silver is high, then oxidative stress might reduce microglia
density on the np-Au substrate. Fig. 2 shows the EDS spectra of
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the four diﬀerent substrates used in our investigation. The
major peaks near 2.13 and 9.71 keV are the unique set of
peaks for gold and are observed for UF-Au ( panel B), UT np-Au
( panel C), np-Au monolith ( panel D) but not glass ( panel A).
Trace amounts of other metals were noted based on the minor
peaks observed at diﬀerent X-ray energies. A noticeable peak
near 0.50 keV (Fig. 2A) is the typical X-ray energy peak for
oxygen (0.53 keV) and is due to the oxide compositions (∼64%
SiO2) of the glass coverslip. The other peaks in Fig. 2A near
1.04 and 1.74 keV belong to sodium and silicon, respectively.
Based on the four X-ray spectra collected, various minute
amounts of residual metals were present on these substrate
surfaces. The X-ray energy peaks for copper (0.93 and 8.04 keV)
and silver (2.98 keV) are insignificant when compared to those
of gold. Therefore, the potential for silver or copper oxide toxicity or oxidative stress that may damage cells or prevent their
adherence to the np-Au substrate is minimal. EDS spectra for
yellow gold and gold foil before the acid de-alloying procedure
are provided in Fig. S1.† The prepared and characterized gold
surfaces were then examined for their ability to support microglial growth and function.
SEM provided topographical imaging of each material
surface. Additionally, this high resolution technique was also
used to visually characterize temporal changes in microglial
cell morphology and cell–cell interactions. The immortalized
BV-2 murine microglial cell line was used in this investigation
and the cells were seeded onto the four surfaces as described
in the Materials and methods section. Fig. 1E & I, F & J, G & K,
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Fig. 2 Energy-dispersive X-ray spectra for (A) glass, (B) UF-Au, (C) UT np-Au, (D) np-Au monolith. The K emission lines for O (0.53 keV),
Na (1.04 keV) and Si (1.74 keV) were observed for glass. The typical X-ray energy peaks for gold are 2.13 and 9.71 keV.

and H & L showed microglia cells on glass, UF-Au, UT np-Au
and np-Au surfaces, respectively. Since BV-2 microglia are
adherent cells, no prior surface modification of these substrates was necessary to artificially assist or improve cell
adhesion onto the substrate surfaces. SEM images showed a
variety of microglia morphologies including rounded, unipolar, bipolar, and flattened (amoeboid) and all were observed
routinely on all four types of substrate surfaces. Microglia on
each of the four substrate surfaces tended to exhibit many
short and branched processes extending outward from the cell
and interacting with neighboring cells and the substrate surfaces. Although major processes were observed on many of the
immobilized microglia, we cannot conclude that a distinct, or
favored, cell morphology was adopted by microglia for any of
the specific types of substrate used. The dimensions of the
microglia were between 15–20 μm on the long axis, and
10–15 μm on the short axis and did not appear to be influenced by the type of substrate used as a platform.
Adherence of microglia to the substrate surfaces
The ability of BV-2 microglia to adhere to glass and diﬀerent
gold substrates was determined by quantifying the number of
adherent microglia after plating of the cells and overnight
incubation at 37 °C in 5% CO2. Microglia adherence was exceptional for glass, UF-Au, and UT np-Au (>94% adherent cells)
but somewhat lower for np-Au (83% adherent cells) (Fig. 3).
There was no significant statistical diﬀerence between
glass, UF-Au, and UT np-Au. However, there was a significant
diﬀerence in microglia adherence between glass and np-Au
( p < 0.001).
Viability of BV-2 microglia
In order to determine whether there were toxic eﬀects of the
gold substrates (with various textures) on microglia after
surface adherence, the metabolic integrity of the seeded microglia was determined using an XTT cell viability assay. The
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Fig. 3 Ability of microglia to adhere to diﬀerent substrates.
BV-2 microglia (2 × 105 cells) were plated on diﬀerent substrates (n = 4
for each surface) and incubated overnight at 37 °C and 5% CO2 to allow
for cell adherence. The number of adherent cells was determined as
described in the Methods. Data and error bars represent the mean and
std error for n = 4 trials in one experiment. A statistically signiﬁcant
diﬀerence, using a student t-test, was found in microglia adherence
between glass and np-Au (*p < 0.001).

standard XTT assay relies on mitochondrial-mediated
reduction of XTT by nicotinamide adenine dinucleotide
(NADH) via trans-plasma membrane electron transport and an
electron mediator.27 This approach generates a water-soluble
orange-colored reduced formazan product which rapidly dissolves into the medium eliminating the need for additional
steps that may interfere with the assay. Since this conversion
only occurs in viable cells, the reduced orange formazan solution can be quantified spectrophotometrically (absorbance at
467 nm). Microglia attached to glass, UF-Au, and UT np-Au
were comparable in their viability (similar production of
reduced XTT) (Fig. 4) and very little toxicity was observed.
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Fig. 4 Analysis of microglia viability by XTT assay. BV-2 microglia (2 ×
105 cells) were plated overnight to allow cell adherence followed by
incubation for 24 h at 37 °C in 5% CO2. The medium was removed and
cell viability was assessed using a XTT assay as described in the
Methods. Reduced XTT absorbance was measured at 467 nm. % cell viability was determined by comparing metabolism of reduced XTT by
microglia on UF-Au, UT np-Au, and np-Au to microglia on glass. Data
and error bars represent the mean and std error for n = 12 measurements
for each condition over two separate experiments. A statistically signiﬁcant diﬀerence was found in microglia viability between glass and np-Au
(*p < 0.001). The other data points were not statistically diﬀerent from
each other.

However, cells incubated on np-Au were significantly restricted
in their ability to metabolize and reduce XTT. Control (cellfree) wells containing each substrate and XTT showed the
background levels of reduced XTT for each sample (Fig. S2†).
All of the cell-free substrates showed insignificant absorbance
(reduced XTT) when compared to substrate platforms with
microglia present. This was expected, as the blank substrates
used in this investigation are not known to react or cause
reduction of XTT. The low absorbance observed for the microglia on np-Au monolith was rather unexpected since the np-Au
monolith contains a similar porous morphology as the UT npAu substrate (Fig. 1). The cell viability data indicated that the
microglia on np-Au monolith were metabolically compromised
despite the earlier findings of morphological normality and
suﬃcient adherence of the microglia on np-Au (Fig. 1 and 3).
However, it is also possible that the thickness of the np-Au
monolith interfered with the production or detection of
reduced XTT. Although gold is known for its inertness, either
flat or in the presence of variable porosity, this scenario was
possible due to the lower levels of background reduced XTT
observed for the np-Au control compared to the other substrates (Fig. S2†).
An alternative analysis of cell viability was used to further
probe the viability of microglia on the np-Au monolith substrate. A lactate dehydrogenase (LDH) release assay was used
to validate the XTT analysis. The presence of LDH activity in
the medium is a general indicator of the leakage of
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Fig. 5 Cell cytotoxicity determined by LDH release assay.
BV-2 microglia (2 × 105 cells) were plated overnight on the four substrate surfaces to allow adherence and then incubated for 24 h as
described in the Materials and methods section. Conditioned medium
was collected for each sample and analyzed for LDH activity (absorbance per min) as described. The levels of LDH activity in the conditioned medium from untreated or saponin-treated microglia on glass
were used as 100% or 0% viability controls respectively. % cell viability
for the other samples was determined by comparing LDH activity to the
viability controls. Data and error bars represent the mean and std error
for n = 3 measurements in one experiment for all conditions.

intracellular LDH from the cells due to disruption or damage
of the membrane integrity. Following incubation of microglia
with the various substrates, the cell culture media was collected, centrifuged and the cell free supernatant examined for
LDH activity (Fig. 5). Minimal LDH activity was observed in the
microglia medium after incubation with all four substrates
(Fig. 5). In particular, the np-Au substrate did not elicit LDH
release from the adherent microglia indicating that the np-Au
monolith was not toxic to microglia. Saponin, a known cellular
toxin via cholesterol removal and membrane integrity disruption, caused significant LDH release from microglia cultured
on glass and served as a positive toxicity control in these experiments (Fig. 5).
Microglia proliferation on substrate surfaces
Cell survival and proliferation are important criteria for substrate biocompatibility. In addition to morphology and toxicity,
the four substrates used in our investigation were evaluated for
their ability to support cell growth and proliferation. Time
dependent studies of microglia seeded onto the four substrate
surfaces were carried out at 24, 48 and 72 h (Fig. 6). Quantification of cell density on these surfaces over time indicated
that the number of adherent microglia progressively increased
on the flat substrate surfaces, such as glass and UF-Au. Microglia density more than doubled from the initial number of
seeded cells on the flat surfaces (circles, triangles, Fig. 6). An
increase in microglia density was also observed on the UT npAu substrate (squares, Fig. 6) at the 48 h time point; however,
microglia density leveled oﬀ after that. The density of
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Fig. 6 Microglia density on diﬀerent substrate surfaces. BV-2 microglia
(2 × 105 cells, dashed line) were plated and allowed to grow at 37 °C and
5% CO2 on glass (circles), UF-Au (triangles), UT np-Au (squares), and npAu (diamonds) substrates. Cell number was quantiﬁed as described in
the Materials and methods section at 24, 48, and 72 h. Data points and
error bars represent the mean and std error for n = 7 measurements for
each condition and time point from two separate experiments. Statistical
analysis was performed using a student t-test and signiﬁcant diﬀerences
in microglia density were observed between np-Au and the other
samples at both 48 and 72 h (*p < 0.001). The other data points were
not statistically diﬀerent from each other.

microglia cultured on np-Au (diamonds, Fig. 6) after 24 hours
of seeding was slightly less than the number of cells plated
(dashed line, Fig. 6) and did not increase or decrease over
time. The diﬀerence in microglia growth was particularly striking at 48 h between np-Au and the other substrates. The
additional observation that continued growth on UT np-Au
was also hampered suggested that the texture had a negative
eﬀect on the process of cell division. To ensure consistency in
the given experiment, all microglial proliferation studies were
carried out simultaneously and similar observation were
attained with repeated experiments. The inability of the microglia to grow or proliferate on the texturized np-Au surface
helped to explain the contradiction between the earlier XTT
and LDH release toxicity results in Fig. 4 and 5. Since the XTT
assay was conducted after overnight plating and an additional
24 h incubation, the number of microglia was significantly
lower on the np-Au compared to the other substrates. The disparity in microglia cell number explained the notably lower
reduced XTT absorbance values for np-Au in Fig. 4.
Microglia morphology upon LPS challenge
LPS, a bacterial-derived endotoxin, is a potent immune system
stimulant and the most commonly used trigger for inducing
microglial activation.23,28,29 In this investigation, a time-dependent morphological examination of LPS-stimulated microglia
on glass and gold surfaces was carried out. Microglia immobilized onto glass, UF-Au, UT np-Au, and np-Au were challenged
with 10 ng mL−1 LPS or control vehicle and imaged using
high-resolution (2000× magnification) SEM after glutaraldehyde fixation at 0, 2, 6, 10 and 24 hour time points (Fig. 7A).
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Data for 2 and 10 h time points is not shown. The most frequently observed morphologies again included rounded, unipolar, bipolar, and flattened (amoeboid) shapes. In general,
the outer surface morphology of the microglia was generally
observed as having rough protrusive structures, such as filopodia, lamellipodia, and surface ruﬄes. Furthermore, most of
the microglia contained many long and short processes (5 μm
to 30 μm in length) projecting out of the cell body. Additionally, some cells contained a major process extending from one
end of the microglial pole (unipolar), while other microglia
had two major processes extending or stretching from two
opposite ends of the microglial poles (bipolar) (Fig. 7A). The
length of these major processes varied from cell to cell with
some of the longest axis extending 20 μm or more. One
common, but striking, observation during SEM acquisition
was the direct interactions between extended major and minor
processes of neighboring microglia. These connecting microglia processes appeared to form conjoining junctions. A global
analysis of microglia morphologies was conducted on lowerresolution SEM images to determine the eﬀect of both surface
composition and LPS treatment on microglia morphology. A
representative image is shown in Fig. S3† along with a description of how the analysis was conducted. The population of
rounded, unipolar, bipolar, and flattened microglia states at
24 h was analyzed in the absence or presence of LPS and this
distribution is shown in Fig. 7B. By far, the most common
microglia morphology was rounded, ranging from 70–85% of
the total number of microglia. Varying amounts of the other
three populations were observed but a consistent trend was
not seen indicating that the four surfaces did not induce cell
morphological changes. Furthermore, the morphology of the
microglia after 10 ng mL−1 LPS challenge did not appear dramatically diﬀerent compared to unstimulated microglia under
the same culture conditions (Fig. 7A, B). However, a slight
increase in non-rounded morphologies was noted in the LPStreated microglia. In a separate experiment, a higher concentration of LPS (100 ng mL−1) was used to treat microglia on the
diﬀerent surfaces and microglia morphology was compared to
both untreated and 10 ng mL−1 LPS-treated cells. Fig. S4†
shows a similar distribution to that in Fig. 7B for the lower
LPS concentration with only small diﬀerences observed at the
higher LPS concentration (Fig. S4†).
Additional studies were done to assess the adherence and
viability of LPS-stimulated microglia on glass and gold substrate surfaces. These experiments were conducted in the same
manner as those presented in Fig. 3–5 using adherence, XTT,
and LDH release assays. No diﬀerences were observed in
microglia adherence or vulnerability to the glass and gold surfaces between unstimulated and LPS-stimulated microglia
(data not shown). The results for LPS-stimulated microglia mirrored those for control microglia in Fig. 3–5 within statistical
error.
Cytokine release from microglia on the substrate surfaces
TNFα is a well-documented pleiotropic proinflammatory cytokine and can be produced in the central nervous system by
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Fig. 7 Microglia morphology on diﬀerent substrate surfaces with
and without challenge by LPS (10 ng mL−1). Panel
A. BV-2 microglia were allowed to adhere to glass, UF-Au, UT npAu and np-Au monolith followed by LPS exposure for 0, 2, 6, 10
and 24 h. At each time point the samples were prepared for SEM
imaging as described in the Materials and methods section.
Images were captured at an accelerating voltage of 5 kV. Data for
2 and 10 hour time points are not shown for space reasons. All
images are 58 μm × 43 μm in size (2000× magniﬁcation) and the
scale bar is equal to 10 μm. Presented images are representative
of n = 12 images for each condition at each time point over four
separate experiments. Panel B. Distribution of microglia morphologies on glass, UF-Au, UT np-Au and np-Au monolith in the
absence or presence of LPS were analyzed as described in
Fig. S3† using lower-resolution SEM images (250× magniﬁcation).
Four distinct shapes were categorized and depicted in the above
plot. Data bars represent the average of six image analyses from
two separate experiments. Standard error values are provided in Table S1† in the supplementary material. The percentage of microglia displaying
each morphology was determined by dividing the counted number for each by the total number of microglia representing all four shapes in the
image. Average total microglia for each condition were glass (−LPS), 424, glass (+LPS), 427, UF-Au (−LPS), 435, UF-Au (+LPS), 268, UT np-Au (−LPS),
316, UT np-Au (+LPS), 282, np-Au (−LPS), 300, and np-Au (+LPS), 306.
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Fig. 8 Microglial inﬂammatory response upon LPS challenge.
BV-2 microglia were allowed to adhere to the substrate surfaces overnight, treated with 10 ng mL−1 ﬁnal concentration of LPS or the same
volume of sterile water and incubated for 24 h at 37 °C and 5% CO2.
Subsequently, the supernatant was collected and analyzed for secreted
TNFα by ELISA. The black bars are unstimulated control microglia and
the gray bars are microglia stimulated with LPS. Values and error bars
represent the mean and std error for n = 6 measurements for each condition over two separate experiments.

activated microglia and astrocytes during the inflammatory
response.30 It is well-established that LPS infection induces
microglial production of TNFα along with other proinflammatory cytokines interleukin (IL)-1 and IL-6. We, and others, have
assessed the level of microglial activation based on the
amount of TNFα production23,31 and we used it here as a
primary marker of the microglia inflammatory response to
LPS. In order to determine if microglia adherence to texturized
gold surfaces had an impact on microglia function, seeded
microglia on glass, UF-Au, UT np-Au and np-Au substrates
were stimulated with LPS (10 ng mL−1) for 24 hours and the
levels of secreted TNFα were measured. This analysis revealed
comparable levels of TNFα production by microglia among the
four substrate surfaces studied (Fig. 8). The findings indicated
that these surfaces did not markedly alter microglial cytokine
production and were biocompatible with microglia proinflammatory studies. The negligible TNFα production observed for
the unstimulated microglia demonstrated that the substrates
alone do not elicit a microglial TNFα response. Therefore,
microglial TNFα production is solely caused by LPS stimulation without any interference from the substrates themselves.
The ability of microglia to retain their normal specific
response to LPS stimulation on glass and both flat and texturized gold surfaces was a good indicator of biocompatibility for
functional microglial assays.

Discussion
The present study describes the general morphology of
BV-2 murine microglia cultured on diﬀerent gold substrate
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surfaces. UF-Au, UT np-Au, and np-Au substrates were prepared to investigate their biocompatibility with microglia. SEM
provided high resolution images of microglia morphologies
and allowed detailed visualization of classic rounded,
elongated, unipolar and bipolar microglial shapes along with
numerous short and branched processes projecting outward of
the cell body. These processes varied in length from 5 μm to
30 μm, although some major processes were many times the
length of a cell body. The in vitro studies demonstrated that
microglia were able to adhere to flat glass and gold surfaces as
well as texturized gold surfaces, albeit with slightly less avidity
to np-Au. The gold surfaces, even the highly grooved UF np-Au
and np-Au monolith, were not toxic to microglia and did not
interfere with LPS-induced TNFα production suggesting good
biocompatibility for microglial functional and morphological
studies.
The use of flat gold as a substrate platform for cell culture
has been widely reported in the literature due to its known biocompatibility,18,19 ease of modification with alkanethiolate
self-assembled monolayers7 and with tailored self-assembled
monolayer-based micropatterned arrays for controlling protein
adsorption and cell adhesion.4,7 Furthermore, a variety of
gold-based compounds have been investigated for their interaction with immune cells. A recent report by Hutter et al. in
2010 demonstrated the uptake of gold nanoparticles (spheres,
rods, or urchin geometries) and microglial activation in vivo,
via bioluminescence imaging. In their study using transgenic
mice, they demonstrated that the geometry of the nanoparticle
(especially the rod and urchin shaped) can influence microglial activation and that the urchin shaped nanoparticles are
preferentially taken up by microglia.15 In this same report,
in vitro studies with microglia demonstrated that gold nanoparticles stimulated several proinflammatory molecules including
granulocyte macrophage colony-stimulating factor, IL-1α, and
nitric oxide, but not TNFα. In the current study, the gold surfaces alone did not stimulate microglial TNFα production
although other proinflammatory molecules were not
measured. However our studies investigated gold macrosurface eﬀects which would not have involved particle internalization and activation of uptake signaling pathways. In 2012,
Seker et al. presented the first eﬀort to utilize the high surfaceto-volume ratio of np-Au (compared to flat gold) as a potential
platform for culturing adherent astrocyte cells and investigated
its feasibility for application as a drug delivery platform.5 They
used an anti-mitotic drug cocktail known to reduce cellular
growth (in a dose-dependent manner) to evaluate the performance of the material for drug release and eﬃcient suppression
of astrocyte proliferation. Their result indicated that the
porous surfaces were minimally fouled by either the adherent
astrocytes or the cell culture media, rendering it a prospective
material favorable for sustained drug delivery.5
Microglia, the phagocytes of the brain, are known to
respond to a myriad of cues (soluble and insoluble) in their
physical environment (temperature, pressure, stiﬀness property of the substrate). Many of these cues induce microglial
migration towards sites of damage or injury in the central
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nervous system. A recent study by Persheyev et al. indicated
that BV-2 microglial morphology can be greatly impacted upon
interaction with nanoparticles that possess micro-protrusions.
The specific protrusions were in the form of either sharp,
homogeneous cones or spikes on a textured substrate prepared
using hydrogenated amorphous silicon (a-Si : H).32 The features on the texturized a-Si : H film in the range of 0.30–2.6 μm
greatly impacted the overall cell morphology and the actin
cytoskeleton with the most significant eﬀects observed when
the micro-protrusions were in the range of 0.90–2.6 μm. The
low impact of the flat and texturized gold surfaces on microglia morphology in our study may be because the gold pores
and ligaments are significantly smaller than the reported
dimensions in Persheyev et al. However the presence of pores
and the discontinuous gold area may hinder the formation of
the needed focal adhesion sites for cell adhesion. Yarmush
and colleagues found that shorter processes were observed
when astrocytes were cultured on porous gold surfaces compared to non-porous surfaces.5 They suggested that the presence of “nanopits” in the nanoporous gold substrate may
accommodate only a limited number of focal adhesion sites
compared to the non-porous gold substrates, thereby reducing
cellular spreading.
The use of SEM at high resolution revealed very little distinction in microglia morphology whether they were cultured
on UF-Au, UT np-Au or np-Au. These observations may be due
to minimal disruption of integrin clustering, resulting in negligible alteration of the microglial shapes by these surfaces.
However, it has been reported that nanotopography or RGD
ligand spacing can greatly impact the focal adhesion of these
cells on the surface.3,32 The ideal spacing of ∼70 nm between
the neighboring features or ligands can eﬀectively promote
integrin clustering, leading to the formation of focal adhesion
complexes and the F-actin network.3 A larger separation distance of the neighboring features or ligands tend to disrupt
the integrin clustering and dramatically influence cell
adhesion quality and dynamic cell behaviors. In the case of
the np-Au substrate, the corrugated surface contains both irregular ligaments and pores. The lack of a continuous smooth
surface and the presence of these gold surface features ( pores
and ligaments) may not impact the exterior morphology of the
microglia, but might directly aﬀect the quality of focal
adhesion or the number of focal adhesion sites. However,
microglia adhesion to UT np-Au was not hampered and only
slightly aﬀected by np-Au (∼14%).
The UT np-Au and np-Au substrates were biocompatible
with cultured microglia in most of our assays except for cell
growth or proliferation. UT np-Au was supportive of microglia
proliferation during the first 48 h but did not sustain growth
at subsequent times. Microglial growth was completely absent
on the texturized np-Au surface which is consistent with a previous observation reported by Leung et al. in 2008.20 In that
study, antiserum against CD11b was used to label endogenous
microglia and macrophages from the retrieved implanted electrode from rats’ brain. A higher number of adherent microglia
were observed on the smooth side of the electrode compared

This journal is © The Royal Society of Chemistry 2014

Paper

to the recording site side, which was composed of grooved
structures, and the number of cells decreased with the implantation time. The greatly diminished microglia growth on the
np-Au monolith surface may be due to several physical properties of the gold that reduce diﬀusion of cell culture
medium and CO2. These include a smaller pore size than UT
np-Au (25 nm vs. 53 nm) and much greater overall thickness
compared to UT np-Au (∼250 μm vs. ∼125 nm). Surface roughness may play a role as well. This property has been well-documented for glass and UF-Au by atomic force microscopy (AFM)
with root-mean-square roughness values of 0.245 nm and
0.2–0.3 nm respectively.33,34 Stine and colleagues have extensively characterized np-Au monoliths8 which have a greater
degree and variability of surface roughness (30–40 nm, data
not shown). Furthermore, they have demonstrated that np-Au
monoliths are open-ended mesoporous materials by (1) AFM
characterization of the np-Au exterior and interior continuous
porous structure,8 (2) successful immobilization of proteins
within the np-Au structure using a flow-through approach,35
and (3) quantification of the surface area and pore volume of
np-Au using nitrogen adsorption/desorption isotherms and
Brunauer, Emmett, and Teller (BET) and Barrett–Joyner–
Halenda (BJH) analysis.36 However, even with flow-through
permitted by the np-Au monolith there may be some nutrient
restrictions compared to the much thinner UT np-Au material.

Conclusions
The findings from this study demonstrated that np-Au as a
microglial cell culture platform was metabolically non-toxic,
non-disruptive to cell membranes, and compatible with microglia functional assays, but did not support microglial growth.
UT np-Au, however did support microglia growth and matched
the other characteristics of np-Au. These materials may have
potential as eﬀective substrates for coating or constructing
nanoelectronic devices, biosensors, and functional biomaterial
coatings for drug delivery.
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DEVELOPMENT OF LPS ANTAGONISTIC THERAPEUTICS: SYNTHESIS AND
EVEALUATION OF GLUCOPYRANOSIDE-SPACER-AMINO ACID MOTIFS

Sophon Kaeothip, Geeta Paranjape, Shana E. Terrill, Aileen F. G. Bongat, Maria L. D. Udan,
Teerada Kamkhachorn, Hope L. Johnson, Michael R. Nichols, and Alexei V. Demchenko

This publication was due to the collaborative efforts of the Nichols and
Demchenko laboratories. The LPS-induced antagonist studies analyzed the antagonistic or
inhibitory effect of six different Lipid A analogs, while also observing each compounds toxicity
and agonistic or stimulatory activity. The results determined one compound that inhibited the
LPS-induced TNFα response with the lowest IC50, while remaining non-toxic and producing no
agonistic activity. The Demchenko laboratory was responsible for the synthesis of the necessary
Lipid A mimics, while the Nichols laboratory was responsible for all the cellular activity assays.
Previous Nichols’ research assistants (Dr. Geeta Paranjape and Dr. Maria L. D. Udan) started all
the cellular assays on the first five compounds, while all my work was completed on the last
compound (compound 24) and the positive control. Further descriptions of this publications and
my experimental work is found in Chapter 5.
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Sepsis is a serious medical condition characterized by bacterial infection and a subsequent massive
systemic inflammatory response. The release of proinflammatory products and mediators from
responding innate immune cells, such as mononuclear phagocytes, directly contributes to the
pathogenesis of sepsis. The primary bacterial trigger of inflammation is lipopolysaccharide (LPS),
which interacts with the germline-encoded macrophage receptor cluster of differentiation 14 (CD14)
via its Lipid A moiety. In an effort to identify compounds that block LPS-induced inflammation we
investigated a series of Lipid A analogs that lack a disaccharide core yet still possess potent
antagonistic activity against LPS. We found it beneficial to develop molecules that contain the
following: a glucopyranoside core, hydrophobic ether substituents, and an amino acid to provide an
ionic character to the constructs. Here we report an efficient synthesis of molecules of this type and
the ensuing biological studies thereof.

Introduction
Septicemia is a serious world-wide health problem associated
with mortality rates of 40–60%.1 It has been estimated that 1% of
hospital patients and 20–30% of ICU patients develop sepsis.
The cardiovascular consequences of septic shock resulting from
bacterial infections include myocardial dysfunction that develops
in nearly all patients,2 vascular tone and permeability abnormalities, as well as abnormal oxygen delivery and metabolism. As a
result, vital organs such as the brain, heart, kidneys, and liver
may be affected or may fail, and this reflects in over 100 000
deaths annually in the US.1 It is well established that septic shock
is initiated by the introduction of a bacterial endotoxin (or
lipopolysaccharide, LPS) into the blood stream. LPS (Fig. 1), a
vital component of the outer leaflet of the gram-negative outer
membrane, has been shown to be a principle mediator of the
depression of left ventricular function and myocardial contractility.3 LPS is comprised of three structural regions. One of these,
the Lipid A region, consists of a polyacylated glucosamine
disaccharide and is largely responsible for the toxic activity.4 The
results of recent studies suggest that the ensuing proinflammatory response to LPS is by far more dangerous than the mere
presence of LPS in circulation.5,6 LPS exerts its effects via
interaction with a plasma LPS-binding protein (LBP), which has
strong affinity for both the Lipid A region of the endotoxin and
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glycosylphosphatidyl inositol-anchored LPS receptor CD14 on
mononuclear phagocytes. The LPS-LBP complex then interacts
with CD14 followed by further complex formation with Toll-like
receptor 4 (TLR4) and its co-receptor MD-2.7 TLR4 is an
integral membrane protein that transmits the LPS signal to the
inside of the cell and initiates the signaling pathways that lead to
production of proinflammatory molecules, such as the cytokine,
tumor necrosis factor a (TNFa).
Recent advances in the understanding of LPS structurefunction relationships have provided some clues on the structural
determinants responsible for the endotoxic activity of Lipid A.8
These determinants include the number and chain length of fatty
acids (lipids), the disaccharide core, and the 1,49-diphosphate
groups of the E. coli type (1, Fig. 1). The fair stability (chemical
or in vitro) of this class of compounds has been a major
drawback in their synthesis and application. Although the exact
role of the phosphate moieties is still unknown, the observation
that a 1-hydroxyl-49-O-phosphate derivative was inactive gave
rise to a belief that the omission of at least one phosphate results
in a complete loss of activity.8,9
In an effort to explore molecules that antagonize LPS
signaling without activating the inflammatory cascade, our
laboratory has designed simplified Lipid A analogs that lack
the complexity of the highly lipidated diphosphorylated disaccharide core yet still maintain potent antagonistic activity
against LPS. Herein we present the synthesis and unprecedented
LPS-antagonistic activity of the methyl glucopyranoside-amino
acid conjugates. This project was inspired by published reports
of compounds that are structurally dissimilar to Lipid A yet
still exhibit potent antagonistic activity. Amongst a myriad of
RSC Adv., 2011, 1, 83–92 | 83
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Fig. 1

Structures of the Lipid A region of E. coli LPS (1 and structural mimetics thereof (2–5).

research articles that have been disseminated in the past years,
the following three noteworthy discoveries served as a justification and guide for our own studies.
First, as reported by Boons et al., a strong binding and
antagonistic effect was achieved even with ‘phosphateless’
Rhizobium syn-1 disaccharide 2, which bears a lactone moiety at
the reducing end (Fig. 1).10,11 This finding indicated that one could
avoid hurdles associated with labile phosphate group installation,
handling, and storage. Second, Shiozaki et al. showed that a strong
anti-LPS antagonistic response can be achieved, even with
disaccharide 3, in which the non-reducing glucosamine is replaced
with glucose.12 In addition, instead of chiral b-hydroxy/acyl esters,
relatively simple alkyl chains were used at the C-3 and 39 positions,
whereas a b-ketoamide moiety was used at C-2.
Third, Peri et al. demonstrated that even simple methyl
glycoside-heterocycle conjugates 4 and 5 which bear alkyl chains
instead of traditional lipids provide antagonistic activity.13 To this
end, we found it attractive to develop molecules that contain the
following: a methyl glucoside monosaccharide core to simplify the
synthesis, hydrophobic chains to facilitate membrane intercalation, and an amino acid to provide an ionic character. Here
we report an efficient synthesis of conjugates of this type and
biological studies of their endotoxic activity in vitro.

4-dimethylaminopyridine (DMAP) in pyridine to afford the
derivative 8 in 71% yield. The carboxyl moiety of the linker was
then coupled with 3-hydroxyl of the protected L-serine derivative
9.15,16 This was accomplished using N,N’-diisopropylcarbodiimide
(DIC) as the coupling reagent in the presence of DMAP in pyridine
to afford conjugate 10 in 80% yield.

Results and discussion
The synthesis began with the conversion of methyl a-D-glucopyranoside 6 into methyl 2,3-di-O-benzyl-a-D-glucopyranoside 714
via sequential 4,6-benzylidene acetal formation, 2,3-dibenzylation,
and acetal cleavage accomplished in 67% yield over three steps
(Scheme 1). 4,6-Diol 7 was then regioselectively succinoylated at
the primary position with succinic anhydride in the presence of
84 | RSC Adv., 2011, 1, 83–92

Scheme 1 Synthesis of monosaccharide–aminoacid conjugates 10–13.
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Having obtained the key construct 10, we decided to pursue
further functional group transformations. The main driving
force for these synthetic manipulations was to obtain a series of
simple analogs that would allow us to investigate the effect of
cationic and anionic character on LPS-antagonistic activity
in vitro. With this objective in mind, carboxylated compound 11
was obtained from 10 by cleavage of tert-butyl ester in the
presence of TFA/DCM in 81% yield. Alternatively, the Fmoc
protecting group could also be removed from compound 10
with piperidine in DMF to afford free amine 12. Subsequently,
we also obtained compound 13 with both carboxyl and amine
groups unprotected. This was accomplished by the treatment

Fig. 2 Compounds 10, 12, and 13 do not display LPS antagonistic
activity. THP-1 human monocytes were treated as described in the
Experimental section with 10 ng mL21 PMA for 24 h at 37 uC and 5%
CO2. The medium was then removed and adherent macrophages were
further treated as described with increasing concentrations of compounds
10 (panel A), 12 (panel B) and 13 (panel C) for 30 min followed by
incubation with 10 ng mL21 LPS for 6 h. Secreted TNFa was measured
by ELISA and the levels (ng mL21) were reported on the y-axis after
normalization by the number of counted macrophages (cells mL21).
Error bars represent the standard error (std err) for 3 different TNFa
measurements from each cell treatment.

This journal is ß The Royal Society of Chemistry 2011

of compound 12 with TFA/CH2Cl2 to give derivative 13 in
75% yield.
The inhibitory activity of compounds 10–13 on LPS-induced
TNFa production was investigated in vitro using THP-1
macrophages prepared as described in the Experimental section.
THP-1 cells are an excellent system for studying inflammatory
processes and serve as a model for peripheral monocytes/
macrophages and their responses to bacterial infection.
Compounds 10, 12, and 13 exhibited no inhibitory activity
against LPS-induced TNFa production in the concentration
range of 0.1 nM to 10 mM (Fig. 2A–C). These compounds were
also tested in the absence of LPS and demonstrated no agonist
activity (data not shown). Compound 11, which has a free
carboxylic group, was able to significantly inhibit LPS-induced
TNFa production at concentrations greater than 10 mM (Fig. 3).
Unfortunately, cell viability measurements using an XTT
reduction assay indicated that compound 11 was toxic to the
cells in the 30–100 mM range. Although there was a notable gap
between inhibition and toxicity at 30 and 50 mM, the similarities
between the inhibition and toxicity curves suggested that much
of the antagonistic activity by 11 was related to toxicity.
With the purpose of gaining further insight into the effect of
various substituents on the endotoxic activity of monosaccharideamino acid conjugates, we obtained an analog of compound 11 in
which benzyl groups have been replaced with acyl (myristoyl, C14)
fatty acid chains. The synthesis of lipidated analog 19 was
accomplished as depicted in Scheme 2. Methyl glycoside 6 was
protected as 4,6-O-(p-methoxybenzylidene) acetal 14 by treatment
with anisaldehyde dimethylacetal in the presence of camphorsulfonic acid in 89% yield. 14 was acylated with myristoyl chloride
in the presence of the pyridine furnished compound 15 in 85%
yield. The benzylidene ring in 15 was reductively opened by
treatment with BH3-THF catalyzed with Cu(OTf)2 to obtain the
unexpected product 16, which was lacking the C-2 acyl chain, in

Fig. 3 Compound 11 displays LPS antagonistic activity and cell
toxicity. THP-1 macrophages were treated as described in the legend of
Fig. 2, with increasing concentrations of compound 11. Secreted TNFa
levels (circles) are the average ¡ std err for n = 2 trials and are reported
as the % response of LPS in the absence of an antagonist compound.
Immediately following the cell treatment described above and in the
Fig. 2 legend, the macrophage viability (triangles) (n = 2 trials) was
determined by XTT reduction as described in the Experimental. Cell
viability is presented as a percentage of the cell viability measured in the
absence of antagonists.
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Scheme 2 Synthesis of monosaccharide–fatty acid–amino acid conjugate 19, a lipidated analog of compound 11.

67% yield. The loss of the acyl chain was rather unexpected, but
this glitch was overcome by regioselective acylation with succinic
anhydride in pyridine at the primary C-6 position followed by C-2
acylation with myristoyl chloride. This two-step one-pot procedure
allowed us to obtain compound 17 in 79% yield.
15
L-serine derivative 9 was linked to the carboxyl group of 17
via DIC-mediated coupling in the presence of DMAP. The
monosaccharide–fatty acid–amino acid conjugate 18 was
obtained in 83% yield. Acid treatment of the fully protected
compound 18 led to concomitant cleavage of the p-methoxybenzyl (pMB) group at C-4 and tert-butyl ester. As a result,
compound 19 was isolated in 75% yield.
For comparative biological studies, we also accomplished the
synthesis of the alkylated analog 24 as depicted in Scheme 3. The
intermediate 14 was di-alkylated at C-2 and C-3 with myristyl
bromide in the presence of NaH to afford compound 20 in 72%
yield. The benzylidene ring in 20 was reductively opened by
treatment with BH3-THF catalyzed with Cu(OTf)2 to obtain
product 22 in 87%. Acylation of 22 with succinic anhydride led
to compound 22 in 89% yield. L-serine derivative 915 was then
linked to the carboxyl group of 22 via DIC-mediated coupling in
the presence of DMAP. The resulting monosaccharide-amino
acid conjugate 23 was obtained in 79% yield. Acid treatment of
the fully protected compound 23 led to concomitant cleavage of
the pMB group at C-4 and tert-butyl ester. As a result, target
compound 24 was isolated in 81% yield.
Having obtained compounds 19 and 24, lipidated and
alkylated analogs of compound 11, respectively, we were well
positioned to perform comparative studies. In addition, as the
comparison point, we obtained the standard positive control
compound 4 as described by Peri et al.13 The lipidated
compound 19 displayed a marked improvement in LPSantagonistic ability. Inhibition of LPS-induced TNFa was found
86 | RSC Adv., 2011, 1, 83–92

beginning at 550 nM 19 (Fig. 4). A reproducible biphasic
response was consistently seen in the activity of 19. This may
indicate multiple binding sites on the macrophages, both higher
and lower affinity for the antagonist compound. 80% of the LPS

Scheme 3 Synthesis of the monosaccharide–alkyl–amino acid conjugate
24, an alkylated analog of compound 11.
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Fig. 4 Compound 19 displays more potent LPS antagonistic activity.
THP-1 macrophages were treated in 3 separate experiments as described
in the Fig. 2 legend, with increasing concentrations of compound 19.
Secreted TNFa levels were determined in the presence (circles) (n = 9
trials) and absence (diamonds) (n = 6 trials) of LPS. Cell viability
(triangles) (n = 9 trials) was also assessed and presented as described in
the Fig. 3 legend.

response was blocked with 5 mM of compound 19 with no
observable toxicity. Cell viability began to be compromised at
10 mM and some agonist activity was found in the 10–30 mM
range (Fig. 4).
The alkylated compound 24 was found to be a very effective
inhibitor of LPS-induced TNFa production in human macrophages (Fig. 5). 70% inhibition was observed at 1 mM of 24 and
overall inhibition reached 90% at 40 mM. Compound 24
exhibited no toxicity or agonist activity in the tested 0.2 to
40 mM range. Curve fitting of the inhibition data in Fig. 5
produced an IC50 value of 470 nM. These results were superior
to those obtained with compound 413 which had an inhibition
range from 3–10 mM and began to show agonist activity at
concentrations > 10 mM (Fig. 6). Compound 4 was only toxic at
high concentrations.

Fig. 5 Compound 24 displays significant LPS antagonistic activity
without toxicity. THP-1 macrophages were treated in 4 separate
experiments, as described in the Fig. 2 legend, with increasing
concentrations of compound 24. Secreted TNFa levels were determined
in the presence (circles) (n = 12 trials) and absence (diamonds) (n = 8
trials) of LPS. Cell viability (triangles) (n = 12 trials) was also assessed
and presented as described in the Fig. 3 legend.
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Fig. 6 LPS antagonistic activity displayed by compound 4. THP-1
macrophages were treated in 3 separate experiments, as described in the
Fig. 2 legend, with increasing concentrations of compound 4. Secreted
TNFa levels were determined in the presence (circles) (n = 8 trials) and
absence (diamonds) (n = 5 trials) of LPS. Cell viability (triangles) (n = 11
trials) was also assessed and presented as described in the Fig. 3 legend.

The potent inhibition displayed by compound 24 of LPSinduced TNFa production without associated toxicity establishes this compound and those in its class as potential
therapeutic and research compounds. These results extend the
work of Boons and co-workers with phosphateless Lipid A
derivatives11 by transitioning from disaccharide-based to monosaccharide-based compounds. The IC50 inhibition constant of
470 nM for compound 24 is the lowest reported for a
monosaccharide compound and its potency in human macrophages significantly improves on the monosaccharide compounds tested in mouse bone-marrow-derived macrophages by
Peri et al.13 Our monosaccharide-based compound in the current
form is not as potent as some of the best disaccharide
compounds such as E5531 (IC50 1.2 nM), E5564 (IC50 1.1 nM)
and E5564 analogues (IC50 0.97 nM).8,12,17 This difference in
potency is balanced by the ease of synthesis and modification of
monosaccharide-based compounds. In fact, the observation that
the replacement of the acyl chains in 19 with alkyl chains (24)
produced a significantly more potent antagonist with less toxicity
suggests that additional modifications may further enhance the
activity. From these studies, it also became clear that subtle
structural changes have an impact on whether a particular
compound displays antagonist or agonist activity. The balance
between these two activities has been explored before18 and
suggests that small modifications to the compounds described in
this investigation may enhance agonist activity, thus providing a
basis for adjuvant development.19–21
In summary, studies described herein provide new information
regarding the structure–activity relationship of a novel class of
compounds that mimic classic Lipid A analogs, and the scientific
basis for future studies to prevent the deleterious effects of
endotoxemia. We believe that the results of these studies
summarized in Table 1 will have far reaching impact on the
treatment of patients diagnosed with endotoxemia. As a
consequence, we can foresee additional efforts to investigate
the molecular mechanisms underlying the antagonistic actions of
the synthetic Lipid A analogs.
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Table 1 Summary of biological activity in human macrophage cells.
Compound TNFa inhibition (IC50) Toxicity
10, 12, 13
11
19
24
4

None observed
46 mM
3 mM
0.5 mM
6 mM

None observed
.10 mM
.10 mM
None observed
.30 mM

Agonist activity
None observed
None observed
10–30 mM
None observed
30–100 mM

Experimental
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General
Column chromatography was performed on silica gel 60 (70–
230 mesh) and reactions were monitored by TLC on Kieselgel 60
F254. The compounds were detected by examination under UV
light and by charring with 10% sulfuric acid in methanol.
Solvents were removed under reduced pressure at , 40 uC.
CH2Cl2 and CH3CN were distilled from CaH2 directly prior to
application. Pyridine was dried by refluxing with CaH2 and then
distilled and stored over molecular sieves (3 Å). Cu(OTf)2 was
co-evaporated with toluene (3 6 10 mL) and dried in vacuo for
2–3 h directly prior to application. N,N’-Diisopropylcarbodiimide, 4-dimethylaminopyridine, piperidine, and anhydrous
DMF were used without further conditioning. Optical rotations
were measured by a ‘Jasco P-1020’ polarimeter. Unless noted
otherwise, 1H-NMR spectra were recorded in CDCl3 at 300 MHz
(Bruker Avance) or at 500 MHz (Bruker ARX-500), 13C-NMR
spectra and two-dimensional experiments were recorded in CDCl3
at 75 MHz (Bruker Avance) or at 125 MHz (Bruker ARX-500).
HR FAB-MS determinations were made with the use of JEOL
MStation (JMS-700) Mass Spectrometer, matrix m-nitrobenzyl
alcohol, with NaI as necessary.
Methyl 2,3-di-O-benzyl-6-O-(3-carboxypropanoyl)-a-Dglycopyranoside (8)
4-Dimethylaminopyridine (DMAP, 32 mg, 0.26 mmol) and
succinic anhydride (0.16 g, 1.56 mmol) were added to a stirred
solution of methyl 2,3-di-O-benzyl-a-D-glucopyranoside 714
(0.5 g, 1.3 mmol) in dry pyridine (5 mL) and the resulting
mixture was stirred for 16 h at room temperature (rt) under
argon. After that, the reaction mixture was concentrated under
reduced pressure, the residue was dissolved in CH2Cl2 (30 mL)
and washed with water (3 6 15 mL). The organic phase was
separated, dried over MgSO4, filtered and concentrated in vacuo.
The residue was purified by column chromatography on silica gel
(ethyl acetate-hexane gradient elution) to give the title compound
8 (0.45 g, 0.95 mmol) as a colorless syrup in 71% yield. Analytical
o
data for 8: Rf 0.43 (ethyl acetate); [a]22
D +7.19 (c = 1.0, CHCl3);
1
H NMR (300 MHz, CDCl3): d, 2.60 (m, 4H, 2 6 CH2), 3.38 (s,
3H, OCH3), 3.44 (dd, 1H, J2,3 = 9.5 Hz, H-2), 3,51 (dd, 1H,
J4,5 = 9.5 Hz, H-4), 3.73 (m, 1H, J5,6b = 4.8 Hz, H-5), 3.80 (dd,
1H, J2,3 = 9.2 Hz, H-3), 4.26 (dd, 1H, J6a,6b = 10.0 Hz, H-6a),
4.42 (dd, 1H, H-6b), 4.61 (d, 1H, J1,2 = 3.5 Hz, H-1), 4.65 (d, 1H,
2
J= 12.1 Hz, K CH2Ph), 4.74–4.79 (m, 2H, CH2Ph), 4.99 (d, 1H,
2
J = 11.3 Hz, K CH2Ph), 7.26–7.36 (m, 10H, aromatic) ppm; 13C
NMR (75 MHz, CDCl3): d, 55.4, 63.7, 69.4, 69.9, 73.3, 75.3,
79.7, 81.0, 98.3, 128.0 (62), 128.1 (62), 128.2 (64), 128.6 (62),
128.7 (62), 138.1, 138.6, 172.6, 177.2 ppm; HR FAB MS
[M+Na]+ calcd for C25H30O9Na 497.1788, found 497.1770.
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Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-3-(tert-butoxy)-3-oxopropyl)oxy-4-oxobutanoyl)a-D-glycopyranoside (10)
DMAP (12.7 mg, 0.01 mmol) and N,N’-diisopropylcarbodiimide
(DIC, 0.16 mL, 1.04 mmol) were added to a stirred solution of
O-tert-butyl N-fluorenylmethoxycarbonyl-L-serine ester 915,16
(0.19 g, 0.52 mmol) in CH2Cl2 (4 mL). After 1 h, carboxylic
acid derivative 8 (0.29 g, 0.62 mmol) was added and the reaction
was stirred for 5–9 h at rt until no further conversion of the
starting material could be detected by TLC. The reaction mixture
was diluted with CH2Cl2 (20 mL), washed with water (2 6
15 mL) and brine (15 mL). The organic phase was separated,
dried over MgSO4, filtered and concentrated in vacuo. The
residue was purified by column chromatography on silica gel
(ethyl acetate–hexane gradient elution) to afford the title
compound 10 (0.34g, 0.41 mmol) as a white powder in 80%
yield. Analytical data for 10: Rf 0.34 (ethyl acetate/hexane, 1/1,
o
1
v/v); [a]27
D +12.1 (c = 1.0, CHCl3); H NMR (300 MHz, CDCl3):
d, 1.48 (s, 9H, t-Bu), 2.53 (d, 1H, J = 2.8 Hz, OH), 2.66 (m, 4H,
2 6 CH2), 3.37 (s, 3H, OCH3), 3.42 (d, 1H, J2,3 = 9.0, H-2), 3.73
(m, 1H, H-5), 3.78 (dd, 2H, J3,4 = 9.1 Hz, H-3, CHFmoc), 4.25
(m, 2H, H-6b, SerCb-H), 4.38 (m, 2H, H-6a, SerCb-H), 4.44 (m,
2H, OCH2Fmoc), 4.52 (m, 1H, SerCa-H), 4.61 (d, 1H, J1,2 =
3.2 Hz, H-1), 4.64 (d, 1H, 2J = 12.1 Hz, K CH2Ph), 4.75 (dd, 2H,
J = 12.0 Hz, CH2Ph), 4.98 (d, 1H, 2J = 11.3 Hz, K CH2Ph), 4.75
(d, 1H, JNH,CH = 8.0 Hz, Ser-NH), 7.27–7.77 (m, 18H, aromatic)
ppm; 13C NMR (125 MHz, CDCl3): d, 28.1 (63), 29.1 (62),
47.3, 54.1, 55.5, 63.9, 64.8, 67.4, 69.4, 70.1, 73.4, 75.7, 79.7, 81.3,
83.3, 98.4, 120.2 (62), 125.4 (62), 127.3, 127.9 (62), 128.1,
128.2 (62), 128.3 (63), 128.7, 128.8 (63), 138.2, 138.9 , 141.5
(62), 144.0 (62), 144.1, 156.0, 168.5, 171.8, 172.6 ppm; HR
FAB MS [M+Na]+ calcd for C47H53NO13Na 862.3415, found
862.3432.
Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-2-carboxyethyl)oxy-4-oxobutanoyl)-a-Dglycopyranoside (11)
Conjugate 10 (0.25g, 0.29 mmol) was dissolved in TFA/wet
CH2Cl2 (1/5, v/v, 2 mL) and the resulting mixture was stirred for
2 h at rt. After that, the volatiles were evaporated under reduced
pressure, the residue was diluted with CH2Cl2 (5 mL) and
neutralized with triethylamine (until pH ~ 7). The volatiles were
removed under reduced pressure and the residue was purified by
column chromatography on silica gel (ethyl acetate/hexane, 1/1,
v/v) to afford the title compound 11 (0.18 g, 0.24 mmol) as a
white foam in 81% yield. Analytical data for 11: Rf 0.5
o
(methanol/ethyl acetate, 1/4, v/v); [a]26
D +22.5 (c = 1.0, CHCl3);
1
H NMR (500 MHz, CDCl3/(CD3)2SO, 2/1, v/v): d = 2.49–2.54
(m, 4H), 3.26 (s, 3H, OCH3), 3.39 (m, 2H), 3.57 (m, 2H), 4.01
(br. s, 1H), 4.12 (m, 2H), 4.22 (m, 2H), 4.32 (dd, 2H, J = 6.6 Hz),
4.43 (d, 1H, J = 5.1 Hz), 4.60 (s, 2H), 4.76 (m, 2H), 7.24–7.93 (m,
18H, aromatic) ppm; 13C NMR (75 MHz, CDCl3/(CD3)2SO, 2/1,
v/v): d, 28.8, 28.9, 31.1, 47.0, 54.7, 54.8, 63.4, 63.9, 65.3, 65.9,
69.8, 70.2, 71.8, 74.5, 79.4, 81.5, 97.3, 120.5 (62), 125.5 (62),
127.4 (62), 127.5, 127.8 (64) , 127.9 (64), 128.0 (63), 128.3
(63), 128.5 (63), 138.9, 139.6, 141.1 (62), 144.2, 156.0, 172.1,
172.2 (62) ppm; HR FAB MS [M+Na]+ calcd for
C43H45NO13Na 806.2789, found 806.2780.
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Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-amino-3-(tert-butoxy)-3oxopropyl)oxy-4-oxobutanoyl)-a-D-glycopyranoside (12)
Piperidine (0.5 mL) was added dropwise to a solution of
monosaccharide 10 (0.1 g, 0.12 mmol) in DMF (2.0 mL) and
the resulting mixture was stirred for 20 min at rt. After that, the
reaction mixture was concentrated in vacuo and co-evaporated
with toluene (63). The residue was purified by flash column
chromatography (ethyl acetate/hexane, 1/1, v/v) to give the title
compound 12 (67 mg, 0.1 mmol) as a yellow syrup in 92% yield.
Analytical data for 12: Rf 0.62 (methanol/ethyl acetate, 1/9, v/v);
o
1
[a]26
D +17.3 (c = 1.0, CHCl3); H NMR (500 MHz, CDCl3): d =
1.49 (s, 9H, t-Bu), 2.52–2.66 (m, 3H), 2.73–2.78 (m, 1H), 3.02
(broad s, 1H, OH), 3.38 (s, 3H, OCH3), 3.46 (d, 1H, J2,3 =
9.4 Hz, H-2), 3.50 (ddd, 1H, J4,5 = 9.5 Hz, H-4), 3.75 (m, 2H,
H-5, Ser-CbH), 3.80 (m, 2H, H-3, Ser-CbH), 4.18 (dd, 1H,
J6a,6b = 10.19 Hz, H-6a), 4.46 (m, 1H, Ser-CaH), 4.52 (dd, 1H,
J5,6b = 4.19 Hz, H-6b), 4.61 (d, 1H, J1,2 = 3.53 Hz, H-1), 4.65 (d,
1H, 2J = 12.5 Hz, K CH2Ph), 4.77 (dd, 2H, J = 11.5 Hz,
CH2Ph), 4.99 (d, 1H, 2J = 9.0 Hz, K CH2Ph), 6.49 (d, 1H,
JNH,CH = 6.95 Hz, Ser-NH), 7.27–7.31 (m, 10H, aromatic) ppm;
13
C NMR (125 MHz, CDCl3): d, 28.2 (63), 29.8, 31.0, 31.1, 55.5
(62), 55.7, 63.3, 63.6, 69.5, 69.8, 73.5, 75.9, 79.8, 81.5, 83.0, 98.5,
128.1, 128.2, 128.3(62), 128.4 (62), 128.7 (62), 138.2, 138.7,
169.6, 172.0, 173.1 ppm; HR FAB MS [M+Na]+ calcd for
C32H43NO11Na 640.2734, found 640.2741.
Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-amino-2-carboxyethyl)oxy4-oxobutanoyl)-a-D-glycopyranoside (13)
Conjugate 12 (0.1 g, 0.12 mmol) was dissolved in TFA/wet CH2Cl2
(1/5, v/v, 2 mL) and stirred for 2 h. Upon completion as assessed by
TLC analysis, solvents were evaporated in vacuo. The residue was
dissolved in CH2Cl2 (5 mL) and neutralized with triethylamine
(until pH y 7). Solvents were removed under reduced pressure.
The residue was subjected to column chromatography on silica gel
(methanol–ethyl acetate gradient elution) to obtain the product 13
(50 mg, 0.09 mmol) as white foam in 75% yield. Analytical data for
13: Rf 0.5 (methanol/ethyl acetate, 1/4, v/v); 1H NMR (500 MHz,
D2O): d, 1.68 (m, 2H), 1.82 (m, 3H), 2.73 (m, 4H), 3.19 (dd, 3H, J =
5.7 Hz), 3.4 (s, 3H, OCH3), 3.58 (ddd, 2H, J = 9.5, 10.0 Hz), 3.80
(dd, 1H, J = 9.2 Hz), 3.87 (d, 3H, J = 4.7 Hz), 4.33–4.37 (m, 2H, J =
4.7 Hz), 4.54 (d, 1H, J = 10.9 Hz), 7.44 (s, 10H, aromatic) ppm; 13C
NMR (75 MHz, D2O): d 29.5, 30.5, 55.4 (62), 61.4, 63.7, 69.7,
69.8 (62), 73.4, 75.5, 79.1 (62), 81.1, 97.8, 128.7, 128.8 (63),
129.0, 129.1 (63), 137.7, 137.9, 174.5 (62), 174.6 ppm; HR FAB
MS [M+Na]+ calcd for C28H35NO11Na 584.2108, found 584.2104.
Methyl 4,6-O-(p-methoxybenzylidene)-2,3-di-O-tetradecanoyl-aD-glucopyranoside (15)
Myristoyl chloride (2.34 mL, 8.67 mmol) and DMAP (70 mg,
0.57 mmol) were added to a stirred solution of methyl 4,6-O-(pmethoxybenzylidene)-a-D-glucopyranoside 1422 (1.0 g, 2.89 mmol)
in pyridine (15 mL) at 0 uC. The mixture was stirred under an
atmosphere of argon for 16 h. Upon completion, the reaction
mixture was concentrated in vacuo. The residue was dissolved in
CH2Cl2 (30 mL), and washed with 1N HCl (2 6 15 mL), water
(2 6 15 mL) and brine (15 mL). The organic phase was separated,
dried over MgSO4, filtered and concentrated in vacuo. The residue
This journal is ß The Royal Society of Chemistry 2011

was purified by column chromatography on silica gel (ethyl
acetate–hexane gradient elution) to afford derivative 15 (1.81 g,
2.48 mmol) as a white foam in 86% yield. Analytical data for 15: Rf
o
0.47 (ethyl acetate/hexane, 3/7, v/v); [a]23
D +23.6 (c = 1.0, CHCl3);
1
H NMR (300 MHz, CDCl3): d, 0.88 (t, 6H, 2 6 CH3), 1,26 (br. s,
40H, 20 6 CH2), 1.59 (m, 4H, 2 6 CH2), 2.29 (m, 4H, 2 6 CH2),
3.40 (s, 3H, OCH3), 3.62 (dd, 1H, J4,5 = 9.7 Hz, H-4), 3.75 (dd, 1H,
J6a,6b = 10.2 Hz, H-6a), 3.78 (s, 3H, OCH3), 3.92 (m, 1H, H-5), 4.28
(dd, 1H, J5,6b = 4.7 Hz, H-6b), 4.82 – 2.94 (m, 2H, H-1, 2), 5.46 (s,
1H, > CHPh), 5.60 (dd, 1H, J3,4 = 9.7 Hz, H-3), 6.86 (d, 2H, J =
8.8 Hz, aromatic), 7.25 (d, 2H, J = 8.7 Hz, aromatic) ppm; 13C
NMR (75 MHz, CDCl3): d, 14.3 (62), 22.9 (62), 25.1 (62),
25.28, 29.2 (62), 29.4, 29.5 (63), 29.6, 29.7, 29.8 (62), 29.9, 32.1
(62), 34.3, 34.5, 55.4, 55.5, 62.5, 68.8, 68.9, 71.6, 76.8, 77.2, 77.6,
79.5, 97.8, 101.6, 113.7 (62), 127.6 (62), 129.62, 160.2, 172.6,
173.4ppm; HR FAB MS [M+Na]+ calcd for C43H72O9Na
755.5074, found 755.5090.
Methyl 4-O-p-methoxybenzyl-3-O-tetradecanoyl-a-Dglucopyranoside (16)
A 1 M solution of BH3-THF in tetrahydrofuran (5 mL, 5 mmol)
was mixed with compound 15 (0.75 g, 1.02 mmol) and the
resulting mixture was stirred for 10 min at rt under argon.
Freshly conditioned copper(II) trifluoromethanesulfonate
(18 mg, 0.05 mmol) was added, and the reaction mixture was
stirred for 2 h at rt. After that, the reaction mixture was cooled
to 0 uC and then quenched by the sequential addition of
triethylamine (0.14 mL, 1 mmol) and methanol (1.8 mL). The
resulting mixture was concentrated under reduced pressure
followed by co-evaporation with methanol. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate–hexane gradient elution) to give the title compound 16
(0.35g, 0.67 mmol) as white solid in 67% yield. Analytical data
o
for 16: Rf 0.40 (ethyl acetate/hexane, 7/3, v/v); [a]22
D +78.5 (c =
1
1.0, CHCl3); H NMR (300 MHz, CDCl3): d = 0.88 (t, 3H, J =
7.02 Hz, CH3), 1.24 (br. s, 20H, 10 6 CH2), 1.63 (m, 2H, CH2),
1.97 (br. s, 1H, OH), 2.23–3.82 (m, 3H, CH2, OH), 3.41 (s, 3H,
OCH3), 3.52–3.82 (m, 5H, H-2, 4, 5, 6a, 6b), 3.79 (s, 3H, OCH3),
4.57 (dd, 2H, J = 12.4 Hz, CH2Ph), 4.75 (d, 1H, J1,2 = 3.7 Hz,
H-1), 5.30 (dd, 1H, J = 9.1 Hz, H-3), 6.85 (d, 2H, J = 8.6 Hz,
aromatic), 7.20 (d, 2H, J = 8.6 Hz, aromatic) ppm; 13C NMR
(75 MHz, CDCl3): d = 14.3, 22.9, 25.1, 29.3, 29.5 (62), 29.6, 29.8
(64), 29.9, 32.1, 34.7, 55.4, 55.5, 61.7, 71.0, 71.9, 74.3, 74.9, 99.6,
114.0 (62), 129.6 (62), 130.1, 159.5, 174.3 ppm; HR FAB MS
[M+Na]+ calcd for C29H48O8Na 547.3247, found 547.3254.
Methyl 6-O-(3-carboxypropanoyl)-4-O-p-methoxybenzyl-2,3-diO-tetradecanoyl-a-D-glucopyranoside (17)
DMAP (8.1 mg, 0.06 mmol) and succinic anhydride (67 mg,
0.67 mmol) were added to a stirred solution of derivative 16
(0.35g, 0.67 mmol) in dry pyridine (5 mL) and the resulting
mixture was stirred for 16 h at rt under argon. After that,
myristoyl chloride (0.21 ml, 0.80 mmol) was added dropwise, and
the reaction mixture was stirred for 2 h at rt. After that, the
resulting mixture was concentrated under reduced pressure. The
residue was dissolved in CH2Cl2 (30 mL) and washed successively with 1N HCl (2 6 15 mL), water (2 6 15 mL) and brine
(15 mL). The organic phase was separated, dried over MgSO4,
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filtered and concentrated in vacuo. The residue was purified by
column chromatography on silica gel (ethyl acetate–hexane
gradient elution) to give compound 17 (0.43 g, 0.52 mmol) as
white syrup in 79% yield. Analytical data for 17: Rf 0.55 (ethyl
o
1
acetate-hexane 1/1, v/v); [a]24
D +42.4 (c = 1.0, CHCl3); H NMR
(300 MHz, CDCl3): d, 0.87 (t, 6H, 2 6 CH3), 1.25 (br. s, 40H, 20 6
CH2), 1.59 (m, 4H, 2 6 CH2), 2.26 (m, 2H, CH2), 2.33 (m, 2H,
CH2), 2.61 (m, 4H, 2 6 CH2), 3.36 (s, 3H, OCH3), 3.59 (dd, 1H,
J4,5 = 9.5 Hz, H-4), 3.90 (m, 1H, H-5), 4.28 (dd, 2H, J5,6b = 4.4 Hz,
J6a,6b = 11.5 Hz, H-6a, 6b), 4.44 (d, 1H, 2J = 10.7 Hz, K CH2Ph),
4.54 (d, 1H, 2J = 10.7, K CH2Ph), 4.87 (m, 2H, H-1, 2), 5.55 (dd,
1H, J3,4 = 9.5 Hz, H-3), 6.84 (d, 2H, J = 8.7 Hz, aromatic), 7.16 (d,
2H, J = 8.6 Hz, aromatic) ppm; 13C NMR (75 MHz, CDCl3): d,
14.3 (63), 22.8 (63), 25.1 (62), 28.8, 29.2, 29.3, 29.4 (62), 29.5,
29.6, 29.7 (64), 29.8 (64), 32.1 (64), 34.2, 34.5, 55.4 (62), 62.7,
68.6, 71.8, 71.9, 74.3, 75.7, 96.9, 114.0 (62), 129.5, 129.8 (62),
159.6, 171.7, 172.8, 173.7 ppm; HR FAB MS [M+Na]+ calcd for
C47H78O12Na 857.5391, found 857.5410.
Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-3-(tertbutoxy)-3-oxopropyl)oxy-4-oxobutanoyl)-2,3-di-O-tetradecanoyla-D-glucopyranoside (18)
DMAP (9.5 mg, 0.07 mmol) and DIC (0.12 mL, 0.78 mmol) were
added to a stirred solution of O-tert-butyl-N-fluorenylmethoxycarbonyl-L-serine 915,16 (0.15 g, 0.39 mmol) in CH2Cl2 (3 mL). After
1 h, the carboxylic acid derivative 17 (0.39 g, 0.46 mmol) was added
and the reaction was stirred for 5–9 h at rt until no further
conversion of the starting material could be detected by TLC. The
reaction mixture was diluted with CH2Cl2 (20 mL), washed with
water (2 6 10 mL) and brine (10 mL). The organic phase was
separated, dried over MgSO4, filtered and concentrated in vacuo.
The residue was purified by column chromatography on silica gel
(ethyl acetate-hexane gradient elution) to afford the title compound
18 (0.38 g, 0.32 mmol) as a white solid in 83% yield. Analytical data
o
for 18: Rf 0.5 (ethyl acetate/hexane, 3/7, v/v); [a]24
D +25.7 (c = 1.0,
CHCl3); 1H NMR (300 MHz, CDCl3): d, 0.88 (t, 6H, 2 6 CH3),
1.25 (br. s, 40H, 20 6 CH2), 1.49 (s, 9H, t-Bu), 1.59 (m, 4H, 2 6
CH2), 1.59 (m, 4H, 2 6 CH2), 2.30 (m, 4H, 2 6 CH2), 3.37 (s, 3H,
OCH3), 3.48 (dd, 1H, J4,5 = 9.5 Hz, H-4), 3.76 (s, 3H, OCH3), 3.90
(m, 1H, H-5), 4.16–4.26 (m, 3H, H-6a, 6b, Ser-CbH), 4.35–4.55 (m,
6H, CH2Ph, Ser-CaH, CHFmoc, OCH2Fmoc), 4.90 (m, 2H, H-1,
2), 5.58 (dd, 1H, J3,4 = 9.7 Hz, H-3), 5.82 (d, 1H, JNH,CH = 8.3 Hz,
Ser-NH), 6.18–7.77 (m, 12H, aromatic) ppm; 13C NMR (75 MHz,
CDCl3): d, 14.2 (63), 22.8 (63), 25.0, 28.0 (64), 29.3 (62), 29.4
(62), 29.5 (63), 29.6 (63), 29.8 (65), 32.0 (63), 34.2, 34.4, 47.2,
54.0, 55.3 (62), 62.6, 67.4, 68.5, 71.7, 71.9, 74.3, 76.7, 83.0, 96.8,
113.9 (63), 120.1 (62), 125.4, 127.2 (62), 127.8 (62), 129.3 (62),
129.6 (62), 141.4 (62), 144.0 (62), 156.0, 159.5, 168.4, 171.5,
171.8, 172.7, 173.5 ppm; HR FAB MS [M+Na]+ calcd for
C69H101NO16Na 1222.7018, found 1222.7023.
Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-2carboxyethyl)oxy-4-oxobutanoyl)-2,3-di-O-tetradecanoyl-a-Dglucopyranoside (19)
Compound 18 (0.2 g, 0.16 mmol) was dissolved in TFA/wet
CH2Cl2 (1/5, v/v, 4 mL) and stirred for 2 h at rt. After that, the
volatiles were evaporated in vacuo, and the residue was diluted
with CH2Cl2 (5 mL) and neutralized with triethylamine (until
90 | RSC Adv., 2011, 1, 83–92

pH ~ 7). The volatiles were removed under reduced pressure and
the residue was purified by column chromatography on silica gel
(ethyl acetate/hexane, 1/1, v/v) to afford the title compound 19
(0.13 g, 0.12 mmol) as a white foam in 75% yield. Analytical data
for 19: Rf 0.5 (methanol-ethyl acetate 1/9, v/v); 1H NMR
(300 Hz, CDCl3): d, 0.88 (t, 6H, 2 6 CH3), 1.25 (br. s, 40H, 20 6
CH2), 1.58 (m, 4H, 2 6 CH2), 2.33 (m, 4H, 2 6 CH2), 2.64 (br.
s, 4H, 2 6 CH2), 3.27 (br. s, 1H, OH), 3.38 (s, 3H, OCH3), 3.47
(dd, 1H, J4,5 = 9.4 Hz, H-4), 3.83 (m, 1H, H-5), 4.21–4.51 (m,
7H, H-6a, 6b, Ser-CbH2, CHFmoc, OCH2Fmoc), 4.67 (m, 1H,
Ser-CaH) 4.86 (m, 1H, H-2), 4.90 (br. s, 1H, H-1), 5.31 (dd, 1H,
J3,4 = 9.1 Hz, H-3), 5.96 (br. s, 1H, JNH,CH = 8.3 Hz, Ser-NH),
7.27–7.76 (m, 8H, aromatic) ppm; 13C NMR (75 MHz, CDCl3);
d, 14.3 (63), 22.9 (63), 25.0 (62), 25.1, 28.9, 29.2, 29.30, 29.4
(62), 29.5 (62), 29.6, 29.8 (62), 29.9, 32.1 (62), 34.2 (62),
34.5, 47.2, 55.5, 62.9, 64.3, 67.6, 69.4, 69.6, 69.9, 71.2, 72.7, 77.4,
96.8, 114.1, 120.2 (62), 124.9 (62), 125.3 (62), 127.3 (62),
127.9 (62), 141.4 (62), 143.8, 143.9, 171.7, 171.8, 174.3, 174.6,
175.1 ppm; HR FAB MS [M+Na]+ calcd for C57H85NO15Na
1046.5817, found 1045.5822.
Methyl 6-O-(3-carboxypropanoyl)-4-O-p-methoxybenzyl-2,3-diO-tetradecanyl-a-D-glucopyranoside (22)
DMAP (7.0 mg, 0.05 mmol) and succinic anhydride (71 mg,
0.70 mmol) were added to a stirred solution of methyl 4-O-pmethoxybenzyl-2,3-di-O-tetradecanyl-a-D-glucopyranoside 2113
(0.40 g, 0.56 mmol) in dry pyridine (5 mL) and the resulting
reaction mixture was stirred for 16 h at rt under argon. After
that, the reaction mixture was concentrated under reduced
pressure. The residue was dissolved in CH2Cl2 (30 mL) and
washed successively with 1N HCl (2 6 15 mL), water (2 6
15 mL) and brine (15 mL). The organic phase was separated,
dried over MgSO4, filtered and concentrated in vacuo. The
residue was purified by column chromatography on silica gel
(ethyl acetate–hexane gradient elution) to give the title compound 22 (0.41 g, 0.50 mmol) as a colorless syrup in 89% yield.
Analytical data for 22: Rf 0.55 (ethyl acetate/hexane, 7/3, v/v);
o
1
[a]24
D +42.9 (c = 1.0, CHCl3); H NMR (300 MHz, CDCl3): d,
0.88 (t, 6H, 2 6 CH3), 1.26 (br. s, 40H, 22 6 CH2), 1.63 (m, 4H,
2 6 CH2), 2.64 (m, 2H, 2 6 CH2), 3.30 (dd, 1H, J2,3 = 9.7 Hz,
H-2), 3.38 (s, 3H, OCH3), 3.39 (m, H-4), 3.59–3.76 (m, 5H, H-3,
5, OCH2, OCH2a), 3.80 (s, 3H, OCH3), 3.86 (m, 1H, OCH2b),
4.28 (m, 2H, J5,6b = 4.7 Hz, J5,6a = 2.3 Hz, J6a,6b = 12.0 Hz,
H-6a, 6b), 4.49 (d, 1H, 2J = 10.5 Hz, K CH2Ph), 4.76 (d, 1H,
J1,2 = 3.5 Hz, H-1), 4.81 (d, 1H, 2J = 10.5 Hz, K CH2Ph), 6.89
(d, 2H, J = 8.9 Hz, aromatic), 7.22 (d, 2H, J = 9.7 Hz, aromatic)
ppm; 13C NMR (125 MHz, CDCl3): d = 14.3 (63), 22.9 (63),
26.2, 26.5, 28.8, 28.9, 29.5 (65), 29.7 (64), 29.8, 29.9, 30.3, 30.8,
32.1 (64), 55.3, 55.5, 63.6, 68.8, 72.0, 74.1, 74.8, 80.9, 81.9, 98.1,
114.1 (63), 130.1 (63), 130.4, 159.6, 172.0, 176.5 ppm; HR FAB
MS [M+Na]+ calcd for C47H82O10Na 829.5805, found 829.5806.
Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-3-(tertbutoxy)-3-oxopropyl)oxy-4-oxobutanoyl)-2,3-di-O-tetradecanyla-D-glucopyranoside (23)
DMAP (6.2 mg, 0.05 mmol) and DIC (0.16 mL, 1.01 mmol) were
added to a stirred solution of O-tert-butyl-N-fluorenylmethoxycarbonyl-L-serine 915,16 (0.39 g, 0.60 mmol) in CH2Cl2 (3 ml).
This journal is ß The Royal Society of Chemistry 2011
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After 1 h, the carboxylic acid derivative 22 (0.41 g, 0.50 mmol)
was added and the reaction was stirred for 5–9 h until no further
conversion of the starting material could be detected by TLC.
The reaction mixture was diluted with CH2Cl2 (20 mL), washed
with water (2 6 10 mL) and brine (10 mL). The organic phase
was separated, dried over MgSO4, filtered and concentrated
in vacuo. The residue was purified by column chromatography
on silica gel (ethyl acetate–hexane gradient elution) to afford the
title compound 23 (0.47 g, 0.40 mmol) as a colorless amorphous
solid in 79% yield. Analytical data for 23: Rf 0.43 (ethyl acetate/
o
1
hexane, 3/7, v/v); [a]24
D +36.1 (c = 1.0, CHCl3); H NMR
(300 MHz, CDCl3): d, 0.88 (t, 6H, 2 6 CH3), 1.17 (m, 40H, 20 6
CH2), 1.38 (s, 9H, t-Bu), 1.54 (m, 4H, 2 6 CH2), 2.53 (m, 4H,
2 6 CH2), 3.18 (dd, 1H, J2,3 = 9.7 Hz, H-2), 3.26 (s, 3H, OCH3),
3.28 (m, 1H, H-4), 3.42–3.66 (m, 5H, H-3, 5, OCH2, OCH2a), 3.67
(s, 3H, OCH3), 3.79 (m, 1H, OCH2b), 4.11–4.46 (m, 9H, H-6a, 6b,
K CH2Ph, Ser-CaH, Ser-CbH2, , CHFmoc, OCH2Fmoc), 4.66
(d, 1H, J1,2 = 3.3 Hz, H-1), 4.71 (d, 1H, 2J = 10.5 Hz, K CH2Ph),
5.71 (d, 1H, JNH,CH = 8.1 Hz, Ser-NH), 6.75–7.64 (m, 12H,
aromatic) ppm; 13C NMR (75 MHz, CDCl3): d, 14.2 (63), 22.8
(63), 26.1, 26.4, 28.0 (63), 28.7, 28.9 (63), 29.5, 29.6 (63), 29.7
(65), 29.8, 30.2, 30.7, 32.0 (63), 47.0, 54.0, 55.2, 55.3 (62), 64.7,
67.3, 68.6, 71.8, 73.8, 74.6, 80.8, 81.8, 83.0, 97.9, 99.7, 113.9 (62),
120.1 (62), 125.2, 125.3, 127.2 (62), 127.8 (62), 129.9 (62),
130.3, 141.4 (62), 143.9 (62), 155.9, 159.4, 168.4, 171.7, 172.0,
181.3 ppm; HR FAB MS [M+Na]+ calcd for C69H105NO14Na
1194.7433, found 1194.7433.
Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-2carboxyethyl)oxy-4-oxobutanoyl)-2,3-di-O-tetradecanyl-a-Dglucopyranoside (24)
Conjugate 23 (0.2 g, 0.17 mmol) was dissolved in TFA/wet CH2Cl2
(1/5, v/v, 4 mL) and the resulting mixture was stirred for 2 h at rt.
After that, the volatiles were evaporated under the reduced
pressure, the residue was diluted with CH2Cl2 (5 mL) and
neutralized with triethylamine (until pH ~ 7). The volatiles were
removed under the reduced pressure and the residue was purified
by column chromatography on silica gel (ethyl acetate/hexane 1/1,
v/v) to obtain the title compound 24 (0.13 g, 0.14 mmol) as a white
amorphous solid in 81% yield. Analytical data for 24: Rf 0.58
o
(methanol/ethyl acetate, 1.5/8.5, v/v); [a]26
D +34.9 (c = 1.0, CHCl3);
1
H NMR (500 MHz, CDCl3/(CD3)2SO, 2/1, v/v): d, 0.78 (t, 6H,
2 6 CH3), 1.45 (br. s, 40 H, 20 6 CH2), 1.47 (m, 4H, 2 6 CH2),
2.5 (m, 4H, 2 6 CH2), 3.10 (dd, 1H, J2,3 = 9.4 Hz, H-2), 3.22–3.33
(m, 7H), 3.41–3.51 (m, 3H), 3.55 (m, 1H, H-5), 3.64 (t, 2H, J =
6.7 Hz), 4.14–4.32 (m, 7H), 4.42 (d, 1H, J = 9.5 Hz), 4.63 (d, 1H,
J1,2 = 3.2 Hz,, H-1), 6.52 (br. s, 1H, Ser-NH), 7.22–7.82 (m, 8H,
aromatic) ppm; 13C NMR (125 MHz, CDCl3/(CD3)2SO, 2/1, v/v):
d, 13.6 (63), 21.9 (63), 25.4 (62), 25.5 (62), 28.6 (63), 28.8, 28.9
(64), 29.0 (65), 29.5, 31.2 (63), 46.6, 54.3 (62), 63.4, 64.9, 65.6,
69.2, 69.4, 70.6, 72.7, 79.6, 80.7, 97.3, 119.4 (62), 124.6, 124.8,
126.6 (62), 127.1 (62), 140.1 (62), 143.4 (62), 155.4, 171.3,
171.6, 178.3, 178.7 ppm; HR FAB MS [M+Na]+ calcd for
C57H89NO13Na 1018.6232, found 1018.6182.
Preparation of compounds for cellular treatment
Synthetic compounds in solid form were dissolved in tetrahydrofuran (THF), aliquotted in small volumes, vacuum-centrifuged
This journal is ß The Royal Society of Chemistry 2011

for 1 h and stored at 280 uC as dry compounds. For cellular
treatment, an aliquot was dissolved in an appropriate volume of
dimethylsulfoxide (DMSO) to give a concentrated working stock
solution. This stock solution was further diluted in DMSO to give
the desired concentration range. The final concentration of DMSO
in the cell treatments was always maintained at 0.6%. Concentrations of Fmoc-containing compounds were verified by absorbance
using an extinction coefficient of 7800 M21cm21 at 301 nm.
Cell culture and LPS antagonism assays
THP-1 cells were obtained from ATCC (Manassas, VA) and
maintained in a RPMI-1640 culture medium (HyClone, Logan,
UT) containing 2 mM L-glutamine, 25 mM HEPES, 1.5 g L21
sodium bicarbonate, 10% fetal bovine serum (FBS) (HyClone),
50 units mL21 penicillin, 50 mg mL21 streptomycin (HyClone),
and 50 mM b-mercaptoethanol at 37 uC in 5% CO2. For cellular
assays, THP-1 monocytes were centrifuged and resuspended in a
fresh growth medium to a cell density of 5 6 105 cells mL21.
Cells were then seeded in a 48-well plate and differentiated into
adherent macrophages by treatment with 10 ng mL21 phorbol
12-myristate 13-acetate (PMA) (Sigma) for 24 h at 37 uC in 5%
CO2. The non-adherent cells were removed and the adherent
cells were washed and replenished with reduced FBS growth
medium. For the two wells set aside for calculating percent
differentiation, the cells were washed with PBS (Hyclone) prior
to removal by 0.25% trypsin-EDTA. Cells in a separate well were
removed with 0.25% trypsin and counted under the microscope
using a hemocytometer to determine the number of adherent
macrophages. For the remaining wells, the cells were preincubated with LPS antagonist compounds at different concentrations for 30 min followed by the addition of 10 ng mL21
ultrapure LPS from E. coli K12 (InvivoGen, San Diego, CA) for
6 h at 37 uC in 5% CO2. 0.6% DMSO was used as a control. The
cell medium was collected and stored at 220 uC until analyzed
by ELISA for secreted TNFa production.
Cell viability measurements
Cell viability was monitored using an XTT [2,3-bis(2-methoxy4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide]
assay.
Macrophage metabolic activity was assessed by probing mitochondrial reduction of XTT (Sigma) which is a measure of
viability (or toxicity) in response to the synthetic antagonists.
Following 6 h treatment with antagonist compounds and LPS,
the macrophages were washed with PBS (Hyclone) and
incubated with XTT (0.33 mg mL21) and phenazine methosulfate (PMS) (8.3 mM) (Acros, Morris Plains, NJ) to a final concentration of 0.33 mg mL21 and 8.3 mM respectively for 2 h at
37 uC in 5% CO2. The cellular toxicity was then assessed in a
platereader using absorbance of reduced XTT at 467 nm.
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CHAPTER 1

INTRODUCTION

1.1 Protein Misfolding and Amyloids
One of the most fundamental and universal examples of self-assembly is the
folding of a protein into its three-dimensional structure. The folding of a protein is
connected to many biological processes, such as trafficking of molecules to their specific
cellular locations and regulation of cellular growth and differentiation. However, only
correctly folded proteins are able to withstand biological environments and, therefore,
selectively interact with their natural partners. Folding of proteins can be variable. In
vivo, some proteins are co-translational; meaning the folding of the protein was initiated
before the completion of the protein synthesis, while the protein was still attached to the
ribosome. However, other proteins endure the majority of their folding in the cytoplasm,
after its synthesis and release from the ribosome. Also, some proteins remain unfolded
until they are in specific compartments, such as the mitochondria or endoplasmic
reticulum (ER) (Dobson, 2003).
The accumulation of proteins with highly abnormal conformations within a cell is
a continuous threat to the cell’s function and viability. If the conformation of a protein is
lost through mutation or post synthetic damage, the cell will attempt to evolve to prevent
the aggregation of unfolded proteins and correctly refold them. But if this is not possible,
the cell is programed to hydrolyze the abnormal polypeptide back to its amino acids. One
1

preventative protein is the chaperone protein; which is a major cell constituent that is
essential to ensure the proper folding and intracellular localization of newly synthesized
polypeptides. However, there are still a large portion of the newly synthesized
polypeptides that fail to achieve their correct configurations and are rapidly digested.
The degradation process of a cellular protein is very selective. This mechanism is
marked by a small polypeptide cofactor, ubiquitin, which leads to the rapid breakdown by
the proteolytic complex, the proteasome (Sherman and Goldberg, 2001, Wang and
Terpstra, 2013).
Many distinct diseases have been linked to the progressive misfolding of specific
proteins into aggregates. Amyloidosis occurs when normally soluble proteins form
insoluble deposits of fibrils, which are high in β-sheet structure (Figure 1.8) and
accumulate in the extracellular space of various tissues. One disease associated with
amyloidosis is Alzheimer’s disease (AD), which is the accumulation of the protein
amyloid-β (Aβ) (Selkoe, 2003). The term amyloid was first coined due to the deposits
having a resemblance to starch due to it positive iodine staining (Virchow, 1851);
however, later, when the amyloids were found to be protein, the term amyloid remained
(Kyle, 2001). In the past, amyloids had solely been associated with human disease;
however, a functional discovery has also been revealed in organisms such as bacteria
(Fowler et al., 2007). Bacteria have been shown to express several cell-surface
proteinaceous filaments which can promote colonization of an epithelial surface, entry
into host cells, exchange of DNA between bacteria, and development of bacterial
communities organized as biofilms, colonies, or multicellular fruiting bodies (Chapman
et al., 2002). The presence of the bacterial biofilms demonstrates that amyloids can be

2

formed in a highly regulated manner and may not always represent a ‘misfolded’ toxic
protein structure (Fowler et al., 2007).
Conformational diseases occur when a specific protein undergoes a
conformational rearrangement that causes it to have a tendency to aggregate and become
deposited in specific tissues or cellular compartments (Kopito and Ron, 2000). These
aggregates show resemblance to extracellular aggregates, due to their insolubility, β-rich
secondary structure, and birefringence with Congo-red (Carrell and Lomas, 1997). A few
examples of conformational diseases include Alzheimer’s and Parkinson’s disease,
amyloidosis, α1-antitrypsin deficiency and the prion encephalopathies. Some of these
diseases can be inherited or induced; however, most of these diseases have unknown
etiology (Kopito and Ron, 2000). Despite the lack of sequence homologies among these
conformational disease proteins and the deficiency in structural folding similarities
during normal non-pathological conditions, all of these proteins form a common amyloid
fibril structure under appropriate conditions. The amyloid fibrils have a cross-β structure
resulting in a β-sheet propagating fibril (Figure 1.4A). However, Chiti and colleagues
showed that this specific fibril formation was not a feature of only a few proteins, but
could be produced by proteins that are not associated with any amyloid diseases (Chiti et
al., 1999). This knowledge shows the importance of understanding the structure and
aggregation of protein folding in order to possibly prevent associated diseases.

1.2 Alzheimer’s Disease: Understanding the Etiology of the Disease
Among the many different neurodegenerative disorders, AD has become one of
the most common types of dementia (Selkoe, 2001). Dementia is a term used to describe

3

many of the neurodegenerative disorders that develop when nerve cells in the brain either
die or no longer retain their normal function. In AD patients, the neuronal loss usually
results in the decline of one’s memory, motor skills, and ability to think clearly. It has
been estimated that in 2013 5.2 million Americans were living with AD and in the
coming decades the baby boom generation is projected to add about 10 million to the
total of Americans with AD. AD is ultimately fatal, with it being the sixth leading cause
of death in the United States and the fifth leading cause of death of Americans over the
age of 65 (Thies and Bleiler, 2013).
Those studying AD have had their share of controversy due to the cytological and
biochemical complexity of the disease. Through the years it has been difficult to agree
on the sequence of events leading to the dementia and which events are the most
important for intervention. However, there has been substantial progress on untangling
the disease due to extremely high incidence. A considerable amount of research has
shown that there are certain molecular events which occur in the brain years or even
decades prior to the first symptoms (Selkoe, 2011). This stage has been termed the
preclinical phase and can last for a decade or more (Bateman et al., 2012). During this
stage of AD, the patient appears to be cognitively intact with normal scores on
neuropsychiatric test, but show evidence of the disease through cerebrospinal fluid (CSF)
analysis or through brain imaging (Zahs and Ashe, 2013). As of now, patients with AD
only marginally and briefly respond to available drugs as treatment and unless new,
disease-modifying drugs become accessible, soon, the number of AD cases will continue
to rise (Bloom, 2014, Thies and Bleiler, 2012).
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1.3 AD Pathology
The signs of AD were observed long before the Bavarian psychiatrist, Alois
Alzheimer, diagnosed AD in 1906. This diagnosis came after the observation of a 51year-old female postmortem autopsy (Selkoe and Podlisny, 2002). Through the
observation of postmortem brain slices, Alzheimer was able to discover that AD is
characterized by two distinctive lesions, the neurofibrillary tangles (NFTs) and senile
plaques (Selkoe, 2004) (Figure 1.1). The NFTs are composed of hyperphosphorylated
tau protein (Grundke-Iqbal et al., 1986), while the major constituent of the senile plaques
is Aβ protein. The plaques are routinely found in the parenchyma and cerebral vessels
(Selkoe, 1994) and are typically found associated with dystrophic neuritis and activated
immune cells, such as astrocytes and microglia (Wisniewski et al., 1989). More recent
observations of senile plaques (Aβ) and NFTs (tau) have shown that the Aβ is more
clearly associated with the cause of AD, while the tau protein is most closely related to
the clinical manifestations of AD (Dickson, 2004).

1.3.1 Neurofibrillary Tangles
The fibrous system of eukaryotic cells is mainly comprised of microtubules,
where tubulin is the basic subunit. The microtubules are generally involved in cellular or
intracellular motion or maintenance of cellular shape, but they are also a large component
of the nerve axons. In the nerve axons, the microtubules are associated with transport
and neurotransmission. In 1975, Weingarten and colleagues isolated a heat stable protein
called tau in which its normal function was to induce microtubule formation (Weingarten
et al., 1975). However, about ten years later, observations were made by several research
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groups showing that tau was one of the main components of the paired helical filaments
(PHFs) and the NFTs (Johnson and Jenkins, 1999), which were found in the entorhinal
cortex, hippocampus, amygdala, association cortices of the frontal, temporal and parietal
lobes, and certain subcortical nuclei that project to these regions (Selkoe, 2011).
Tau was found to be highly asymmetric with little defined secondary structure,
which may result from high number of proline and glycine residues in its primary
structure (Johnson and Jenkins, 1999). Jameson and colleagues presented data in 1980
that suggested the increase in phosphorylation of the tau protein decreased its ability to
promote microtubule assembly (Jameson et al., 1980). This information led to the
observation that hyperphosphorylated tau was the predominant tau structure of the PHFs
and NFTs in the AD brain (Johnson and Jenkins, 1999). The hyperphosphorylated tau
was found to form oligomers, which are thought to be converted to highly insoluble
fibrils in the frontal cortex of the brain (Figure 1.2). An increase in the tau oligomer
levels may be a very early sign of the formation of NFTs and AD (Giacobini and Gold,
2013, Maeda et al., 2006). The fibrillar formation is not clearly associated with the
phosphorylation of the tau protein, but the phosphorylation is known to reduce the
affinity of tau for the microtubules, thus decreasing its ability to promote microtubule
assembly, as mentioned above. The reduced affinity for the microtubules leads to the
destabilization of the microtubules and increased degeneration of associated neurons
(Bramblett et al., 1993). The tau aggregates within the NFTs are also commonly
associated with ubiquitin. This association may be the cells attempt at removing the tau
filaments by degradation in the proteasome, but the process appears to be unsuccessful
(Selkoe, 2011).
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Figure 1.1. Pathology of AD, showing the senile plaques and the NFTs. AD has been
characterized by these two pathological hallmarks, which are composed of Aβ and tau
protein, respectively. http://petridishtalk.com/2011/05/
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Figure 1.2. Formation of NFTs (Luna-Muñoz et al., 2013). The tau protein forms part
of the microtubule, which helps transport nutrients and other important substances from
one part of the nerve cell to another. However, in AD the tau protein becomes
phosphorylated and causes the microtubules to destabilize. The hyperphosphorylated tau
can then aggregate in the PHFs and cause NFTs within the neurons (Luna-Muñoz et al.,
2013).

8

1.3.2 Senile Plaques
Senile or neuritic plaques consist of extracellular deposits of Aβ protein (Figure
1.1). In 1984, high performance liquid chromatography (HPLC) along with automated
amino acid sequencing showed the presence of two nearly identical proteins which make
up the vast majority of the senile plaques of AD patient’s brains (Glenner and Wong,
1984). A few years later it was identified that those proteins were two different isoforms
of the Aβ protein, Aβ(1-42) and Aβ(1-40), differing by the addition of two amino acids,
isoleucine and alanine (Kang et al., 1987). The core of the senile plaques are composed
of insoluble Aβ fibrils, while immunological research has shown the presence of other
more diffused Aβ forms within and surrounding the plaque-like deposits (Tagliavini et
al., 1988, Yamaguchi et al., 1988).
Early characterization of the Aβ plaques led to the assumption that the plaques
mostly consisted of the Aβ(1-40) peptide (Mori et al., 1992); however, more current data
supports the predominance of Aβ(1-42) (Roher et al., 1993). It is likely, however, that
these two peptides probably both exist in the Aβ plaques. Different ratios of Aβ(142):Aβ(1-40) were found when investigating the Aβ plaques from different regions of the
AD brain. Roher and colleagues observed that the plaques found within the
leptomeningeal vessels had an average ratio of 58:42 Aβ(1-42):Aβ(1-40), while plaques
found within the parenchymal vessels had an average ratio of 75:25 Aβ(1-42):Aβ(1-40)
(Roher et al., 1993). These and many other studies have provided knowledge showing
that the ratio of Aβ(1-42):Aβ(1-40) plays a more significant role in the load of Aβ
plaques compared to the overall total amount of Aβ (Yin et al., 2007).
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1.3.3 The Influence of Tau on Aβ
The building blocks of the insoluble plaques and tangles, soluble Aβ and tau, have
been more recently shown as the main toxic components of AD and have also been
shown to have a connection in their pathways that lead to the AD pathology (Bloom,
2014). Through the use of transgenic mice with a P301L mutation that causes the
accumulation of tau tangles, along with the injection of Aβ into the brain of the mice, it
was found that there is an increase in the accumulation of the tangles near the injection
site (Gotz et al., 2001). These in vivo mouse studies showed that Aβ causes an increase
in the tau pathology and functions upstream of the tau protein (Bloom, 2014). More in
vivo transgenic mouse models have shown that the tau pathology is not a secondary effect
of the Aβ pathology, but that Aβ initiates the cascade of events that leads to the taudependent synaptic dysfunction and neuronal death (Bloom, 2014, Roberson et al., 2007).
In contrast, some data has shown evidence that the tau protein influences Aβ and
challenges the notion that Aβ exclusively works upstream of tau (Leroy et al., 2012).
Considering both possible pathways, leads to the possibility that Aβ could starts a
pathological feedback loop with the tau protein (Figure 1.3) (Bloom, 2014).
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Figure 1.3. Possible feedback loop through Aβ and tau drives AD (Bloom, 2014).
Aβ senile plaques accumulate in the brains of AD patients because off different genetic
insults, while other genetic interactions and environmental risks also contribute. The
toxic Aβ species are able to activate the formation of pathological tau through modulating
protein kinases and phosphatases that regulate tau phosphorylation (Bloom, 2014).
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1.4 Amyloid-β Metabolism
The Aβ peptide which makes up the senile plaques in AD patient’s brain is
formed through the proteolytic cleavage of a larger single transmembrane polypeptide,
amyloid precursor protein (APP). This glycoprotein is 770 amino acids in length and its
gene is localized on chromosome 21. The location of the APP gene led to the realization
of the development of cerebral amyloid deposits within the brains of patients with
Down’s syndrome, due to trisomy 21 (three copies of chromosome 21). However, the
plaques of Down’s syndrome patients were observed to be unassociated with any neuritic
dystrophy, gliosis, or NFTs (Selkoe, 1994).
APP is part of a conserved type 1 membrane protein, including APP-like protein
(APLP) 1 and APLP2 (Coulson et al., 2000, Senechal et al., 2006). The function of APP
remains unclear; however, it has been proposed that it plays a role in trafficking,
neurotrophic signaling, cell adhesion and cell signaling (Dawkins and Small, 2014,
Hoareau et al., 2008, Reinhard et al., 2005, Zheng and Koo, 2006). Through the use of
Northern blot analysis and in situ hybridization, it was found that APP is widely
expressed in the majority of all neural and non-neural mammalian tissues with the highest
expression levels being located in the brain and kidney. Within the brain, it was observed
that the neurons showed very high levels of expression (Selkoe, 1994). In vivo studies
have shown that knocking out APP did not have any adverse phenotypes, but knocking
out both APP and its homolog resulted in a lethal phenotype (von Koch et al., 1997).
However, it was shown later that APP knock out (KO) mice actually had behavioral
defects in locomotor activity and passive avoidance learning, defective long term
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potentiation (LTP) and increased gliosis (Dawson et al., 1999, Phinney et al., 1999,
Senechal et al., 2008).
After obtaining the full-length cDNA sequence of APP, it was known that the
precursor polypeptide contains a single hydrophobic stretch near its carboxyl terminus
and has properties of a membrane-spanning domain (Kang et al., 1987). The protein also
contains a large cysteine-rich globular ectodomain (E1), a helix-rich acidic domain (E2)
and part of the Aβ domain that begins 28 amino acids amino terminal to the single
transmembrane domain and extends several residues into the transmembrane domain
(Figure 1.5) (Dawkins and Small, 2014, Selkoe, 1994).
APP can also undergo a variety of proteolytic cleavages to eventually release
secreted Aβ derivatives into the vesicle lumens and extracellular space. The first
proteolytic cleavage is through α- or β-secretase (Figure 1.4). The specific secretase
determines the pathway in which the APP will continue. If APP is first cleaved by αsecretase, it will then continue through the non-amyloidogenic pathway. The α-secretase
cleaves the APP, within the Aβ domain, creating a soluble amino-terminal ectodomain
(sAPPα) and a carboxyl-terminal domain within the cell membrane (Selkoe, 2001).
When the α-secretase cleaves in the middle of the Aβ domain, it prevents the formation
of intact Aβ (Sisodia et al., 1990). The carboxyl-terminal domain is then cleaved within
the membrane by a second secretase, known as γ-secretase. γ-secretase is a multiprotein
complex, which contains 4 different proteins including presenilin 1 (PS-1), an aspartyl
protease which carries out the catalysis, nicastrin, APH-1 and presenilin 2 (PS-2). When
the complex is formed, it becomes an active enzyme complex which catalyzes the
cleavage within the transmembrane APP domain (De Strooper et al., 1998, Edbauer et al.,
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2003). In the nonamyloidogenic pathway, the cleavage by γ-secretase leaves a short
fragment, known as the P3 fragment and an APP intracellular domain (AICD). The
second pathway in that APP can pursue is the amyloidogenic pathway. In this pathway,
the APP is first cleaved by β-secretase, which only acts upon APP that has not already
been cleaved by α-secretase (Selkoe, 2001). β-secretase is known as β-site APP-cleaving
enzyme (BACE-1). BACE-1 is an aspartyl protease and its activity is present in most
tissues (Haass, 2004). BACE-1 cleaves near the amino-terminus of the Aβ domain, at or
near the cell surface (Haass, 2004, Seubert et al., 1993). This initial cleavage creates a
slightly shorter amino-terminal ectodomain (sAPPβ) and a slightly longer carboxylterminal domain within the cell membrane. The carboxyl-terminal domain created by the
cleavage of β-secretase can then be cleavage by γ-secretase. Cleavage by the γ-secretase
in the amyloidogenic pathway creates the same AICD as in the nonamyloidogenic
pathway but also creates the Aβ fragment that is 39-42 amino acids in length (Figure 1.4)
(Nixon, 2007, Selkoe, 2001).
The Aβ fragments that are most abundantly produced by the cleavage of APP are
Aβ(1-40) followed by Aβ(1-42). These peptides are found in low concentrations
(nanomolar) in normal individuals’ CSF. The Aβ peptides are also found in other
biological fluids and cell culture medium during normal circumstances of APP
processing. Even though these two isoforms have very similar primary structures, their
biophysical properties are very different. Aβ(1-42) is widely known as the isoform that is
highly fibrillogenic and more prone to aggregate compared to Aβ(1-40) (Pauwels et al.,
2012). This leads to the belief that AD may be due to impairment in the balance between
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Figure 1.4. APP proteolytic processing and generation of Aβ fragments (modified
from (Nixon, 2007)). The proteolytic cleavage of APP requires the activity of α-, β(BACE-1), and γ-secretase. α-secretase cleaves the APP transmembrane protein creating
a soluble APP fragment (sAPPα) and leaves an 83-amino acid C-terminal fragment
within the membrane. BACE-1 cleavage also results in a soluble APP fragment (sAPPβ)
and a membrane spanning C-terminal fragment, however the sAPPβ is slightly shorter
than the sAPPα and this membrane spanning C-terminal fragment is 99 amino acids in
length. The resulting C-terminal fragments can then be further processed by γ-secretase.
γ-secretase processing after β-secretase cleavage creates an amyloidogenic peptide that is
39-42 amino acids long. This cleavage also generates an APP intracellular domain
(AICD) (Nixon, 2007).
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the production of Aβ and its ability to be cleared (Haass et al., 1994, Seubert et al., 1993,
Shoji et al., 1992, Walsh et al., 2000), which raises the possibility that proteins involved
in the amyloidogenic processing of APP could be a good choice for drug targets against
AD.

1.5 Genes Associated with the Development of AD
The majority of AD cases are seen in patients over the age of 65 and known as
late-onset AD (LOAD); however, familiar cases of AD have also been identified. The
familiar or hereditary cases are seen at earlier stages of the patient’s life and are primarily
documented as early-onset AD (EOAD). There are four different known genes that cause
all heritable AD cases: APP, PS1, PS2 and ApoE. Mutations of the initial three genes
have been linked to rare, autosomal dominant forms of AD and are associated with less
than 1% of all known AD cases (Daw et al., 2000, Selkoe and Podlisny, 2002, Thies and
Bleiler, 2013). APP, PS1 and PS2, discussed earlier in Section 1.4, play a role in APP
processing and the production of Aβ through the amyloidogenic pathway. Mutations in
these genes have shown to generate the 42 amino acid Aβ peptide to a greater extent
(Selkoe and Podlisny, 2002).
Mutations within the APP gene are heterozygote mutations, where the mutation is
of only one allele. The mutations within the APP gene that cause AD occur at or near α-,
β-, and γ-secretase cleavage sites (Selkoe and Podlisny, 2002) (Figure 1.5). These
mutations result in an increase in overall Aβ peptide (Citron et al., 1992), an increase of
Aβ(1-42) over Aβ(1-40) (Scheuner et al., 1996) and/or an increase in the aggregation
propensity (Fraser et al., 1992, Selkoe and Podlisny, 2002). There are also known
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mutations located near the middle of the Aβ sequence of APP clustered around the central
hydrophobic region of the Aβ peptide (Selkoe and Podlisny, 2002). Five point mutations
have been associated with hereditary diseases that are similar to or identical to AD.
These mutations include: A21G Flemish mutation, E22K Italian mutation, E22G Arctic
mutation, E22Q Dutch mutation and the D23N Iowa mutation (Figure 1.5). The intra-Aβ
mutations impact the production, degradation and aggregation of the Aβ peptide;
therefore, all the factors that regulate Aβ monomer levels (Betts et al., 2008, Hendriks et
al., 1992, Levy et al., 1990).
Recently, a mutation within the APP gene has been discovered that actually
protects against the development of AD and cognitive decline. This gene mutation
(A673T) leads to a 40% reduction in the processing of the amyloidogenic pathway and
formation of the causative Aβ peptide (Tiiman et al., 2013). The mutation is located next
to the β-secretase cleavage site in the APP gene; therefore, it reduces the cleavage of APP
by β-secretase and protects against the disease (Jonsson et al., 2012).
Around the same time that the APP gene mutations were being discovered,
research was suggesting a link between the presence of EOAD and chromosome 14.
Soon thereafter, another homologous gene on chromosome 1 was found to be the site of
missense mutations in EOAD patients. The two genes were renamed PS1 and PS2
(Selkoe and Podlisny, 2002). PS1 and PS2 encode for homologous transmembrane
proteins localized in the ER (Haass, 1997, Schon and Area-Gomez, 2010) and make up
part of the enzyme complex of γ-secretase, as mentioned above. ELISA studies showed
that AD patients from pedigrees with PS1/PS2-linked mutations have a significantly
higher extracellular ratio of Aβ(1-42) to Aβ(1-40) compared to family members who are
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B

Figure 1.5. APP structure and mutations. (Panel A) Represents the hypothetical 3dimensional structure of APP based on the protein data bank files of each individual
domain (Dawkins and Small, 2014). (Panel B) This figure points out the α-, β-, and γsecretase cleavage sites and the transmembrane domain of APP. The known sites (amino
acids) for missense mutations are indicated in the table, along with the given name of that
particular mutation and effect to the levels of Aβ (Ghosh and Osswald, 2014).
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unaffected by AD (Scheuner et al., 1996). Similar results were found when observing
transfected cells and transgenic mouse models that co-expressed human PS and APP
genes. Cells transfected with PS1 or PS2 mutants showed an increase in the Aβ(1-42)
secretion, while PS1 transgenic mice showed overproduction of Aβ(1-42) within the
brain. In this study, different PS mutations were observed and all showed differential
effects on the production of Aβ. However, they all showed a dominant gain in function
by increasing the production of Aβ(1-42) and therefore increasing the amount of cerebral
β-amyloidosis (Citron et al., 1997). A double missense mutation (K595N/M596L) has
also been observed in a Swedish AD family. In transfected cell lines and primary skin
fibroblast, this double missense mutation initiated an increase of the overall amount of
Aβ released into the conditioned media and an increase of BACE-1 activity (Citron et al.,
1995). Missense mutations in PS1 cause the earliest and most-aggressive forms of AD.
These patients are known to have the onset of symptoms in the fifth decade of life and
most likely to face death in the sixth decade. PS2 mutations, on the other hand, usually
start showing symptoms slightly later in life (Selkoe and Podlisny, 2002).
The fourth gene associated with sporadic and familiar AD is apolipoprotein E
(ApoE). ApoE is important in the regulation of plasma lipoprotein metabolism and is
found in the liver and central nervous system (CNS) (Holtzman et al., 2000). This
protein is located on chromosome 19 and has three common known alleles in humans: ε2,
ε3 and ε4 (Corder et al., 1993, Holtzman et al., 2000, LaDu et al., 1994). In AD, the ε4
allele has shown to be a genetic risk factor, while ε2 allele has shown to be protective
(Cleary et al., 2005, Corder et al., 1993, Holtzman et al., 2000). Data has revealed that
ApoE-ε4 is an important factor in the etiology of over half of all AD patients. It is
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estimated that between 40% and 65% of people with AD have one or two copies of the
ApoE-ε4 gene (Thies and Bleiler, 2013). ApoE has been discovered to accumulate
extracellularly in the senile plaques and intracellularly in the NFTs (LaDu et al., 1994),
which may suggest that ApoE may be involved in the formation of these lesions
(Strittmatter et al., 1993). There have been many different mechanisms which have
explained the ApoE isoform dependency on the predisposition to AD, including variation
in total Aβ concentrations, the formation and clearance of plaques, formation of tau
tangles, and the impairment of neuronal signaling pathways (Beffert and Poirier, 1996,
Buttini et al., 2002, Herz and Beffert, 2000, Holtzman et al., 2000, LaDu et al., 1994).
The clearance of Aβ has shown dependency on the ApoE isoforms with the amount of
clearance being in the order of 4<3<2 (Ulrich et al., 2013). Many mechanisms have been
proposed how each ApoE isoform contributes to the pathogenesis of AD, but the exact
mechanism still remains unknown. However, many in vitro and in vivo genetic studies
have shown importance in implicating AD and provide a basis for potential therapeutic
approaches.

1.6 Mechanisms of Aβ Aggregation
Aβ is formed by the proteolytic cleavage of APP by β- and γ-secretase (Nixon,
2007, Selkoe, 2001). The Aβ peptide was able to be isolated, purified, and characterized
from the post mortem brain of AD patients in 1985. Using techniques like liquid
chromatography and Western blot, it was discovered that the Aβ peptide monomers are 45 kDa in size (Masters et al., 1985). Under normal physiological conditions the
monomeric Aβ peptide is highly soluble, but by a mechanism that is not fully understood
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the Aβ starts to aggregate and form amyloid deposits within the brain (Jarrett et al.,
1993).
The main focus of research on the Aβ peptide has been on its ability to aggregate
and form fibrils as well as its role in neurodegeneration. Many research groups have
shown that synthetic Aβ peptides are able to form fibrils in vitro that are
indistinguishable from the fibrils that have been isolated from AD brains (Halverson et
al., 1990, Hilbich et al., 1991, Kirschner et al., 1987). These realizations led to further
investigations on understanding the structural and functional properties of fibril
assembly, such as aggregation mechanism, kinetics, and intermediates. During the past
decade, studies have used X-ray fibril diffraction (XRD) (Madine et al., 2008), solid state
nuclear magnetic resonance (SSNMR) (Lynn and Meredith, 2000, Middleton, 2011),
spectroscopic methods (Fernandez-Busquets et al., 2008) and molecular dynamics to
explore the conformation and aggregation of Aβ peptides. The C-terminus of Aβ
contains 14 consecutive hydrophobic residues, along with the prevalence of residues
valine and isoleucine, which are β-branched residues, and glycine every fourth residue.
The β-branched residues are satirically constrained and allow for extension of
conformation, therefore likely populating the β-sheet structure of the Aβ fibrils (Jarrett
and Lansbury, 1992). Due to the conformational flexibility of the glycine residue, the Aβ
peptide may be able to obtain confirmations that are not normally populated by
crystalline proteins (Chou et al., 1982, Jarrett and Lansbury, 1992).
Aβ aggregation studies have provided knowledge on the process in which the
monomer noncovalently self-assembles into higher-ordered Aβ morphologies. However,
these studies have been limited by the capability or sensitivity of certain techniques.
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Early methods included turbidity or retention of the insoluble filtrate to observe fibril
formation, but these were limited to only observing the final insoluble stages of
aggregation (Bush et al., 1994, Jarrett et al., 1993). Thioflavin T (ThT) fluorescence and
atomic force microscopy (AFM) or electron microscopy (EM) can also be used to
observe Aβ aggregate but they have limitations too. ThT is dependent on the
concentration, size and extent of fibrillar structure; as the fluorescent compound does not
bind to oligomeric Aβ as well as fibrillar Aβ (Lee et al., 2011). Microscopic techniques
have been shown to be less effective at imaging lower-ordered Aβ species. AD research
has recently been focused on understanding the soluble oligomeric and protofibrillar Aβ
species and the use of conformation-specific antibodies to detect specific aggregated
species not only in solution, but also in human tissue and CSF. Conformation-specific
antibodies has been one strategy that has shown significant sensitivity (Coalier et al.,
2013, Gong et al., 2003, Kayed et al., 2003, Lee et al., 2006).
Similar to crystallization, amyloid formation follows a nucleation-dependent
kinetic mechanism which results in ordered protein polymerization. This mechanism is
kinetically controlled by the nucleation and elongation rates of the Aβ peptide (Jarrett and
Lansbury, 1992). The first step in the nucleation-dependent polymerization is the
formation of a nucleus, seed, or paranuclei, which are the initial and minimal structure for
Aβ assembly (Figure 1.6). The nucleus formation is a slower phase and represents the
lag phase before the addition of monomers to the previously formed nucleus resulting in a
linear growth phase and formation of protofibrils and eventually fibrils. The equilibrium
between the monomer and the paranucleus is very rapid, which was proven by its
presence immediately after the peptide was resuspended. The paranuclei can also
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oligomerize by themselves to form larger beaded oligomers. The extent of the lag phase
is dependent upon the concentration of the Aβ monomer. The conversion to protofibrils
is slower due to the fact that the monomers, paranuclei and large oligomers are
predominately unstructured and have to undergo substantial conformation rearrangement
to predominately β-sheet/β-turn structures. The final stage is the maturation of the
protofibrils to fibrils, where the fibrils will reach a plateau and the monomer is at
equilibrium with the fibrils (Figure 1.6) (Bitan et al., 2003, Burdick et al., 1992, Jarrett
and Lansbury, 1992). Circular dichroism (CD) analysis has provided evidence in which
the soluble morphologies transition structurally from predominately random coil, as
monomer, to increasing amounts of β-sheet structure and continue to eventually produce
insoluble fibrils (Harper et al., 1999, Walsh et al., 1999).
Burdick and colleagues showed that the length of the hydrophobic carboxyl
terminus is an important parameter for assembly of the Aβ peptide into amyloid
structures, but so are pH, peptide concentration and time of incubation. pH has been
shown to affect both the rate and the extent of Aβ assembly. The sequence of Aβ has an
equal number of acidic residues (aspartic acid and glutamic acid) and basic residues
(lysine, arginine, and histidine) and a predicted isoelectric point of approximately 5.18 –
5.31 (Burdick et al., 1992, Hortschansky et al., 2005). The pH range of insolubility can
be explained by the precipitation of the peptide when the net charge is close to zero
(Burdick et al., 1992).
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Figure 1.6. Aβ assembly model (Bitan et al., 2003). The monomer rapidly forms into a
paranuclei, which oligomerizes into a larger beaded structure. The equilibrium between
monomer and the paranuclei is very rapid whereas the formation to protofibrils is slower
but also reversible. There are many different pathways in which the protofibrils may
form and this “linear” pathway many not be the only one. However the final step in the
overall pathway is the maturation of the protofibril into fibrils.
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1.7 Aβ Aggregation Kinetics
As mentioned above, the Aβ protein undergoes nucleation-dependent
polymerization. This process is characterized by a slow nucleation phase, a growth
phase, and a steady state phase. The nucleation, or lag phase, occurs when the protein
undergoes multiple unfavorable association steps to form an ordered oligomeric nucleus
(Harper and Lansbury, 1997, Nilsson, 2004). This rate-determining, or slowest, step may
be the one of the keys to understanding AD because it may be responsible for protecting
the normal individuals from amyloid formation. The growth phase occurs when the
nucleus quickly grows to form larger polymers. The steady state phase occurs when the
fibrils and monomers reach equilibrium. During this process, polymers are unable to
form until the monomer concentration is above its critical concentration (Harper and
Lansbury, 1997). Identifying the key steps and knowing the numerical values of
nucleation and elongation rates in the formation of fibrils may aid in revealing promising
therapeutic targets for inhibition.
Studies have shown that fibrillogenesis pathways may differ depending on
whether or not the protein concentration (C) is above or below its critical concentration
(c*) (Lomakin et al., 1997), which is determined by measuring the concentration in which
the rate of fibril formation and dissolution are equal (Harper and Lansbury, 1997). When
C > c*, the initial rate of elongation is independent from the concentration, also when the
concentration is much greater then c*, the fibril size is also independent of total protein
concentration. However, when C < c*, the elongation rate is proportional to the
concentration and the fibril size surpasses the size of the fibrils when C > c* (Lomakin et
al., 1997).
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The critical concentration should be equal to the remaining Aβ concentration after
reaching equilibrium and formation of amyloid fibrils. When comparing the critical
concentration of Aβ(1-40) and Aβ(1-42), it was found that Aβ(1-42) has a critical
concentration which is five-times lower than that of Aβ(1-40) (Harper and Lansbury,
1997). However, these concentrations are higher than the concentrations observed in
vivo. In vivo concentrations are in the nanomolar range. Therefore, it is thought that in
vivo there is local supersaturation which allows the nucleation and polymerization to
occur in cellular compartments (Harper and Lansbury, 1997, Jarrett and Lansbury, 1992,
Lomakin et al., 1997).

1.8 Amyloid Cascade Hypothesis

1.8.1 Original Hypothesis
The amyloid cascade hypothesis was first declared by Hardy and Higgins in 1992.
The purpose of the hypothesis was to provide a possible sequence of events that would
lead to the development of AD. Their hypothesis stated that the deposition of the Aβ
protein is the cause of Alzheimer’s pathology. They claimed that the Aβ protein
deposition directly results in the presence of NFTs, cellular loss, vascular damage, and
dementia (Giacobini and Gold, 2013, Hardy and Higgins, 1992, Selkoe, 2000, Tamaoka,
2013). In this hypothesis, there are two sequential events which must happen to produce
AD pathology. First, the Aβ has to be generated and then the peptide must enable or
cause neuronal death and formation of NFTs (Hardy and Higgins, 1992). This causative
hypothesis has also been implicated in other neurodegenerative diseases, such as
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Parkinson’s disease (Tiiman et al., 2013). Numerous studies have provided confirmation
as to why this hypothesis may be true. The most prevalent evidence is genetics (Tiiman
et al., 2013). Another indication is the presence of AD in Down syndrome patients
caused by trisomy of chromosome 21, which contains the APP gene. This shows that
deposition of Aβ is probably an early event in the disease (Mann et al., 1989). In vitro
studies suggested that the Aβ peptide is neurotoxic by itself, while others have shown that
Aβ provoked neurotoxicity by causing the neurons to be more sensitive to excitotoxic
damage (Kowall et al., 1991, Pike et al., 1991, Roher et al., 1988, Yankner et al., 1989).
One possible mechanism for Aβ to promote neuronal loss is through the known
disruption of calcium homeostasis and increased intraneuronal calcium concentration.
Therefore, it is possible that the Aβ peptide may induce NFTs through its ability to
increase the concentration of intracellular calcium (Lee et al., 1991).
Mutations within the APP gene only account for a small portion of AD cases;
therefore indicating that most AD cases are sporadic, which suggests other causes of the
disease. According to the amyloid cascade hypothesis, these other causes will most
likely act by prompting the deposition of the Aβ peptide; one example may be the
relationship between accidental head trauma and the presence of AD where the amyloid
deposits due to the response to neuronal injury (Mortimer et al., 1991). These studies
show that the Aβ peptide is the most likely candidate for the initiation of the cascade of
events leading to AD; however, the entire process takes a long time for the development
of the full disease. Future studies in transgenic mice and further discoveries of additional
mutation in APP and other genes associated with AD will aid in refining the amyloid
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cascade hypothesis and eventually help in finding new therapeutic targets for intervention
(Hardy and Higgins, 1992).

1.8.2 Evidence Contrary to the Amyloid Cascade Hypothesis
There is a general consensus that the Aβ peptide is pivotal in the pathology of
AD, but there are still some questions left unanswered, such as what causes the Aβ
deposition into plaques, which Aβ morphology is most toxic and what are the
connections between the events that occur in the brain (Tiiman et al., 2013). While trying
to answer some of these questions, some recent findings revealed evidence that conflicts
with the original amyloid cascade hypothesis and lead to the identification of other
possible hypothesis. Some hypotheses trying to explain the cause of AD are the neuronal
cytoskeletal degeneration hypothesis, oligomeric hypothesis, cholinergic hypothesis,
inflammation hypothesis, oxidative damage hypothesis, mitochondrial dysfunction
hypothesis, and metal hypothesis (Tiiman et al., 2013).
The most evident conflict is the postmortem analysis of non-demented (ND)
elderly control patients, AD patients, and high pathology control (HPC) patients showed
that there was no correlation between the amount of amyloid plaques and the cognitive
decline of the patient. The HPC patients were chosen by meeting certain pathological
criteria, but no synaptic loss or symptoms of dementia (Lue et al., 1999, Naslund et al.,
2000). The data showed that plaque type was insignificantly different when comparing
the HPC and AD patients (Lue et al., 1999). Recent clinical reports have also shown a
significant number of human subjects who were cognitively normal, but still have the
presence of amyloid plaques within their brains (Morris et al., 2009, Rentz et al., 2010).
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Impairment and inhibition of LTP was also observed prior to or even independently of
complete plaque formation (Moechars et al., 1999, Mucke et al., 2000).
AD patients and mouse models of the disease have shown that the greatest
amount of synaptic loss is found near senile plaques (Koffie et al., 2009), providing
evidence supporting the original amyloid cascade hypothesis. However, many studies are
reporting that the early Aβ intermediates, such as oligomers and protofibrils, are the most
toxic species (McLean et al., 1999, Paranjape et al., 2012, Wang et al., 1999), supporting
the oligomeric hypothesis (Tiiman et al., 2013). These soluble species are hypothesized
to associate with postsynaptic density around the surface of the plaques, therefore causing
a loss of synapses and spines surrounding the plaques (Koffie et al., 2009). The toxicity
and synaptic loss caused by the intermediate species contradict the original amyloid
cascade hypothesis due to the presence of neuronal damage well before the formation of
the Aβ senile plaques.

1.8.3 Modified Amyloid Hypothesis
As mentioned above, extensive work has recently been aimed at understanding
the pathways leading to AD and a lot of that effort has been recently focused on the
intermediate species. Co-localization imaging techniques have shown the presence of Aβ
oligomers and neuronal loss surrounding the senile plaques (Koffie et al., 2009). It has
also been found that neuronal death can be mediated by the tau protein (Roberson et al.,
2007). Due to all of the reports, either for or against, the original amyloid cascade
hypothesis indicates that AD is a very complex process and even though Aβ deposition
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may be one of the main triggers of AD, there could be a combination of factors that all
contribute to the final pathology (Figure 1.7).
In 2011, Hyman suggested that the amyloid hypothesis needed to be reformulated.
Hyman proposed a two-stage process beginning with the initiation of a cascade by the Aβ
but followed by pathophysiological consequences that are independent of the initial Aβ.
If Hyman’s hypothesis is relevant, it would explain the number of individuals who have
accumulated amyloid plaques, but do not show signs of dementia. A cross-sectional
autopsy study showed that the amount of amyloid deposition in the brain was similar
across a variety of clinical severity levels and the number of plaques that accumulate
seem to reach a plateau while neuronal loss, synaptic loss, and number of tangles increase
along with the disease. The first stage of this hypothesis is the local disruption of the
neutrophils, loss of dendritic spines, remodeling of neurites, and an inflammatory
response initiated by the Aβ peptide. The second stage is the continuing development of
the disease, including the presence of tangles, neuronal loss, synaptic loss, glial responses
in limbic and association cortices and eventually organ failure. AD may be adding to the
numerous other medical conditions in which the cause of the accumulating illness, such
as symptoms and life expectancy, can be separated from the initial insult. One example
is how the amyloid deposition causes an increase in calcium dyshomeostasis, oxidative
stress, and mitochondrial dysfunction, which together can activate other signaling
pathways in the immune and nervous systems. This both explains the failure of drugs
designed to target Aβ taken after cognitive impairment has already developed and gives
insight to new therapeutic targets which need to be based on the specific stage of
progression (Hyman, 2011).
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Figure 1.7. Modified amyloid cascade hypothesis (Giacobini and Gold, 2013). The
pathway provided in this figure indicates the roles of both Aβ and tau oligomeric
aggregates as soluble neurotoxic species that possibly lead to the formation of amyloid
plaques and NFTs, respectively. This also includes one of the remaining questions of
whether or not Aβ plays a role in triggering tau toxicity resulting in the formation of
PHFs and neuronal loss. Lastly this figure recognizes the fact that tau pathology may be
able to proceed independently of Aβ, by the direct hyperphosphorylation (Giacobini and
Gold, 2013)
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1.9 Aβ Morphologies

1.9.1 Aβ Fibrils
The Aβ peptide is able to form many different species through non-covalent
interactions, which gives rise to β-sheet secondary structure (Walsh et al., 1999). XRD
analysis of filamentous protein of amyloid deposited tissue showed the presence of a
cross-β pattern. The interpretation by Eanes and Glenner in 1968 was that the amyloid
polypeptide formed a pleated sheet and folded upon itself, so that adjacent peptide
segments were laterally arranged in an antiparallel manner. It was also observed that the
axes of the peptide ran transversely to the axis of the filament (Eanes and Glenner, 1968).
Since then, several other techniques, such as electron diffraction, cryogenic EM,
proteolysis, chemical cross-linking, and mutagenesis have supported the presence of the
cross-β structure of the amyloid fibrils (Serpell et al., 2000, Sunde and Blake, 1997).
The amyloid fibrils are rigid, unbranched, resistant to denaturation and
birefringent when stained with Congo Red (Lansbury et al., 1995). The insoluble and
non-crystalline nature of the fibrils makes them unsuitable for high resolution techniques,
such as solution-phase nuclear magnetic resonance (NMR) and x-ray crystallography
(Benzinger et al., 1998). Therefore, selective incorporation of 13C into the polypeptide
backbone allowed for the use of Fourier-transform infrared spectroscopy (FTIR) and
SSNMR to further observe the fibrillar structural details. Early structural analysis of a
nine-residue peptide, Aβ(34-42), by SSNMR predicted antiparallel β-sheet structure with
alternating hydrogen bond registries (Lansbury et al., 1995). SSNMR analysis of a
longer Aβ peptide, Aβ(10-35), showed the presence of parallel β-sheet structure
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(Benzinger et al., 1998) in accordance with multiple quantum (MQ) NMR and SSNMR
of Aβ(1-40) and Aβ(1-42) (Antzutkin et al., 2002, Antzutkin et al., 2000, Balbach et al.,
2002). Other techniques such as EM, scanning transmission electron microscopy
(STEM), XRD, electron paramagnetic resonance (EPR) and Hydrogen/deuterium
exchange mass spectrometry (HDX-MS) further supported the observation of parallel βsheet structure of the longer to full length Aβ peptides, while shorter fragments of the Aβ
peptide including Aβ(16-22), (34-42), and (11-25) continued to adopt the antiparallel βsheet structure (Balbach et al., 2000, Petkova and Tycko, 2004).
One of the most widely known structural models of Aβ was composed from
SSNMR data of Aβ(1-40) fibrils, which incorporated the intermolecular distances and the
cross-β motif that is common to all amyloid fibrils. There are several significant features
of this model. The model omits residues 1-8 because the N-terminus of the peptide has
been found to be unstructured. The structure has a 180° bend formed by residue 25-29
which separates two β-strands. The residues that make up the core of the fibril structure
are neutral and primarily hydrophobic with the exception of D23 (aspartic acid) and K28
(lysine), which form a salt bridge across the bend of the fibril. There are also a few
charged and polar side chains which are distributed on the outer surface of the fibril
(Figure 1.8) (Petkova et al., 2002).
Further evaluation of the Aβ fibrils has shown that they commonly exhibit
multiple distinct morphologies. This polymorphism could result from individual modes
of lateral association of protofilaments without significant changes is the molecular
structure or from variations in the molecular structure at the protofilament stage. Most of
the data defends the possibility that the variation is from the molecular structure of the
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Figure 1.8 Structural model for Aβ(1-40) fibrils (Petkova et al., 2002). Panel A. a
schematic of a single molecular layer, or cross-β unit. The yellow arrow shows the
direction of the long axis of the fibril, which matches the direction of the intermolecular
backbone hydrogen bonds. The cross-β unit is a double-layered structure with in-register
parallel β-sheets, represented here by the orange and blue ribbons, residues 12-24 and 3040, respectively. Panel B. Aβ(1-40) residues 10-40. The colors are coded on the basis of
their side chains as hydrophobic (green), polar (magenta), positive (blue) and negative
(red).
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protofilaments due to their morphology and molecular structures being sensitive to
environmental elements during fibril growth, such as pH, temperature, buffer
composition, and concentration. (Petkova et al., 2005, Shivaprasad and Wetzel, 2006,
Stine et al., 2003, Tycko, 2011).

1.9.2 Aβ Protofibrils
An attempt to structurally and kinetically characterize the beginning stages of Aβ
fibrillation discovered additional Aβ intermediates. These intermediates were termed
protofibrils. With the use of AFM, the Aβ(1-40) protofibrils were measured at a diameter
of 3.1 nm, while the Aβ(1-42) protofibrils were measured at 4.2 nm in diameter (Harper
et al., 1997). By TEM, the protofibrils were found to be predominately small, soluble
curvilinear structures that were 4-10 nm in diameter (Walsh et al., 1997) and less than
200 nm in length (Harper et al., 1997, Walsh et al., 1997). When observing the kinetics
of the protofibril formation and disappearance, it was confirmed that they were
intermediates in the pathway to amyloid fibrils (Walsh et al., 1997).
Further observations of the protofibrils concluded that protofibrils irreversibly
mature into fibrils. In these studies, the protofibrils were examined by ThT fluorescence
and CD. The ThT dye is dependent on β-sheet structure and showed that the protofibrils
had significant β-sheet structure (Paranjape et al., 2013, Walsh et al., 1999), while the CD
data showed that both the protofibrils and fibrils had extensive and equivalent amounts of
β-sheet structure with less random coil and the least amount of α-helix. During the
process to fibrils, there is a transitory α-helical component, where the Aβ transitioned
from predominately random coil to an increase in α-helix and finally to a predominately
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β-sheet structure. The hydrophobic core is an important portion of the Aβ peptide during
the formation of protofibrils. This was evident by the substitution of residues within the
hydrophobic core with glycine or proline, two residues known to destabilize β-sheet
structure. These substitutions caused the peptide to no longer form protofibrils (Hartley
et al., 1999, Kheterpal et al., 2003). The core hydrophobic residues were also shown to
be protected after the peptides formed the protofibril structure. HDX-MS revealed that
40% of the amide protons within the hydrophobic core were protected and the amount of
protection increased as the peptide transitioned from monomer, to protofibril and
eventually to fibril (Kheterpal et al., 2003).
The transition from protofibrils to fibrils was thought to involve some structural
organization. One observed structure was the “beaded” substructure due to the
periodicity of the protofibrils (Walsh et al., 1999). The periodicity was first observed by
Harper and colleagues in 1997 by AFM. Harper observed periodicity of both Aβ(1-40)
and Aβ(1-42) to be about 22 nm (Harper et al., 1997). A couple years later, Walsh used
rotatory shadowing and TEM of the protofibrils and observed a beaded pattern of 3-6 nm
(Walsh et al., 1999).
The hydrodynamic radius (RH) of the Aβ(1-40) protofibrils were initially 27.8 ±
1.8 nm and over time grew to 80.6 ± 14.4 nm (Walsh et al., 1999), while the Aβ(1-42)
protofibril were determined to have a RH of 21.9 ± 4.0 nm (Paranjape et al., 2013). Size
exclusion chromatography (SEC) has been used for many years to separate the
protofibrils from the lower molecular weight or monomeric Aβ. The separation on a
Superdex 75 column elutes the protofibrils in the void volume, while the monomers elute
later in the included volume. The protofibrils have consistently been formed at a
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physiological pH and in a solution with considerable ionic strength (Paranjape et al.,
2013, Walsh et al., 1999). Ionic strength is important in the length of the protofibrils
along with the rate at which the protofibrils elongate (Harper et al., 1999). In agreement
with the many studies showing that Aβ(1-42) aggregates more rapidly than Aβ(1-40), it
was observed by SEC that the Aβ(1-42) protofibrils were able to form very rapidly, while
the Aβ(1-40) require an incubation time of 24 hours. The SEC protofibril peak showed
an increase in time, while the monomer peak decreased simultaneously; however, both
peaks eventually decreased indicating the formation of fibrils and confirming that the
protofibrils are intermediates of fibrillogenesis (Paranjape et al., 2012).
Protofibril elongation has been found to be first-order in [Aβ]. This measured
first order relationship is from the elongation of monomeric Aβ adding to the growing
protofibril ends (Harper et al., 1999) without an increase in the protofibril diameter
(Nichols et al., 2002). The elongation process of the protofibrils may be more complex
with the possibility that protofibrils may elongate by the coalescence of existing
protofibrils (Harper et al., 1999). It has also been seen that the protofibrils association
can occur through lateral association which results in a disordered fibril structure
(Nichols et al., 2002).

1.9.3 Aβ Oligomers
The soluble Aβ oligomers are another intermediate formed by the Aβ peptide and
have been isolated from the brain, plasma, CSF, transfected cells, and cells derived from
human brain (Stine et al., 2003). AFM of Aβ(1-42) oligomers showed the appearance of
small punctate globular structures with a diameter of 2-5 nm (Dahlgren et al., 2002,
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Kayed et al., 2003, Stine et al., 2003). The molecular mass of the oligomers were also
observed to range from 10-100 kDa (Roher et al., 2000). Oligomers are a representation
of a protein micelle (Kayed et al., 2003) of as few as two molecules or as many as tens of
molecules (Pham et al., 2013). These structures include Aβ dimers, trimers, tetramers,
hexamers, and dodecamers, and even some larger oligomers with spherical or annular
morphologies; however, determining the structure of full-length Aβ oligomers at atomic
resolution has been agonizing (Pham et al., 2013). The Aβ oligomers form this structure
due to its amphipathic surface. The formation of the oligomer is dependent on a critical
concentration and correlates with the hydrophobicity of the environment (Kayed et al.,
2003). The assembly of the oligomers seems to form under conditions that block fibril
formation (Lambert et al., 1998).
The mechanism the oligomers go through to cause neurodegeneration in AD is
still not fully understood, but a few of the plausible mechanisms consist of binding to
cell-surface receptors, the generation of pores or channels in the cell membrane, or
perturbing the membrane structure (Pham et al., 2013). Data has shown that the
oligomers are able to kill hippocampal neurons at concentrations as low as the nanomolar
range (Lambert et al., 1998). There is also previous data supporting the existence of
synaptic toxicity caused by oligomers. Oligomers have been found, by multiphoton in
vivo imaging with oligomer-specific antibodies, surrounding the dense plaques in the
brain, forming a halo. This is relevant due to the presence of neuronal loss in the
immediate region of the oligomeric halo (Koffie et al., 2009). These observations
support the oligomer hypothesis and explain the presence of neuronal loss before the
detection of plaque formation.
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1.10 AD and Inflammation
Despite which cascade hypothesis is correct, the two pathological hallmarks are
not sufficient for the full development of the neurodegenerative pathology that is
observed in AD transgenic animals (Rogers et al., 1996). Recently, inflammation within
the brain has been accepted as a hallmark of AD. The inflammation refers specifically to
the innate inflammatory response by the nervous system in an attempt to clear the
different Aβ pathological species (Rogers, 2008). The innate immune system is the
body’s first line of defense against pathogens. The innate immune system is in the CNS
and is made up of macrophages, neutrophils, dendritic cells, natural killer cells, and
microglia (Kielian, 2006). An inflammatory response involves many different processes
including removal of debris and healing (Ferrero-Miliani et al., 2007). The majority of
the time, an innate immune response is self-limiting, but in some cases and in some
diseases the inflammatory response can linger and cause a state of chronic inflammation.
Rather than being beneficial to the host, a chronic state of inflammation can actually
become detrimental to the host. In AD, if the innate immune system is unable to remove
its activated trigger, then it can lead to a chronic state of inflammation. This chronic state
of inflammation has been suggested to be one of the primary mechanisms leading to the
neurodegeneration in AD and has even been suggested to intensify the amount of Aβ
deposition (Golde, 2002). One piece of evidence suggesting that the innate immune
system is involved in AD is the presence of activated immune cells, such as microglia
and astrocytes, and proinflammatory markers within and surrounding the Aβ deposits in
the brain (Figure 1.9) (Barton, 2006, Heneka and O'Banion, 2007, Rogers et al., 1996);
however, how or when inflammation arises during the course of AD is not fully
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Figure 1.9. Activated microglia surrounding the senile plaque (Barton, 2006). Bone
marrow derived microglia (green fluorescent protein-green) are attracted to the senile
plaque (red) and are able to clear some of the Aβ by phagocytosis. The nuclei of the
microglia are stained blue.
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understood (Akiyama et al., 2000).

1.11 Cells Involved in Causing Inflammation in AD

1.11.1 Neurons
Neurons were not originally thought of as immune cells; however, more recent
data has shown that neurons exhibit more abundant signal for complement mRNAs than
any other cell type in the AD brain. Neurons can express virtually all the proteins like
interleukins (IL-1 and IL-6), tumor necrosis factor-alpha (TNFα) and macrophage
colony-stimulating factor (M-CSF). Studies have indicated that there is an increase of
neuronal proteins in AD brains compared to control brains. Due to the increase of these
proteins, it was thought that the neurons might contribute to exacerbation of the AD
pathology along with microglia and astrocytes. The activation of neurons by TNFα
induces the expression of protective molecules, including manganese superoxide
dismutase (MnSOD). Neurons also have a high expression of APP and are suggested to
be the primary source of brain Aβ (Akiyama et al., 2000).

1.11.2 Glia
Glia were once overlooked as supportive elements of the nervous system;
however, these non-neuronal cells have recently been more appreciated due to their
ability to integrate neuronal inputs and modulate synaptic activity. The glia of the CNS
consists of microglia, astrocytes, and oligodendrocytes. Altogether, these cells are
responsible for neuronal homeostasis, synaptic plasticity and repair (Haydon, 2001).
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1.11.2.1 Astrocytes
Astrocytes are highly numerous and have many divergent roles within the CNS
(Haydon, 2001). Astrocytes are the major glial cell type of the CNS and can participate
in an inflammatory response; however, their immune responses are more limited due to
the fact that they are not classical immune cells (Hanke and Kielian, 2011). Astrocytes
are closely associated with the neurons of the CNS and can wrap around the synaptic
terminals and have extensive contacts with endothelial cells from the capillaries. They
are located within the brain and participate in the signaling between astrocyte-astrocyte,
neuron-neuron, and neuron-capillary (Haydon, 2001).
Astrocytes have been found to play a vital role in the maintenance of synaptic
plasticity, which is linked to cognitive processing in the brain. They are located near
many central synapses and are able to respond to many neurotransmitters, including
glutamate by an increase in the intracellular calcium levels. In return, the astrocytes
release glutamate and other neuroactive molecules that affect the neuronal activity and
modulate the strength of the synapse (Schummers et al., 2008). Glia are thought to play
an import role in the antioxidant defense within the brain because of their highly resistant
nature to oxidative stress compared to neurons. In subcultures of both neurons and glia,
the glial cells protect the neurons from hydrogen peroxide (H2O2) toxicity via
maintenance of the neuronal glutathione levels or by scavenging the free radicals (IwataIchikawa et al., 1999, Langeveld et al., 1995). It was also shown that conditioned media
from glial cells were able to promote the survival and differentiation of neuronal cells and
protect them from L-DOPA toxicity (Engele et al., 1991, Iwata-Ichikawa et al., 1999,
Mena et al., 1996).
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Activated astrocytes up-regulate a number of different inflammatory molecules,
including cytokines, interleukins, growth factors, proteases and protease inhibitors
(Eddleston and Mucke, 1993). Several of these inflammatory molecules have been
recognized in the AD pathology and overexpression within astrocytes of these molecules
has been shown to increase Aβ deposition and behavioral decline (Wyss-Coray et al.,
1997). More recent studies have recognized that astrocytes may not produce cytokines
during activation, but are definitely the prevalent source of chemokines after an insult or
infection of the CNS (Hanke and Kielian, 2011). One study showed that Aβ was able to
stimulate the release of the chemokines that were then able to act as potent in vitro
microglial and macrophage chemoattractants (Johnstone et al., 1999).

1.11.2.2 Microglia
Microglia are the main immune cells within the CNS and make up as much as
12% of the cells within the CNS (González-Scarano and Baltuch, 1999). Microglia
originate from bone marrow (BM) and enter the CNS as monocytes (Barton, 2006). The
monocytes migrate through the blood-brain barrier (BBB) into the parenchyma during the
early embryonic stages of life and later stages of life and eventually differentiate into
microglia. Studies have shown that peripheral monocytes are able to cross the BBB in
response to an inflammatory stimulus and differentiate into microglia-like cells
indistinguishable from microglia (Malm et al., 2005, Simard and Rivest, 2004).
Microglia can structurally form many different morphologies in accordance to
their environment, such as round, amoeboid and ramified. Before this observation was
known, the nature and identity of the microglia were under much debate. Now it is
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remarkably clear that microglia are highly flexible and able to adapt both structurally and
functionally (Graeber, 2010, Graeber and Streit, 2010). SEM images of microglia on
different gold surfaces allowed detailed visualization of many different microglial
morphologies along with many short and branched processes projecting outward from the
microglial cell body. When measuring the length of some of the branches, it was shown
that they can range anywhere from 5 μm to 30 μm in length (Tan et al., 2014). Timelapse imaging using in vivo two photon imaging showed that microglia of even a normal,
healthy brain are constantly surveying the environment around them representing a
constant dynamic state instead of a resting state (Nimmerjahn et al., 2005). In the
presence of an injury or insult within the brain, the microglia respond by rapid and direct
expansion/growth of the processes towards the site of injury and initiate a signaling
cascade (Davalos et al., 2005).
Microglia are known to respond to traumatic injury or the presence of pathogen
associated molecular patterns (PAMPs), such as a bacterial coat or viral proteins (Colton
et al., 2006). The microglia then migrate to the specific site of injury where they begin to
proliferate and become activated. The activated microglia have increased levels of
antigens and also become phagocytic. Similar to macrophages of other tissues, the
microglia begin to release inflammatory cytokines, which in return amplify the immune
response by recruiting more microglia to the injured site (González-Scarano and Baltuch,
1999).
Microglia have a programed response to stimuli that includes the induction of
specific gene profiles and production of cytoactive factors, such as TNFα, nitric oxide
(NO), and IL-1. These cytoactive factors all protect against tissue invaders. Peripheral
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macrophages first phase of activation is “classical activation”. This phase involves Th-1
cytokines, such as interferon-γ (IFN-γ). At the site of injury and after the initiation of
classical activation, the microglia gene profile changes to start the production of antiinflammatory factors, such as IL-4, IL-13, IL-10, transforming growth factor –β (TGF-β)
and scavenger receptors (SR) for the activation of phagocytosis, which aids in tissue
repair and wound healing. The gene induction of IL-4 and IL-13 is known as alternative
activation. The second phase of activation produces genes like arginase 1 (AG1),
mannose receptors (MRC1) and genes associated with tissue remodeling, such as Found
in Inflammatory Zone 1 (FIZZ1) and chitinase 3-like-3 (YM1) (Colton and Wilcock,
2010, Nimmerjahn et al., 2005).
Activated microglia can be assessed by different markers, such as major
histocompatibility complex II (MHCII) and cell surface receptors CD11b, CD-45, and
peripheral benzodiazepine receptors (Colton and Wilcock, 2010). As the activation of
microglia is very important within the CNS and chronic microglia activation sustained
over a long period of time may result in microglia over-activation followed by microglial
degeneration. This phenomenon has shown an increase prevalence in AD and in Down’s
syndrome patients (Graeber and Streit, 2010). It was reported that there is an increase in
the amount of activated microglia within the cortex of the AD brain, but the increase was
not closely correlated with the increase in deposited Aβ plaque, but rather correlated with
the amount of cognitive decline (Edison et al., 2008, Okello et al., 2009).
Microglia play a few different roles in AD including amyloid removal and
mediation of fibrillar Aβ toxicity (Graeber and Streit, 2010). It is also known that
microglia are activated in the presence of Aβ and are able to upregulate the expression of
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different pro- and anti-inflammatory genes and ROS (Cameron and Landreth, 2010,
Meda et al., 1995, Paranjape et al., 2012, Yates et al., 2000). The microglia are able to
internalize soluble Aβ from the extracellular milieu though a fluid phase macropinocytic
mechanism. This mechanism is distinctly different from that of phagocytosis and
receptor-mediated endocytosis. Within the microglia, Aβ is able to activate a purinergic
autocrine/paracrine stimulatory loop in which the P2X receptor is a required component.
Other signaling pathways, such as the toll-like receptors (TLRs), have also been
implicated in the mediation and activation of the microglia via Aβ (Graeber and Streit,
2010).
Microglia have previously been proven to be associated with cerebral amyloid
deposits (Itagaki et al., 1989, Stalder et al., 1999, Wegiel and Wisniewski, 1990). With
the use of a double transgenic AD mouse model crossed with the overexpression of green
fluorescent protein (GFP) in microglia, it was shown that the microglia of control mice
continually survey their environment, while the microglia of the plaque bearing APP/PS1
mice showed ongoing uptake of Aβ (Bolmont et al., 2008). Human in vivo positron
emission tomography (PET) and carbon-11-labelled (R)-PK11195, a specific ligand for
the peripheral benzodiazepine binding site (activated microglia), also showed increased
[11C](R)-PK11195 binding in AD demented patients suggesting that the activation of
microglia is an early event in AD pathogenesis (Cagnin et al., 2001).
Many studies have examined the microglia association with Aβ plaques. These
studies have shown that the Aβ plaques were able to activate the microglia, stimulate
microglial proliferation and cause the microglial processes to extend toward the plaque,
resulting in rapid movement and clustering around the Aβ plaque (Barton, 2006, Itagaki

46

et al., 1989). Literature has suggested that neurons and glia cells actually participate in
the formation, growth, and morphologies of the Aβ plaques. Data has shown that
microglia are able to assist the aggregation of the diffuse soluble Aβ species into a more
insoluble aggregate due to failure of the Aβ clearance mechanism (Nagele et al., 2004,
Qiao et al., 2001). The amyloid plaques mostly consist of Aβ protein, but microglial
cells, dystrophic neurites, and bundles of astrocyte processes have also been detected
(Frautschy et al., 1998, Nagele et al., 2004). The microglia-Aβ plaque association was
confirmed in an AD mouse model by the co-localization of both IL-1β and TNFα
immunopositive microglia with ThT-positive Aβ plaques (Benzing et al., 1999). This
association, however, has not been confirmed with the more diffuse Aβ species. In this
study, very few of the diffuse Aβ plaques contained activated microglia; however, most
of the activated microglia were associated with the classic plaques in the cerebral cortex
and cerebellum of AD patients. This study, along with others, has shown that microglial
associations are not present in the early stages of Aβ plaque formation but become
increasingly apparent during the transition to the classic, insoluble Aβ plaque (Sasaki et
al., 1997).

1.12 Aβ Receptors Found on Microglial Cells
The inflammatory process plays a fundamental role in the pathogenesis of AD and
studies have indicated that an increase in the production of Aβ species can activate the
innate immunity system through pattern recognition receptors (PRRs) and induce AD
pathology. The innate immune system is the body’s guardian again pathogens and
danger insults and the way the body discriminates between self and non-self. The
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recognition of pathogens and danger insults have been based on specific structures that
are conserved across a broad subclass of pathogens (Kielian, 2006) known as PAMPs.
The body can also recognize pathogen-free self-derived danger signals and tissue injuries
through danger-associated molecular patterns (DAMPs). In both cases of environmental
and inherent threats (PAMPs and DAMPs), organisms use the same PRRs to defend
themselves (Salminen et al., 2009). Microglia display many different receptors which
interact with specific ligands, usually PAMPs and DAMPs, which initiate a downstream
signaling cascade leading to the production of pro- and anti-inflammatory cytokines or
Aβ clearance (Graeber, 2010). AD pathogenesis has been shown to be triggered by the
innate recognition of microglial receptors of different Aβ species. This recognition
causes the activation of overlapping signaling pathways that affect not only the functional
phenotype of the microglia, but also the surrounding cells (Salminen et al., 2009).

1.12.1 Toll-Like Receptors (TLRs)
TLRs are part of the PRR family and are expressed on cells of the innate immune
system. They allow for the recognition of PAMPs located on bacteria, fungi, and viruses
(Kielian, 2006) or for the recognition of DAMPs (Salminen et al., 2009). To date, there
have been 11 TLRs identified within humans and mice along with at least one agonist for
each receptor with the exception of TLR10 (Kielian, 2006). TLR1, TLR2, TLR4 and
TLR6 have been found located on the cell surface, forming the first line of defense
against pathogens, while TLR3, TLR7, TLR8 and TLR9 have been found in the
endosomes and are particularly adept at recognizing viruses. TLR activation is regulated
by several co-receptors, such as MD-2, CD14, and CD36. The stimulation of TLRs
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activate several protein kinase cascades that modulate gene expression through various
transcription factors, such as AP-1, NF-κB, IRF-3 and IRF-7 (Salminen et al., 2009).
Multiple TLRs and accessory proteins play a role in the proinflammatory
response evoked by Aβ in monocyte/macrophages and microglia including CD14, TLR4,
and TLR2 (Fassbender et al., 2004, Jana et al., 2008, Liu et al., 2012, Reed-Geaghan et
al., 2009, Udan et al., 2008) and TLR4 and TLR6 in concert with CD36 (Stewart et al.,
2010). Fassbender et al., 2004, showed that the lipopolysaccharide (LPS)-receptor CD14,
which is considered to transmit a signal through TLR2 and TLR4, binds Aβ fibrils and
mediate microglia and monocyte activation and neuronal toxicity. This was
demonstrated by the use of neutralization with antibodies against CD14 along with
genetic deficiency for this receptor, which showed a significant reduction in the Aβ fibril
induced microglial activation and toxicity (Fassbender et al., 2004). TLR2 was again
shown to be a key receptor in the mediation of an inflammatory response induced by Aβ
fibrils, in 2008. This study used methods, such as antisense knockdown of TLR2 and
functional blocking of the receptor by antibodies in both primary murine and BV-2
microglia, along with TLR2-/- knockout microglia, where both alleles of the TLR2 gene
are knocked out within the mice (Jana et al., 2008). Our lab also provided evidence
indicating a major role for TLR2 and TLR4 in the activation of human monocytic THP-1
cells induced by Aβ(1-42) fibrils. TLR2 neutralization resulted in ~50% reduction in the
cellular response induced by Aβ(1-42) fibrils, completely blocked the cellular response
induced by Pam3CSK4 (a known TLR2 ligand), and had no effect on the cellular response
induced by LPS (a known TLR4 ligand). However, when TLR4-specific antibodies were
used to neutralize the TLR4 receptor, there was ~35% reduction in the cellular response
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induced by Aβ(1-42) fibrils, complete reduction in the cellular response induced by LPS
and no effect on the cellular response induced by Pam 3CSK4. Lastly this study showed
that a combination of TLR2 and TLR4-specific antibodies for neutralization of both
receptors in addition to neutralization of CD14, which was previously shown to mediate
Aβ fibril inflammation, was much more effective at blocking the Aβ(1-42) fibril induced
cellular response then any of the antibodies by themselves. Taken together, this study
showed that Aβ(1-42) fibrils trigger an innate immune response, where both TLR2 and
TLR4 receptors play a role (Udan et al., 2008). One year later it was also shown that
CD14, TLR2, and TLR4 are important in the Aβ induced innate immune response. The
study specifically indicated that CD14, TLR2, and TLR4 functionally interact with other
members of the microglial fibrillar Aβ receptor complex, such as α6β1 integrin, CD36,
and CD47, to initiate intracellular signaling cascades resulting in an activated microglial
phenotype (Reed-Geaghan et al., 2009). TLR2 was shown to be a major receptor in
mediating a neuroinflammatory response triggered by Aβ by the use of real-time surface
plasmon resonance spectroscopy and conventional biochemical pull-down assays. This
study showed a direct interaction between TLR2 and the aggregated Aβ(1-42) of human
Aβ. The use of site-directed mutagenesis of tlr2 gene identified amino acids EKKA
(741-744) as a critical cytoplasmic domain for the transduction of inflammatory signals
(Liu et al., 2012).
TLR4 and TLR6 have also been proven to mediate Aβ-induced inflammation.
Stewart et al., 2010, showed that Aβ triggers an inflammatory response through a
heterodimer of TLR4 and TLR6 and that the heterodimer is regulated by signals from the
SR CD36 (Stewart et al., 2010). Taken altogether, the evidence demonstrates that TLR2,
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TLR4 and TLR6 are primary receptors for Aβ induced neuroinflammation and suggests
that the inhibition of these receptors could be beneficial in AD pathogenesis.

1.12.2 NOD-Like Receptors (NLRs) and NLRP3 Inflammasome
Recently, the activation of the TLRs has also been recognized as one of two
signal processes for the activation of a multi-subunit complex known as the
inflammasome (Figure 1.10). The requirement for two signals to produce mature IL-1β
represents a regulatory checkpoint to avoid fabricated immune responses that are capable
of harming the host (Sutterwala et al., 2014). The inflammasome is formed by the
oligomerization of cytoplasmic nucleotide-binding oligomerization domain (Nod)-like
receptors (NLRs) and its activation, “signal two”, is responsible for the processing of proIL-1β to mature IL-1β, via caspase-1 (Hanamsagar et al., 2012). There are many
different NLRs families which contain a variance in their N-terminal protein-protein
interaction region. For example, the best characterized inflammasome, NLRP3 also
known as NALP3, contains common features like a central nucleotide-binding domain
(NACHT) and C-terminal leucine-rich repeat (LRR) (Sutterwala et al., 2014), along with
an N-terminal pyrin domain which interacts with the adaptor molecule apoptosisassociated speck-like protein containing a CARD (ASC), where CARD is a caspase
recruitment domain, through a pyrin-pyrin interactions (Hanamsagar et al., 2012).
Additional assembly of the inflammasome involves a CARD-CARD interaction which
brings procaspase-1 to the complex (Schroder and Tschopp, 2010). Other
inflammasomes, such as NLRC4, contain an N-terminal CARD that interacts directly
with caspase-1 (dos Santos et al., 2012). The inflammasome complex then activates pro-
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Figure 1.10. Two signal activation of the NLRP3 inflammasome.
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caspase-1 by proteolytic cleavage to produce the active form of caspase-1. Active
caspase-1 then triggers the proteolytic cleavage of pro-IL-1β to mature IL-1β (Schroder
and Tschopp, 2010). NLRP3 and ASC are important in the production of IL-1β. This
has been shown by knocking out both the NLRP3 and ASC, which significantly reduced
the production of IL-1β after exposure to S. aureus (Hanamsagar et al., 2011). NLRP3 is
also essential in the amount of AD pathology, which was publicized by Heneka and
colleagues. With the use of a well-established AD mouse model also deficient in the
NLRP3 inflammasome, they were able to observe a reduction in the AD pathology
(Heneka et al., 2013).
The two signals start with the transcriptional induction of pro-IL-1β and NLRP3
mRNA followed by the proteolytic processing though the activation of the
inflammasome. Signal one can be elicited by known TLR ligands, such as LPS, or by a
number of other ligands that are known to activate NF-κB (Sutterwala et al., 2014),
whereas signal two has been found to be activated by several DAMPs, including poreforming toxins, ATP, K+ efflux, and silica and uric acid crystals (Hanamsagar et al.,
2012). Cellular studies have shown that the different aggregation species of Aβ have
distinct toxic and biological activities and potencies, including their ability to be a
proinflammatory stimulus (Dahlgren et al., 2002, Paranjape et al., 2012, Walsh et al.,
2002). This is most likely the case with the two signal activation of the TLRs and the
inflammasome leading to the production and secretion of IL-1β. There have only been a
few reports regarding inflammasome activation by soluble Aβ species. Therefore, most
of the research investigating the inflammasome and its activation by Aβ has been with
fibrillar Aβ. In 2008, Halle and colleagues used a fibrillar Aβ preparation to study the
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effect fibrillar Aβ has on the activation of the NLRP3 inflammasome. Using this
preparation, a novel inflammasome signaling pathway was observed showing that
fibrillar Aβ can activate the NLRP3 inflammasome in microglia. However, the exact
process of how the inflammasome is becoming activated was still unknown. Halle et al.,
2008 proposed that the mechanism of inflammasome activation may be linked to the
physical structure of the stimulus, due to the fact that the use of the reverse Aβ peptide
(Aβ42-1) or unaggregated peptide was unable to stimulate the inflammasome (Halle et
al., 2008). Their investigation also found that phagocytosis of the fibrillar Aβ was
necessary for the activation of the inflammasome. The phagocytosis of the fibrillar Aβ
led to the release of the lysosomal component, cathepsin B, into the cytoplasm. IL-1β
release was found to be dependent on the release of the cathepsin B (Halle et al., 2008,
Murphy et al., 2013). Treatment of primary rat glial cultures with recombinant human
Aβ also showed an increase in cathepsin B activation in the cytosol, formation of the
inflammasome components ASC and NLRP3, activation of caspase-1 and the release of
IL-1β (Murphy et al., 2013). Wu and colleagues came to a similar conclusion while
comparing fibrillar Aβ to chromogranin A (CGA). CGA is a neurosecretory acidic
glycoprotein known to strongly activate cultured microglia to induce the production and
secretion of IL-1β. Along with many of the other studies, fibrillar Aβ was unable to
stimulate both signal one and signal two of the inflammasome processing of pro-IL-1β to
mature IL-1β. All of the studies mentioned here used LPS as a priming step to initiate
the activation of the TLR4 and production of the pro-IL-1β. Fibrillar Aβ was then used
as a secondary treatment to activate the second step, the inflammasome, and continue the
processing to mature IL-1β (Wu et al., 2013).
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Although fibrillar Aβ was originally thought to be the primary entity responsible
for AD, more recent studies have suggested that soluble oligomeric Aβ, which is found in
the cortex of AD patients and could contribute to the pathogenesis of AD (Lambert et al.,
1998). Therefore, more current studies have considered the possibility of soluble Aβ
species activating the NLRP3 inflammasome. Sheedy et al., 2013 investigated the role
that the CD36 receptor plays in the activation of the NLRP3 inflammasome by
cholesterol crystals and Aβ. This investigation found that the uptake of soluble Aβ
results in the activation of the NLRP3 inflammasome, similar to that of fibrillar Aβ
(Sheedy et al., 2013). Other studies have specifically researched oligomeric Aβ (oAβ)
and its activation of the inflammasome. Parajuli et al., 2013 found that oAβ increases the
processing of pro-IL-1β into mature IL-1β in microglia by activating caspase-1 and the
NLRP3 inflammasome via ROS and partially NADPH oxidase-induced ROS. When
comparing oAβ to fibrillar Aβ, it was found that inhibition of phagocytosis and cathepsin
B inhibited the fibrillar Aβ-induced IL-1β release and caspase-1 activity, while the oAβinduced IL-1β secretion and caspase-1 activity was unaffected (Parajuli et al., 2013).
To date, little to no experimental work has been completed on the capability of
Aβ protofibril-induced NLRP3 activation. In the past several years, there has been an
increase in understanding the link between NLRP3 inflammasome signaling and AD
pathology. The research has shown that there are distinct differences in the Aβ-induced
NLRP3 inflammasome activation and that it may be dependent on the morphology of the
Aβ species. Each individual species along the nucleation-dependent polymerization
process to insoluble fibrils could play individual distinct roles in the mechanism of
activating the NLRP3 inflammasome and processing pro-IL-1β into its mature form of
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IL-1β. Therefore, an improved explanation of the molecular mechanism of how each Aβ
species induces inflammasome activation and contributes to the pathology of AD could
aid in the development of future therapeutic opportunities.

1.13 Cytokines
There are many inflammatory molecules involved in AD, including
proinflammatory cytokines. Proinflammatory cytokines, such as TNFα and IL-1β, are
upregulated in microglia which are located near the senile plaques within the brains of
AD patients (Dickson et al., 1993, Sardi et al., 2011).

1.13.1 TNFα
TNF is a soluble cytokine termed tumor necrosis factor and is produced by the
activation of the immune system. It is produced as a type II transmembrane protein and
arranged as a homotrimer. The homotrimer is released by the proteolytic cleavage of the
membrane-integrated form by the metalloprotease TNFα converting enzyme (TACE).
TNFα regulates several cellular pathways, including inflammation, differentiation, and
cell death, through activation of TNF receptor 1 (TNFR1) or TNFR2 (Wajant et al.,
2003). In the CNS, microglia are thought to be the primary source of TNFα. Studies
have indicated that there is an increased level of TNFα within the brain and plasma of
AD patients. It has also been found as a critical mediator in the reduction of LTP induced
by Aβ (Medeiros et al., 2007).
TNFα induces the activation of the transcription factor, NF-κB, which results in
the regulation of many proinflammatory cytokines, including IL1, IL8, IL6 and
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granulocyte macrophage colony-stimulating factor (GM-CSF) and survival factors, such
as MnSOD. As the name suggest, TNFα is known to cause cell death by necrosis, which
does not involve caspase or ATP as apoptosis does and is linked to inflammation in vivo.
However, both processes are indirectly triggered by TNFα through the generation of ROS
(Wajant et al., 2003).
TNFα protects neurons from Aβ-induced damage by upregulating receptors
involved in microglia chemotaxis towards Aβ clearance (Cui et al., 2002). Bruce and
colleagues generated mice deficient of TNF receptors to determine the role of TNF in the
cells of injured brains. The results showed that the microglial activation was suppressed
in TNFR-KO mice, indicating a neuroprotective role for TNF by stimulating antioxidant
pathways (Bruce et al., 1996). It was also shown that blocking the action of TNFα by
pharmacological inhibitors or genetic deficiency reduces Aβ-induced cognitive
dysfunction (Medeiros et al., 2007).

1.14.2 IL-1β
IL-1 has two produced isoforms: IL-1α and IL-1β. Both isoforms are able to
activate their only respective receptor, IL1R1, to produce other inflammatory molecules,
such as prostaglandins, collagenase, and phospholipids (Arai et al., 1990).
Immunostaining of AD patients’ brains and the brains of AD mouse models
showed the presence of IL-1β surrounding both diffuse and senile plaques (Benzing et al.,
1999, Sardi et al., 2011). IL-1β is an important proinflammatory mediator in the innate
immune response in AD and has also been shown to be elevated in both the brain and
plasma of Alzheimer patient’s postmortem (Ojala et al., 2009). A mouse model
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developed to harbor human IL-1β produced a localized inflammatory response when
activated, however these same mice crossed with APP/PS1 mice showed reduced
amyloid pathology (Rivera-Escalera et al., 2014). An important aspect of TLR signaling
is production of IL-1β mRNA and the pro-form of IL-1β protein (pro-IL-1β). IL-1β is
processed by the inflammasome. The activation and oligomerization of NLRs of the
inflammasome activates caspase-1 which then proteolytically cleaves the pro-IL-1β (31
kDa) to mature IL-1β (17 kDa) (Figure 1.8) (Hanamsagar et al., 2012).
The results, discussed in Section 1.13.2, have shown that the mechanism for oAβinduced processing of mature IL-1β by the NLRP3 inflammasome is different than that
induced by fibrillar Aβ (Parajuli et al., 2013), and it is possible that other species of Aβ,
such as protofibrils, maybe able to induce IL-1β by completely different mechanisms,
also.
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CHAPTER 2

METHODS

2.1 Cell Culture

2.1.1 WT and MyD88-/- Primary Microglia Isolation and Culture
WT and MyD88 knock-out (MyD88-/-) primary murine mixed microglia were
obtained from neonatal C57BL/6 mouse pups (Harlan laboratories Inc. and Tammy
Kielian’s lab at University of Nebraska Medical Center, respectively). Post natal mice
(3-4 days) were euthanized with inhaled isoflurane (Fisher). The brains were isolated and
meninges were removed under sterile conditions by rolling the brains over slightly
moistened gauze in a petri dish. The isolated brains were then collected in a 50 mL sterile
conical tube that contained 20 mL of phosphate buffered saline (PBS, Hyclone)
supplemented with antibiotics and placed on ice. After isolating all of the brains, the
brain tissue was transferred to a 100 mm cell-culture dish and minced using the sharp
edge of two separate forceps in a scissor action. The minced tissue was then resuspended
in 5 mL 0.05% trypsin (Hyclone) followed by an incubation at 37 °C for 20 minutes on a
shaker to allow further dissociation of the tissue. Successively, the cells were
resuspended in 10 mL of complete Dulbecco’s modified Eagle’s medium without
pyruvate (DMEM, 4.5 g/l glucose, Hyclone) containing 10% heat-inactivated fetal bovine
serum (FBS, Hyclone), 4 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin
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and 0.25 μg/mL amphotericin-B (P/S/A triple antibiotic mixture, Fisher Scientific), 10
μM oxaloacetic acid, 4.5 μM pyruvate, 0.002 U/mL insulin (OPI medium supplement,
Sigma-Aldrich), and 0.5 ng/ml recombinant mouse GM-CSF (Invitrogen). The cell
suspension was triturated using a 10 mL pipette and filtered through a 70-μm cell strainer
to remove tissue debris (Fisher Scientific). The flow through cell suspension was
centrifuged at 200 x g for 5 minutes at 25 °C, resuspended in complete medium, and
seeded into a 150 cm2 flasks (Corning). Each 150 cm2 flask contained 30 mL of total
cells. The number of flasks per single litter of mouse pups was determined by the size of
the litter. Each flask contained 3-5 isolated brains. The cells were cultured at 37 °C in
5% CO2 until confluent (1-2 weeks). The microglia morphology typically looked like
round cells resting on the top of a granular astrocytic layer. The microglia were
selectively harvested from the adherent astrocyte layer by overnight shaking of the flask
at 37 °C in 5% CO2 (at a speed between 5-6 on the shaker in the cell culture laboratory)
and collection of the medium. The flasks were replenished with fresh complete growth
medium and incubated further to allow proliferation of remaining microglia. Typically,
this procedure was repeated 3-4 times for one flask (Esen and Kielian, 2007) without
removal of the astrocyte layer before the flasks were discarded.

2.1.2 BV-2 Microglia Culture
The BV-2 mouse microglia cell line was a gift from Dr. Landreth (Case Western
Reserve University). The BV-2 microglia were maintained in DMEM (4.5 g/l glucose,
Hyclone) containing 50 U/mL penicillin, 50 μg/mL streptomycin, 50 μM βmercaptoethanol and 5% FBS (Hyclone). These cells were typically passaged twice a
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week, which consisted of washing the confluent cells 1 x with PBS and the addition of 1
mL of 0.25% trypsin. The cells were then incubated at 37 °C and 5% CO2 for 10
minutes. After the incubation time, 9 mL of growth medium was added to inactivate the
trypsin. Of the resuspended 10 mL of cells, 1 mL was centrifuged for 7 minutes at 500 x
g and resuspended in 10 mL of fresh growth medium. The freshly resuspended cells
were then added to a 75 cm2 flask and incubated at 37 °C and 5% CO2 until the next
passage. BV-2 cells were used until passage #50, after which the cells were discarded. A
few passages before passage 50, a new frozen aliquot (frozen in the year 2008 by M.L.D.
Udan at passage #33-36) was thawed and cultured in fresh growth medium as described
above. However, while thawing the new cells, one washing step was added before
culturing, which involved centrifugation for 7 minutes at 500 x g to remove any residual
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis) present in the cryopreservation
medium.

2.1.3 THP-1 Human Monocyte Culture
The human peripheral blood THP-1 monocytes were obtained from ATCC
(Manassas, VA, USA) and maintained in RPMI-1640 culture medium (Hyclone) which
contained 2 mmol/L L-glutamine, 25 mmol/L HEPES, and 1.5 g/L sodium bicarbonate
and was also supplemented with 10% FBS (Hyclone), 50 U/mL penicillin and 50 μg/mL
streptomycin (Hyclone), and 50 μmol/L β-mercaptoethanol (Fisher). The monocytes
were grown by incubating at 37 °C and 5% CO2. The growth of the THP-1 monocytes
were maintained by two dilutions a week, with a 1:1 dilution at the beginning of the week
and a 3:10 dilution at the end of the week. The 1:1 dilution was completed by removing
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half of the cells from the flask and replacing with the same volume of fresh growth
medium for propagation. For the 3:10 dilution, 3 mL of the THP-1 cells were removed
from the culture flask and centrifuged at 500 x g for 10 minutes. After centrifugation, the
supernatant was removed and the pelleted cells were resuspended in 10 mL of fresh
growth medium. The cells were then transferred to a new cell culture flask and again
incubated at 37 °C and 5% CO2 for further propagation.
While observing these cells over time, it was apparent that the proinflammatory
response starts to decrease as the monocytes reach about 2 months of continuous subculturing. To avoid this problem, staggering the culture of the THP-1 monocytes was
conducted.

2.1.4 THP-1 Human Differentiated Macrophages
THP-1 human monocytes were cultured and maintained as stated above, however
the monocytes were differentiated into macrophages by the addition of phorbol 12myristate 13-acetate (PMA, Sigma). PMA, also known as 12-O-tetrade-canoylphorbol13-acetate (TPA), was found to change THP-1 cells into cells with the functional
characteristics of mature macrophages (Tsuchiya et al., 1982). THP-1 monocytes were
treated with a final concentration of 10 ng/ml PMA in 300 uL of ~7.0 x 105 cells/mL (48
well plate) and incubated for 24 hours at 37 °C and 5% CO2. The next day two wells
were detached from the bottom of the plate with 0.25% trypsin for the calculation of
percent adherence.
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2.1.5 Mononuclear Cells
The human peripheral blood mononuclear cells (hMNC-PB) from a single donor
were obtained from PromoCell (Heidelberg, Germany) and maintained in mononuclear
cell medium provided by PromoCell, which contained all the growth factors and
supplements necessary for optimal short-term maintenance. After being thawed the cells
were plated at a density of 1 x 106 cells per mL and allowed to survive at 37 °C and 5%
CO2 for at least 18-24 hours to avoid clumping. The cells were then harvested after 24
hours by collecting the cellular medium and centrifuging for 10 minutes at 240 x g and
resuspending in fresh, pre-warmed mononuclear medium. The cellular medium was then
changed only when the medium looked diminished. It was observed that these cells do
not grow and divide very quickly so they either need to be cryopreserved or used
immediately for experiments.

2.2 Preparation of Aβ
Aβ peptide has a high tendency to aggregate and to become highly polymorphous.
This aggregation is thought to involve nucleation-dependent polymerization (Jarrett et al.,
1993, Walsh et al., 1997), where the monomeric Aβ noncovalently associates and forms
nuclei, or “seeds”. These seeds can then go on to form soluble protofibrils and oligomers
and insoluble fibrils (Harper et al., 1999). Therefore, in order to obtain a homogenous
solution of Aβ, any pre-formed seeds needed to be removed, which was accomplished by
the treatment of 100% hexafluoroisopropanol (HFIP). High concentrations of fluorinated
alcohols, like HFIP, have been commonly used for solubilizing peptides and proteins
(Buck, 1998).
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Synthetic Aβ(1-40) and Aβ(1-42) peptides (Keck Center, Yale University) were
dissolved in 100% HFIP (Sigma) at a concentration of 1 mM for one hour at room
temperature with the vial lid closed to prevent evaporation. The completely dissolved Aβ
was then aliquotted into sterile microcentrifuge tubes and evaporated overnight under the
fume hood, uncovered, at room temperature. The next day the aliquots were vacuumcentrifuged for 1 hour to remove any remaining HFIP and then stored at -20 °C.
When forming the Aβ(1-42):Aβ(1-40) ratios, the individual peptide aliquots were
re-aliquotted to form ratios of 5:0, 4:1, 1:1, 1:4, and 0:5. The ratio aliquot volumes were
calculated based on a final total Aβ concentration of 200 μM for SEC purification.
Briefly, 1 aliquot from each of the individual Aβ(1-42) and Aβ(1-40) 1 mg peptide
aliquots from above were resuspended in 243 μL and 254 μL HFIP, respectively, for a
concentration of 1 mM. The ratios of 4:1, 1:1, and 1:4 were formed by the same original
individual aliquots by aliquotting the Aβ/HFIP into three separate tubes. The 4:1 aliquot
was formed by mixing 160 μL of Aβ(1-42) (0.72 mg) and 40 μL of Aβ(1-40) (0.17 mg),
while the 1:1 aliquot was formed by mixing 100 μL of Aβ(1-42) (0.45 mg) and 100 μL of
Aβ(1-40) (0.43 mg), and lastly the 1:4 aliquot was a mixture of 40 μL of Aβ(1-42) (0.18
mg) and 160 μL of Aβ(1-40) (0.69 mg) (Table 2.1). The 5:0 and 0:5 ratios, however,
required their own individual Aβ peptide aliquots. For the 5:0 the Aβ(1-42) was
resuspend at 1 mM in 243 μL HFIP and 200 μL (0.90 mg) was aliquotted into a separate
tube. The same procedure was used for the 0:5 ratio except Aβ(1-40) was resuspended at
1 mM in 254 μL and 200 μL (0.86 mg) was aliquotted into a separate tube (Table 2.1).
Another Aβ(1-42):Aβ(1-40) ratio of 4:1 was also produced, but for this aliquot the
volume was determined for a final total Aβ concentration of 250 μM. This 4:1 ratio was

64

formed by the addition of 200 μL (0.9 mg) from the 1 mM Aβ(1-42)/HFIP and 50 μL
(0.22 mg) from the 1 mM Aβ(1-40)/HFIP solutions (Table 2.1). The Aβ(1-42):Aβ(1-40)
ratio aliquots were then left in a fume hood uncovered, at room temperature, and
overnight to allow for evaporation of the HFIP. The next day the aliquots were vacuumcentrifuged to remove any remaining HFIP and stored in a desiccant at -20°C.

2.2.1 SEC-Purified Aβ Monomer and Protofibril Preparation
SEC has shown to be useful in separating Aβ protofibrils from low molecular
weight Aβ (Walsh et al., 1997). Walsh et al., 1997 prepared Aβ protofibrils by
resuspending the Aβ peptide in sodium hydroxide (NaOH, Fisher Scientific) and then
diluted into PBS and separated all aggregated morphologies by SEC. The use of an
initial basic substrate, NaOH, prevents rapid Aβ aggregation around its isoelectric point
of (~5.5) (Jan et al., 2010). For isolation of the Aβ monomer and protofibrils, AKTA-fast
protein liquid chromatography (FPLC) was used along with a SEC. SEC is a method of
protein separation, which separates the proteins based on their shape and size with the
larger molecules eluting from the column first in the void peak followed by the smaller
protein molecules in the included peak.
For Aβ experiments, our protocol was slightly modified from the original method
of Walsh et al.1997, 1 aliquot of 1 mg lyophilized Aβ(1-42), Aβ(1-40) or mixed ratios
were dissolved in 100 μL of 50 mM NaOH to give a 2.5 mM Aβ solution. After making
sure all the Aβ went into solution, the Aβ was further diluted to 250 μM using artificial
cerebrospinal fluid (aCSF, 15 mM NaHCO3, 1 mM Na2HPO4, 130 mM NaCl, and 3 mM
KCl at pH 7.8), modified from a protocol in Tzounopoulos et al., 2004
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Table 2.1. Preparation of Aβ(1-42):Aβ(1-40) ratios.
Ratio

Aβ
Aβ(1-42)

Dry Aβ
peptide
1 mg

Volume
in HFIP
243 μL

[Aβ] in
HFIP
1 mM

Aliquot
volume
200 μL

Dry Aβ
peptide
0.90 mg

SEC
[Aβ]
200 μM

Aβ(1-40)

-

-

-

-

-

-

Aβ(1-42)

1 mg

243 μL

1 mM

160 μL

0.72 mg

160 μM

Aβ(1-40)

1 mg

254 μL

1 mM

40 μL

0.17 mg

40 μM

Aβ(1-42)

1 mg

243 μL

1 mM

100 μL

0.45 mg

100 μM

Aβ(1-40)

1 mg

254 μL

1 mM

100 μL

0.43 mg

100 μM

Aβ(1-42)

1 mg

243 μL

1 mM

40 μL

0.18 mg

40 μM

5:0

4:1

1:1

1:4
Aβ(1-40)

1 mg

254 μL

1 mM

160 μL

0.69 mg

160 μM

Aβ(1-42)

-

-

-

-

-

-

0:5
Aβ(1-40)

1 mg

254 μL

1 mM

200 μL

0.86 mg

200 μM

Aβ(1-42)

1 mg

243 μL

1 mM

200 μL

0.90 mg

200 μM

Aβ(1-40)

1 mg

254 μL

1 mM

50 μL

0.22 mg

50 μM

4:1

Total
[Aβ]
200
μM

200
μM

200
μM

200
μM

200
μM

250
μM

This table provides all the volumes, molecular weights, and dry weight of the individual
peptides which constitute the Aβ(1-42):Aβ(1-40) ratios.
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(Tzounopoulos et al., 2004), that was pre-filtered through a 0.2 μM filter (Thermo
Scientific). The Aβ(1-42) and the ratios were either immediately centrifuged at 18,000 x
g for 10 minutes with a Beckman-Coulter Microfuge®18 or incubated for 4 hours at room
temperature before centrifugation to generate more protofibrils, centrifuged and then
immediately subjected to SEC. Aβ(1-40), on the other hand, was incubated for 24 hours
at room temperature before centrifugation and SEC-purification. The centrifuged
supernatant was then eluted from a Superdex 75 HR 10/30 column (GE Healthcare) in
aCSF. Before the elution of Aβ, the Superdex 75 column was coated with 2 mg bovine
serum albumin (BSA, Sigma) to reduce the amount of non-specific binding of Aβ to the
column resin. The Aβ was eluted from the column at 0.5 ml/min, and the amount of
eluted Aβ was continuously monitored using in-line UV absorbance at 280 nm. Fractions
were continuously collected in 0.5 ml volumes and immediately placed on ice. The
fractions that eluted in the void peak were labeled as protofibrils, whereas the fractions
that eluted in the included peak were labeled as monomer. The collected fractions either
remained as individual fractions or were grouped together. The Aβ was then used to
either treat the cells to compare the cellular response between different Aβ species or to
perform aggregation studies using the freshly SEC-purified protofibril and monomer.
The protofibril and monomer concentrations were determined by using the SEC in-line
absorbance measurements at 280 nm along with the Aβ extinction coefficient of 1450
cm-1 M-1, which is for the Aβ peptide containing on tyrosine residue (Gill and von
Hippel, 1989, Nichols et al., 2002).
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2.2.2 SEC-Purified Aβ Monomer Preparation
Aβ(1-42) and Aβ(1-40) monomer was also obtained using an alternate protocol. To
obtain solely monomer, 1 mg Aβ peptide was resuspended in 6 M guanidinium
hydrochloride (GuHCl, Fisher Scientific) and 10 mM ammonium hydroxide (NH4OH,
Fisher Scientific) at a total volume of 1 mL. The Aβ solution was then subjected to all
the same conditions as mentioned above with the protofibril protocol. Briefly, the
solution was centrifuged, injected on the column, and eluted in 0.5 mL fractions in aCSF
and stored on ice. This preparation elutes only one Aβ peak, monomer, which elutes in
the included peak. The collected fractions either remained as individual fractions or were
grouped together. The Aβ was then used to either treat the cells to compare the cellular
response between different fractions or to perform aggregation studies using the freshly
SEC-purified monomer. The monomer concentrations were determined by using the
SEC in-line absorbance measurements at 280 nm along with the Aβ extinction coefficient
of 1450 cm-1 M-1, which is for the Aβ peptide containing on tyrosine residue (Gill and
von Hippel, 1989, Nichols et al., 2002).

2.2.3 SEC-Purified Aβ(1-42) Oligomer Preparation
Aβ oligomers were prepared from an aliquot of lyophilized Aβ(1-42), as previously
described by Stine et al., 2003 (Stine et al., 2003). Briefly, one 1 mg lyophilized Aβ(142) aliquot was resuspended in sterile DMSO at a concentration of 5 mM. After making
sure all the Aβ was in solution, the sample was diluted to 100 μM in pre-filtered aCSF
and incubated at 4 °C for 24 hours. The sample was then treated exactly the same as the
protofibril preparation, as it was centrifuged, loaded on the SEC column to separate the
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monomers, and oligomers in 0.5 mL fractions and placed on ice. The fractions that
eluted in the void peak were labeled as oligomers; the fractions that eluted in the included
peak were labeled as monomer. The fractions of oligomers or monomers were then used
to treat the cells and compare the cellular response between the different species of Aβ.
The monomer and oligomer concentrations were determined by using the SEC in-line
absorbance measurements at 280 nm along with the Aβ extinction coefficient of 1450 cm 1

M-1, which is for the Aβ peptide containing on tyrosine residue (Gill and von Hippel,

1989, Nichols et al., 2002).

2.2.4 Aβ(1-42) Fibril Preparation
Aβ fibrils were prepared as previously described by Stine et al., 2003 (Stine et al.,
2003). Briefly, a 1 mg lyophilized Aβ(1-42) aliquot by resuspending it in sterile DMSO
at a concentration of 5 mM. After making sure all the Aβ was in solution, the sample was
diluted to 100 μM in 10 mM HCl and incubated at 37 °C for 24 hours.

2.3 Microglia Stimulation Experiments with Aβ
Literature has shown that Aβ induces a proinflammatory response via TLRs,
especially TLR 2, 4, and 6 (Bamberger et al., 2003, Stewart et al., 2010, Udan et al.,
2008, Walter et al., 2007). Due to the involvement of the TLRs in the Aβ-induced
proinflammatory response, well known TLR ligands were able to be utilized as positive
controls for cellular stimulation (Figure 2.4-2.6). For experiments in WT and MyD88-/primary microglia with Aβ, the cells were released from the astrocytic layer within the
cell culture flask by overnight shaking, as mentioned above. The medium containing the
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primary microglia was then centrifuged at 200 x g for 10 minutes at room temperature.
The cellular pellet was resuspended in fresh complete microglial growth medium
containing 10% FBS and GM-CSF, plated in a 96 well sterile culture plate at 5 x 105 cells
per mL (100μL) and incubated for 24 hours at 37 °C and 5% CO2 to allow adhesion of
the microglia to the plate. After a 24-hour incubation, the cell culture medium was
replenished with complete microglia assay medium without FBS and GM-CSF. Freshly
SEC-purified monomer and protofibrils were added to the primary microglia at a final
concentration of 15 μM. In each experiment, the concentration of monomers and
protofibrils varied. Therefore, the volume of Aβ that was added to the microglia to
achieve a final concentration of 15 μM was slightly different in each experiment. This
also meant that the amount of assay medium that was added to the microglia in each
experiment varied slightly too, in order to keep the final Aβ concentration consistent and
the final volume at 100 μL. For example, a typical experiment would have an Aβ
protofibril concentration of about 51 μM and a monomer concentration of 62 μM.
Therefore, in this experiment the protofibril treatment would include 29.5 μL of the
protofibril fraction and 70.5 μL assay medium, while the monomer treatment would
include 24 μL of the monomer fraction and 76 μL of assay medium. Also, for each of
these treatments a negative control would be tested. The negative controls consisted of
the addition of equal volumes of buffer as compared to the Aβ protofibril or monomer
and the equivalent volume of assay medium. After the addition of Aβ the cells were
incubated for a specific amount of time at 37 °C in 5% CO2. For extracellular cytokine
analysis, the cellular medium was collected and stored at -20 °C until analyzed by
enzyme-linked immunosorbent assay (ELISA). For intracellular cytokine analysis, the
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cells were washed with cold, sterile PBS and lysed with cold RIPA buffer containing 150
mM NaCl, 20 mM Tris, 1 mM EDTA, 1% Triton X-100, 1% deoxycholic acid, and 0.1%
sodium dodecyl sulfate (SDS). The medium was then supplemented with 40x protease
inhibitor cocktail (Sigma) before use and stored at -20 °C until analyzed by ELISA or
Western blot. Aβ experiments also included comparing different concentrations of Aβ
and different time points of incubations.
All BV-2 microglia cellular experiments were carried out in the same manner as
the primary microglia experiments with respect to the number and volume of cells that
were plated and the volume of Aβ and assay medium added to the microglia. BV-2
microglia were removed from the flask for an experiment by treatment with 1 mL of
0.25% trypsin. The trypsin was incubated at 37 °C and 5% CO2 for 7 minutes, and then 9
mL of BV-2 growth medium was added to stop the trypsin reaction. The microglia were
centrifuged at 500 x g for 7 minutes at room temperature and resuspended in fresh growth
medium and plated in a sterile 96-well culture plate. The microglia were then incubated
overnight at 37 °C and 5% CO2. The next day the culture medium was exchanged for
fresh BV-2 assay medium without FBS, and the Aβ was added, as mentioned above.
Again the treatment was incubated for certain time points, and then the medium was
collected and stored at -20 °C until used for analysis.
Caspase-1 inhibition studies were also performed on the microglia. Prior to
cellular treatment with the stimulus, the microglia were treated with z-YVAD-fmk
caspase-1 inhibitor (EMD Millipore) for 30 minutes at final concentrations of 0 μM, 5
μM, 10 μM, and 20 μM in 0.05% DMSO. The inhibitor was prepared by dissolving in
100% DMSO and then diluting further in sterile water to obtain 25% DMSO and 0 μM,
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250 μM, 500 μM, and 1 mM inhibitor. After 30 minutes treatment with the different
concentrations of inhibitor, the microglia were then treated with a final concentration of
15 μM Aβ(1-42) for 6 hours at 37 °C and 5% CO2. The cellular medium was then
collected and analyzed by ELISA for secreted IL-1β.

2.4 Inhibition of LPS-Induced Inflammation
Our lab collaborated with the Demchenko laboratory in hopes of developing a
LPS antagonist that could be used to inhibit a systemic inflammatory response from a
serious medical condition known as sepsis (Kaeothip et al., 2011). All compounds were
prepared by the Demchenko laboratory and given to our lab as a solid powder.
Compound 24 (Table 5.2) powder, 5 mg, was dissolved in 100 μL tetrahydrofuran (THF)
in the cold room and quickly divided into 15 μL aliquots. The aliquots were then
vacuum-centrifuged for one hour to allow evaporation of the THF. The compound was
then stored at -80 °C until ready for an experiment.
These inhibition experiments were completed in human THP-1 monocytes which
were differentiated into macrophages as described in 2.1.4. The THP-1 macrophages are
a respectable cellular system when studying inflammation and they act as a model for
peripheral macrophages by their response to bacterial infections (Kaeothip et al., 2011).
Briefly, the THP-1 monocytes are centrifuged and resuspended in fresh growth medium
at a cell density of 5 x 105 cells mL-1. The monocytes were then plated in a 48-well
sterile culture plate and differentiated into adherent macrophages by treatment with PMA.
The cells were allowed to differentiate for 24 hours at 37 °C in 5% CO2. After 24 hours
the non-adherent cells were removed and the remaining adherent macrophages were
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replenished with 293 μL assay medium containing 2% FBS. Before treating the cells,
there were two wells set aside for calculating the percent differentiation. This was
accomplished by washing the wells with PBS just before removing the adherent cells
with 0.25% trypsin-EDTA and incubation at 37 °C for 7-10 minutes. Growth medium
was then added to the wells to the stop trypsin reaction, and the cells were counted under
a microscope with a hemocytometer. The remaining wells were pre-incubated with 2 μL
of the LPS antagonist (compound 24) at different concentrations for 30 minutes before
the treatment of 5μL ultrapure LPS from E. coli K12 (InvivoGen, San Diego, CA) at a
final concentration of 10 ng mL-1. The LPS antagonist was diluted in 100% DMSO and
then into the microglia medium to make final concentrations of 0.55, 1.0, 3.0, 5.5, 10, 30,
55, and 100 μM, and 0.6% DMSO. DMSO at a final of 0.6% was also used as a control.
The macrophages were then incubated at 37 °C in 5% CO2 for 6 hours and then the
cellular medium was collected and stored at -20 °C until ready for TNFα production
analysis by ELISA. The ELISA data was then fit to a 3-parameter hyperbolic decay plot,
using the equation

(Kaeothip et al., 2011).

The actual concentrations of the compound were later calculated by measuring the
absorbance of the Fluorenylmethyloxycarbonyl (Fmoc) group located on the compound
at 301 nm. The compound was diluted to 180 μM in DMSO, and the absorbance was
read at 301 nm after correcting the background absorbance for DMSO by itself. The
absorbance was read on the UV-visible spectrophotometer Cary 50 (Agilent
Technologies, Santa Clara, CA). After obtaining the absorbance the actual concentration
of the compound was calculated using the extinction coefficient of the Fmoc group, 7800
M-1 cm-1, which is for the piperidine-fluorenone adducts (Johansson et al., 2003,
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Kaeothip et al., 2011). Once the actual concentration was calculated the percentage of
inhibitor was then able to be calculated. Therefore the actual concentration of each
dilution and final concentration was then obtained using the calculated percentage.

2.5 Cytokine Determination
Secreted and intracellular TNFα, IL-1β, and pro-IL-1β protein, and mRNA
cytokines were determined using three different techniques: ELISA, Western blot, and
reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR). ELISA has
become common technique for the detection and determination of cytokine levels in
cultured medium. Both the detection and quantification of cytokines within the cell or
secreted medium is important for evaluating inflammation. This method has an
advantages of being highly specific and proficient when analyzing a large number of
samples (Turner et al., 2004). Another protein analysis method that is widely used is
Western blotting, or immunoblotting. This technique is also a sensitive technique for the
detection and characterization of proteins. Western blotting uses the advantages of
antibody recognition and their specificity towards an antigenic sequence in the protein of
interest (Burnette, 1981). The last method that was used for the detection of cytokines
was through the detection of mRNA in a technique known as RT-qPCR. This technology
has become a mainstream research tool for three reasons: it does not need any post-PCR
processing due to it being a homogeneous assay, the assay has a wide dynamic range and
therefore allows comparisons between RNAs that are significantly quantitatively
different, and because the method is both quantitative as well as qualitative (Bustin et al.,
2005).
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2.5.1 TNFα ELISA
Measuring the levels of secreted TNFα in the cellular condition medium was
determined by ELISA as previously described (Udan et al., 2008). Udan et al., 2008
described the measurements of human TNFα, which was used for the human THP-1
monocytes and macrophages, while the protocol for the measurements in the mouse
primary microglia and BV-2 microglia had to be modified slightly. Briefly, 96 well
plates were coated overnight at room temperature with 0.4 μg/mL monoclonal anti-mouse
TNFα capture antibody (stock aliquots were stored at -80 °C at 200 μg/mL in PBS). The
next day the wells were washed with PBS containing 0.05% Tween 20, then blocked with
for 1 hour at room temperature with PBS containing 1.0% BSA, 5.0% sucrose and 0.05%
sodium azide (NaN3), and again followed by a wash step. Successive treatments at room
temperature with washing in between were completed with samples or standards for 2
hours, biotinylated polyclonal anti-mouse TNFα detection antibody for 2 hours,
streptavidin-horseradish peroxidase (HRP) conjugate for 20 minutes, and equal volumes
of HRP substrates 3,3’,5,5’- tetramethylbenzidine (TMB) and hydrogen peroxide for 25
minutes. The mouse TNFα detection antibody was added to the wells at a final
concentration of 0.2 μg/mL (stock aliquots stored at -80 °C at 50 μg/mL in detection
antibody diluent) in 20 mM Tris with 150 mM NaCl and 0.1% BSA. The reaction was
stopped by the addition of 1% H2SO4 solution. The SpectraMax 340 absorbance plate
reader (Molecular Devices, Union City, CA) was used to read the optical density of each
sample at 450 nm with a reference reading at 630 nm. The concentration of TNFα in the
experimental samples was calculated from a TNFα standard curve of 15-2000 pg/mL.
When necessary, the samples were diluted to fall within the standard curve. TNFα
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concentrations for absorbance values below the lowest 15 pg/mL standard were
determined by extrapolating of the standard curve regression line.

2.5.2 IL-1β ELISA
Measuring the levels of intracellular and extracellular IL-1β was determined by
ELISA. This ELISA method was similar to TNFα ELISA method, as mentioned above,
however, two changes were made. The two changes that had to be made for the mouse
IL-1β specific ELISA were the capture and detection antibodies. To briefly explain, 96well plates were again coated overnight at room temperature, but for this ELISA they
were coated with 2.0 μg/mL monoclonal anti-mouse IL-1β capture antibody (stock
aliquots were stored at -80 °C at 720 μg/mL in PBS). The detection antibody was also
changed according to mouse IL-1β specificity. The biotinylated polyclonal anti-mouse
IL-1β detection antibody was added to the wells at a final concentration of 0.5 μg/mL
(stock aliquots stored at -80 °C at 180 μg/mL in detection antibody diluent) in 20 mM
Tris with 150 mM NaCl and 0.1% BSA. The reaction was again stopped by the addition
of 1% H2SO4 solution, and the optical density was read by the SpectraMax 340
absorbance plate reader (Molecular Devices, Union City, CA) for each sample at 450 nm
with a reference reading at 630 nm. The concentration of IL-1β in the experimental
samples was calculated from an IL-1β standard curve of 15-2000 pg/mL. Occasionally
the samples were diluted to fall within the standard curve. IL-1β concentrations for
absorbance values below the lowest 15 pg/mL standard were determined by extrapolating
of the standard curve regression line.
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Before being able to use this IL-1β ELISA on samples, the standard curve had to
be optimized with the correct concentrations of IL-1β capture and detection antibodies.
The recommended concentrations of the antibodies, by R & D Systems, were 4.0 μg/mL
for capture antibody and 1.0 μg/mL for detection antibody. In order to optimize the
standard curve, lower concentration of one or both IL-1β antibodies were investigated.
Standard curves using the recommended concentrations given by R & D Systems were
performed, along with 4 μg/mL and 0.5 μg/mL, 2 μg/mL and 1 μg/mL, and 2 μg/mL and
0.5 μg/mL capture and detection antibodies, respectively (Figure 2.1). All of the
combinations of antibody concentrations gave similar standard curves with correlation
coefficients of .9844 or better and slopes of 0.7914 to 0.8774. Due to the fact that all the
standard curves were very similar, the standard curve that was chosen to calculate the
sample concentrations was made using 2 μg/mL capture antibody and 0.5 μg/mL
detection antibody. This decision was made because less material was used and very
similar standard curves were received.

2.5.3 Pro-IL-1β ELISA
Measuring the levels of intracellular pro-IL-1β was determined by ELISA also.
This ELISA method was similar to TNFα and IL-1β ELISA method as mentioned above;
however, an ELISA kit was used. A kit was purchased from eBioscience and the
protocol was followed. The kit contained capture and detection antibodies, standard proIL-1β protein, streptavidin-HRP, TMB substrate, assay diluent buffer, and coating buffer.
The assay diluent buffer was used as the blocking buffer and to dilute the standard
protein, detection antibody, and streptavidin-HRP, while the coating buffer was used to
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Figure 2.1. IL-1β standard curves. Optimization of the IL-1β ELISA was completed
by varying the concentration of one or both of the capture and detection antibodies. The
combination of capture and detection antibodies that were used was 4 μg/mL and 1
μg/mL, 4 μg/mL and 0.5 μg/mL, 2 μg/mL and 1 μg/mL, and 2 μg/mL and 0.5 μg/mL,
respectively. The later concentrations were chosen as the optimal concentrations for
determining the concentrations of the samples.
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dilute the capture antibody. The materials that were not provided, such as the 96-well
plates, wash buffer and stop solution, were used as mentioned above in the previous
ELISAs. As far as the experimental procedure, it was very similar to the ELISA
mentioned above. The protocol was followed by coating a 96-well plate with pro-IL-1β
capture antibody overnight at 4 °C. The next day the wells were washed with wash
buffer and then blocked with assay diluent buffer for 1 hour at room temperature and
again followed by a wash step. Successive treatments at room temperature with washing
in between were done with samples or standards for 2 hours, pro-IL-1β detection
antibody for 2 hours, streptavidin-HRP conjugate for 30 minutes, and TMB substrate for
15 minutes. The reaction was stopped by the addition of the stop solution. The
SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA) was used
to read the optical density of each sample at 450 nm with a reference reading at 630 nm.
Again, the concentration of protein, pro-IL-1β, in the experimental samples were
calculated from the pro-IL-1β standard curve of 15-2000 pg/mL. When necessary, the
samples were diluted to fall within the standard curve. Pro-IL-1β concentrations for
absorbance values below the lowest 15 pg/mL standard were determined by extrapolating
the standard curve regression line.
The experimental procedure of this kit was verified, before being performed on
experimental samples, by the trial of a pro-IL-1β standard curve (Figure 2.2). The
specificity of the pro-IL-1β was also observed. This was completed by using both the
capture and detection antibodies for recognition of the pro-IL-1β along with the addition
of both the pro-IL-1β standard curve and the mature IL-1β standard curve. This
confirmed the specificity by observing that the serial dilution of the mature IL-1β protein
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Figure 2.2. Pro-IL-1β standard curve. Optimization of the Pro-IL-1β ELISA was
completed by varying all the materials that were supplied in the eBioscience Pro-IL-1β
ELISA Kit, together with the materials that were not included and were supplied by our
lab. The standard curve provided a correlation coefficient of 0.9852 and a slope of
1.2278.
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standards was not detected by the pro-IL-1β-specific antibodies (Figure 2.3).

2.5.4 Western Blotting
Measuring the levels of intracellular Pro-IL-1β, IL-1β and α-tubulin was also
determined by Western blotting. The primary microglial cells within a 96-well cell
culture plate were lysed using RIPA buffer containing 150 mM NaCl, 20 mM Tris, 1 mM
EDTA, 1% Triton X-100, 1% deoxycholic Acid, 0.1% SDS, and supplemented with 40x
protease inhibitor cocktail (Sigma) before use. Similarly treated wells were added
together to concentrate the sample and immediately placed on ice. Once the lysates were
collected, they were centrifuged at 9,000 x g at 4 °C to remove cell debris. The samples
were then diluted 2 fold with Laemmli sample buffer (Bio-Rad) containing 5% βmercaptoethanol (Sigma), denatured at 95 °C for 5 minutes, and run on a 15% Tris-HCl
Ready Gel (Bio-Rad). The gels were run in running buffer containing 25 mM tris, 192
mM glycine, 0.1% SDS at pH 7.8 using a Mini Protean 3 Cell (Bio-Rad) under 120V
current at room temperature. The amount of time necessary to run the gel was between
1.5 and 2 hours or until the tracking dye was just above the bottom of the gel. The gel
was then soaked in transfer buffer containing 0.025 M tris base, 0.192 M glycine, and
10% methanol at pH 8.3 for 15 minutes. The protein within the gel was transferred to
polyvinylidene difluoride (PVDF) membrane (Milipore) in cold transfer buffer using a
Tank Electroblotting system VEP-2 (Owl Separation systems). The PVDF membrane
was prepared by being soaked in methanol for 15 seconds, water for 2 minutes and
transfer buffer until ready for the actual transfer. The gel and membrane were arranged
for the transfer by placing the black side of the transfer cassette down flat followed by a
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Figure 2.3. Pro-IL-1β standard curve specificity. Serial dilutions of pro-IL-1β (162,000 pg/ml, circles) and mature IL-1β (31-16,000 pg/ml, triangles) were prepared and
analyzed using a pro-IL-1β ELISA (eBioscience).
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support pad, filter paper, previously run SDS-PAGE gel, PVDF membrane, another filter
paper, and support pad. The support pads and filter papers were also previously soaked
in transfer buffer. The transfer system was placed in the cold room at 4 °C on a stir plate
with a small magnetic stirrer. A current of 0.4 mA was applied to the system for 2 hours.
After the proteins were transferred to the membrane, the membrane was blocked for 1
hour at room temperature with 5% nonfat dry milk and 0.1% Tween 20 in PBS with slow
rotation and probed with 500x 3ZD monoclonal antibody (National Cancer Institute) or
200x IL-1β (H-153) (Santa Cruz Biotechnology) for both pro- and mature IL-1β in PBS
with 1.0% milk and 0.1% Tween 20 for overnight incubation at 4 °C with slow rotation.
The membranes were then washed in PBS containing 0.2% Tween and subjected to a
secondary antibody, goat anti-mouse immunoglobulin (IgG)-HRP (R & D systems) and
goat anti-rabbit IgG-HRP (R & D systems), respectively, which was diluted 1000x in
PBS containing 1.0% milk and 0.1% Tween 20 for 1 hour at room temperature with slow
rotation. The membrane was again washed and placed in equal amounts of enhanced
chemiluminescence (ECL) Western Blotting Substrate Detection reagent 1 and 2 (Pierce)
for 1 minute at room temperature with vigorous rotation. Lastly, the visual
chemiluminescence of the blot was developed onto X-ray film (Kodak) by exposure of
the membrane to the film for 1 minute in a metal film cassette. The film was then
subjected to Kodak GBX developer for 15 seconds and fixer solution for 5 seconds.
After development, the film was washed with water and hung to dry. To be sure that the
same amount of protein was loaded into each lane of the gel, a loading control was used.
To visualize the loading control, α-tubulin, the membrane was washed, after previous
development, with PBS containing 0.2% Tween 3 times for 5 minutes each at room
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temperature with slow rotation and stripped of the previous antibodies by 1x Restore
western blot stripping buffer (Thermo Scientific) for 15 minutes at room temperature
with slow rotation. The membrane was then blocked with 5% nonfat dry milk and 0.1%
Tween 20 in PBS for 1 hour with slow rotation and re-probed over night at 4 °C with
200x α-tubulin (TU-02) (Santa Cruz Biotechnology) in 1.0% milk and 0.1% Tween 20
with slow rotation. The next day the membrane was again washed with PBS containing
0.2% Tween 3 times for 5 minutes each at room temperature with slow rotation and then
the addition of 1000x goat anti-mouse IgG-HRP for 1 hour at room temperature in 1.0%
milk and 0.1% Tween 20 with slow rotation. After the secondary antibody the membrane
is again ready for development.

2.5.5 mRNA Quantitative Analysis

2.5.5.1 RNA Extraction
Measuring the levels of TNFα, IL-1β and β-Actin was also determined by RTqPCR. First the total RNA was obtained using a GeneJET RNA purification kit
(Fermentas). The procedure was completed by following the manufacturer’s guidelines.
Following treatment of primary microglial cells within a 96-well cell culture plate, the
microglia were lysed using lysis buffer (Fermentas) supplemented with βmercaptoethanol and 96-100% ethanol. The total contents were then collected and
transferred to a spin column (Fermentas). The samples from similarly treated wells were
added into the same spin column, up to 5 samples, to concentrate the amount of mRNA in
each sample. Each sample was washed once with Buffer 1 (Fermentas) and twice with
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Buffer 2 (Fermentas) with centrifugation for 1 minute at 12,000 x g between each wash.
Lastly, nuclease free water was added to each spin column to elute the total RNA,
centrifuged for 1 minute at 12,000 x g, and the flow through was collected. It was
observed that if the elution was completed during two spin cycles that the mRNA elution
from the column was more efficient. The total RNA concentration was then determined
using the Epoch Nano-Drop (BioTek Instruments, Winooski, VT) absorbance at 260/280
nm ratio and the highest amount of total RNA available up to 1 μg was concentrated. The
purified RNA was now ready for further downstream applications or can be stored at -20
°C for short time storage or -70 °C for longer storage.

2.5.5.2 Genomic DNA Removal
After determining the total RNA concentration and determining the total volume
needed to obtain the same concentration for each sample, the volume of each sample was
then reduced down to further concentrate the samples by vacuum-centrifugation. The
genomic DNA was removed using a DNase I kit (Fermentas) and the procedure was
followed according to the manufacture’s protocol. Treatment consisted of the addition of
10x reaction buffer with MgCl2 (Fermentas), DNase I (Fermentas), and 1 unit/μL RNase
inhibitor (Fermentas), which was in addition to the kit but recommended by the DNase I
manufacture, to each sample and an incubation at 37 ˚C for 30 minutes. The reaction was
then stopped by the addition of 50 mM EDTA (Fermentas), incubation at 65 ˚C for 10
minutes, and placement on ice and ready for further downstream applications.
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2.5.5.3 cDNA Synthesis
The synthesis of cDNA was also done according to the manufacturer’s guidelines
(RevertAid Kit, Fermentas). While the samples carried over from the genomic DNA
removal step were on ice an oligo (dT)18 primer (Fermentas) was added. The samples
were then mixed gently, centrifuged briefly, incubated at 65 ˚C for 5 minutes to open up
any secondary structures and placed back on ice. The next step involved the addition of
5x reaction buffer (Fermentas), RiboLock RNase inhibitor (1 unit/μL) (Fermentas), and
RevertAid M-MuLV Reverse Transcriptase (10 units/μL) (Fermentas) to each sample.
The samples were then mixed, centrifuged, and incubated for 60 minutes at 42 ˚C.
Lastly, the reaction was terminated by heating the samples to 70 ˚C for 5 minutes and
then the samples were stored at -20 ˚C for one week or at -80 °C until ready for PCR
applications.

2.5.5.4 RT-qPCR
Selected sequences of specific cytokines were amplified using RT-qPCR (C100
Thermocycler, BioRad, Hercules, CA). Each sample was prepared by adding Maxima
SYBR Green qPCR Master Mix (Fermentas), forward (sense) primer, reverse (antisense)
primer (Table 2.1), and template cDNA. RT-qPCR was run using Bio-Rad CFX
Manager software. A three-step cycling protocol was set at an initial denaturation
temperature of 95 ˚C for 3 minutes, 40 cycles of denaturation at 95 ˚C for 10 seconds,
annealing at 55 ˚C for 10 seconds, and extension at 72 ˚C for 30 seconds. mRNA levels
were then calculated and reported as relative quantities (RQ). The RQ was determined
by the equation RQ=E(Cq, control – Cq, stimulated), where Cq is the quantification cycle value
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Table 2.2. RT-qPCR primers.

Primer

Forward (5’ to 3’)

Reverse (5’ to 3’)

TNFα

TTCCCAAATGGCCTCCCTCTCATC

TCCTCCACTTGGTGGTTTGCTAC

IL-1β

CCTGTGTAATGAAAGACGGCACAC

ATTGATTGGGATCCACACTCTCC

Β-Actin

ACAGCTTCTTTGCAGCTCCTTCG

ATATCGTCATCCATGGCGAACTGG

Forward and reverse primers for cytokines TNFα and IL-1β and for the control mRNA,
β-Actin.
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obtained by the fluorescence amplification plot and E is the efficiency with a value of 2.
In numerous experiments β-actin was used as an internal control and did not vary
significantly between samples regardless of microglia stimulation state.

2.6 Characterization of MyD88-/- Primary Murine Microglia
Primary microglia are known to express an assortment of TLRs (Cameron and
Landreth, 2010). The WT microglia were characterized in Geeta Paranjape’s
dissertation. However, the characterization of the MyD88 -/- primary microglia needed to
be completed and compared to the WT microglia. In order to estimate and compare the
proinflammatory response of the MyD88 -/- microglia to the WT microglia various TLR
ligands were used in the presence of both types of cells and analyzed by ELISA to
quantify TNFα and IL-1β secretion. The TLR ligand experiments were carried out in
dose-dependent manner for the known TLR ligands: LPS (TLR4 ligand), Pam3CSK4
(TLR 1 and 2 ligand) and FSL-1 (TLR 2 and 6 ligand). However, TLR ligands are not
expected to induce IL-1β secretion unless a second stimulus is provided which activates
the NLRP3 inflammasome. LPS and Pam3CSK4 were aliquotted at 600 μg/mL and FSL1 at 60 μg/mL, stored at -20 °C and were further diluted to make the correct final
concentrations for addition to the cells. Both WT and MyD88-/- primary microglia were
harvested as mentioned above. The microglia were plated in fresh primary microglial
growth medium at a volume of 100 μL and incubated at 37 °C and 5% CO2 for 24 hours.
The following day the growth medium was replaced with medium devoid of GM-CSF
and FBS, and the ligands were added to the cells to make final concentrations of 3, 10,
30, and 100 ng/mL. After 6 hours of incubation at 37 °C and 5% CO2, the cellular
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medium was collected and analyzed by TNFα and IL-1β ELISAs, as described in
Sections 2.2.1 and 2.2.2.
The TLR4 ligand, LPS, was able to produce a substantial TNFα response in the
WT primary microglia with concentration dependence at the lower concentrations and
plateauing at the higher concentrations. However, when knocking out both alleles of
MyD88 in the MyD88-/- microglia the response was significantly reduced (Figure 2.4A).
When measuring the cytokine IL-1β there was little to no amount of secreted IL-1β in
both WT and the MyD88-/- microglia (Figure 2.4B). This response was due to the fact
that the LPS was not able to activate the NLRP3 inflammasome which is needed in the
production of mature IL-1β. Similar responses were seen during activation of the WT
and MyD88-/- microglia with the TLR1 and -2 and TLR2 and -6 agonist, Pam3CSK4
(Figure 2.5A,B) and FSL-1 (Figure 2.6A,B), respectively. The only difference was in the
TNFα concentration dependence in the WT microglia, where the Pam3CSK4 showed
concentration dependence and the FSL-1 did not. The little to no IL-1β secretion by the
Pam3CSK4 and FSL-1 was also due to not being able to activate the NLRP3
inflammasome.

2.7 Aβ Concentration Determinations

2.7.1 BCA Assay
Bicinchoninic acid (BCA), sodium salt, is a stable, water-soluble compound that
complexes with cuprous ion (Cu1+) in an alkaline environment and forms an intense
purple color. The color produced increases in a proportional fashion with a broad range
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Figure 2.4. Concentration-dependence of LPS-induced TNFα and IL-1β response in
primary WT and MyD88-/- microglia. WT and MyD88-/- microglia were plated for 24
hours in growth medium with FBS and GM-CSF and the next day replaced with assay
medium without FBS and GM-CSF, treated with LPS at final concentrations of 3, 10, 30,
and 100 ng/mL for 6 hours. The cellular medium was analyzed by ELISA for
quantifying TNFα and IL-1β.
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Figure 2.5. Concentration-dependence of Pam3CSK4-induced TNFα and IL-1β
response in primary WT and MyD88-/- microglia. WT and MyD88-/- microglia were
plated for 24 hours in growth medium with FBS and GM-CSF and the next day replaced
with assay medium without FBS and GM-CSF, treated with Pam3CSK4 at final
concentrations of 3, 10, 30, and 100 ng/mL for 6 hours. The cellular medium was
analyzed by ELISA for quantifying TNFα and IL-1β.
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Figure 2.6. Concentration-dependence of FSL-1-induced TNFα and IL-1β response
in primary WT and MyD88-/- microglia. WT and MyD88-/- microglia were plated for
24 hours in growth medium with FBS and GM-CSF and the next day replaced with assay
medium without FBS and GM-CSF, treated with FSL-1 at final concentrations of 3, 10,
30, and 100 ng/mL for 6 hours. The cellular medium was analyzed by ELISA for
quantifying TNFα and IL-1β.
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of increasing concentrations. The previous method used to measure protein
concentration, known as the Lowry method, used Folin-Ciocalteu reagent to enhance the
sensitivity of the Biuret reaction, while this assay uses the bicinchoninic Acid to enhance
the sensitivity of the Biuret reaction. The Biuret reaction results in the formation of a
light blue complex by the chelation of copper with protein in an alkaline environment.
The intense purple color is then formed when two bicinchoninic acid molecules reacts
with one reduced cuprous cation. The BCA assay is known to have a greater tolerance
toward commonly encountered interferences, such as nonionic detergents and simple
buffer salts and can be strongly influenced by amino acids such as cysteine, tyrosine, and
tryptophan. The stability of this method and its resulting chromophore allows for a more
simplified technique and one-step analysis (Smith et al., 1985).
In addition to in-line UV absorbance, the BCA assay was also utilized to measure
Aβ concentrations. A standard curve was constructed using SEC-purified Aβ(1-40)
monomer diluted in aCSF typically in the concentration range of 5 μM to 80 μM. Aβ(140) standards or Aβ(1-42) samples (10 μL) were added to 100 μL of 50:1 mixture of
BCA Reagent A to Reagent B (Thermo Fisher Scientific) and mixed thoroughly in
individual wells of a 96-well plate. Reagent A contains sodium carbonate, sodium
bicarbonate, bicinchoninic Acid detection reagent and sodium tartrate in 0.1N sodium
hydroxide, while Reagent B contains an oxidized copper reagent. The plate was then
covered and incubated for 30 minutes at 37 °C followed by cooling for an additional 15
minutes. Absorbance was then determined for each well at a wavelength of 562 nm.
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2.7.2 Bradford Assay
The Bradford assay is also a method for determining protein concentration and
involves the binding of Coomassie Brilliant Blue G-250 to protein. The binding causes a
shift in the absorption maximum of the dye from 465 to 595 nm. This method has shown
to be very reproducible, rapid and stable. There have been little to no interferences
reported other than a small color change in the presence of strong alkaline buffers or
detergents such as sodium dodecyl sulfate, Triton X-100, and commercial glassware
detergents, however, the assay is reliable if the correct buffer controls are used (Bradford,
1976).
Aβ(1-40) standard curves were also evaluated using the Bradford method
(Bradford, 1976) to determine Aβ protein concentrations. Briefly, 10 μL from Aβ(1-40)
standard solutions ranging from 20-60 μM were placed on the bottom of a polystyrene
semi-micro disposal cuvette (Perfector Scientific), 1.5 ml 1x Bradford reagent (BioRad)
was then added, the cuvette was then inverted several times and incubated for 10 minutes
at room temperature. After the incubation, the absorbance was determined at 595 nm.

2.7.3 Aβ C-terminal Selective ELISA
Even though the ratios formed, as described in the methods above 2.4, obtained a
specific amount of Aβ(1-42) and a specific amount of Aβ(1-40), it was unclear how much
of each peptide populated the SEC-isolated protofibrils and monomers. Therefore our lab
established an Aβ C-terminal selective ELISA in an attempt to observe how much Aβ(142) and Aβ(1-40) was incorporated into each SEC-isolated species.
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The Aβ antibodies used were received as a generous gift from Mayo Clinic. Cterminal selective antibodies Ab2.1.3 (Aβ42 specific) and Ab13.1.1 (Aβ40 specific) were
employed as capture antibodies, while the detection antibody used, Ab5, recognized both
Aβ peptides (Chakrabarty et al., 2010). For this purpose Ab5 was conjugated to HRP,
based on the method from Wisdom et al., 2005 (Wisdom, 2005), and performed by Ben
Colvin.
Measuring the levels of Aβ(1-42) and Aβ(1-40) in each SEC-isolated Aβ(142):Aβ(1-40) protofibril and monomer fraction was determined by ELISA. While this
protocol was based on the protocols used for the measuring cellular cytokines as
mentioned above and in our laboratories previous publications (Paranjape et al., 2013),
this protocol had to be modified slightly. Briefly, a 96-well plate was coated overnight at
room temperature with 5.0 μg/mL Ab2.1.3 (Aβ42 specific) or Ab13.1.1 (Aβ40 specific)
capture antibodies (stock aliquots were stored at -20 °C at 1.6 mg/mL determined by Ben
Colvin). The next day the wells were washed with PBS containing 0.05% Tween 20,
then blocked with for 1 hour at room temperature with PBS containing 1.0% BSA, 5.0%
sucrose and 0.05% NaN3 and again followed by a wash step. Successive treatments at
room temperature with washing in between were done with samples or standards for 2
hours, HRP-Ab5 detection antibody for 2 hours, and equal volumes of HRP substrates
TMB and hydrogen peroxide for 25 minutes. The Ab5 detection antibody-HRP
conjugate was added to the wells at a final concentration of 0.12 μg/mL, determined by
Ben Colvin (stock aliquots stored at -20 °C at concentrations determined by SEC
purification: SEC fraction 13 is 0.0572 mg/mL, SEC fraction 14 is 0.2467 mg/mL and
fraction 15 is 0.1461 mg/mL) in 20 mM Tris with 150 mM NaCl and 0.1% BSA. The
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reaction was stopped by the addition of 1% H2SO4 solution. The SpectraMax 340
absorbance plate reader (Molecular Devices, Union City, CA) was used to read the
optical density of each sample at 450 nm with a reference reading at 630 nm. The
concentrations of Aβ(1-42) and Aβ(1-40) were calculated from a SEC-isolated Aβ(1-42)
or Aβ(1-40) monomeric standard curve of 1000-10000 pg/mL. The standards were
produced using the Aβ monomer preparation mentioned in the methods 2.4.2 and then
stored at 4 °C. The samples were diluted to fall within the standard curve.
When optimizing this method it was observed that the Aβ(1-42) standard curve
was gradually producing a smaller absorbance range over the same Aβ concentrations.
Due to the known fact that Aβ(1-42) aggregates faster than Aβ(1-40) the reduction in
absorbance was hypothesized to be caused by aggregation. To confirm this hypothesis
SEC-freshly purified Aβ(1-42) monomer was diluted into three different concentrations,
10, 1.0 and 0.1 μM, because the rate of aggregation is also known to be slowed at lower
Aβ concentrations. Therefore if the different concentrations were used to perform
multiple standard curves over time, it could then be observed whether aggregation plays a
role in the reduced absorbance readings. The hypothesis was confirmed by measuring the
10 μM Aβ(1-42) monomer over a 32 day time period. It was observed that as the
incubation time increased the absorbance range decreased (Figure 2.7A), however the
observed slopes varied only minimally. Once it became obvious that the absorbance was
decreasing for the standard curve from the 10 μM stock, the lower concentrations were
tested (1 and 0.1 μM) after 17 days of incubation at 4 °C (Figure 2.7B). It was detected
that the 1.0 μM stock Aβ(1-42) monomer showed a greater absorbance range indicating
that aggregation does affect the standard curve absorbance and possibly plays a role in
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detection by the Aβ antibodies. It was also observed that the lowest stock concentration
(0.1 μM) showed little to no absorbance; these low absorbance readings were attributed
to the possible loss of a small amount of Aβ during incubation, due to the stickiness of
the Aβ and its adherence to the microcentrifuge tube. Another way to conclude that
aggregation affects the absorbance reading during the Aβ ELISA is to dilute the
aggregated Aβ in a denaturant to break up some of the aggregated species. This method
was performed by the use of GuHCl. To test this the standard curve of the 10 μM Aβ(142) monomer stock after 32 days of incubation was compared to the same stock monomer
but diluted first in GuHCl (Figure 2.7C). The GuHCl also showed that aggregation does
play a role in the reduction of the standard curve optical densities. Taking into account
the data presented here (Figure 2.7) the standards for both the Aβ(1-42) and Aβ(1-40)
ELISA along with the unknown ratio samples were first diluted into GuHCl to reduce the
amount of aggregation and increase the absorbance and possibly the efficiency of the Aβ
antibodies. Ben Colvin also examined the selectivity of the antibodies by performing an
Aβ(1-42) standard curve with the Aβ(x-40) selective antibody and an Aβ(1-40) standard
curve with the Aβ(x-42) selective antibody. The absence of an increase in absorbance
confirmed that both antibodies were selective for their own antigen (unpublished).

2.8 Viability and Proliferation of cells After Treatment

2.8.1 XTT Cell Viability Assay
Viability of the BV-2 microglia and THP-1 macrophages were monitored using
the XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide]
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Figure 2.7. Optimization of Aβ C-terminal selective ELISA. Panel A. A log-log plot
of the 10 μM SEC-isolated Aβ(1-42) monomer standard curve over time. The Aβ(1-42)
monomer was incubated at 4 °C over a 32 day period and a standard curve was performed
on various separate days. Panel B. A log-log plot of standard curves from SEC-isolated
Aβ(1-42) monomer that have been incubated at 4 °C for 17 days at 10, 1, and 0.1 μM.
Panel C. A log-log standard curve plot of SEC-isolated Aβ(1-42) monomer that has been
incubated for 32 days at 4 °C at 10 μM. One standard curve the Aβ(1-42) was diluted
normally in standard diluent and the second standard curve the Aβ(1-42) was first diluted
into GuHCl and then further diluted into standard diluent.
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assay. XTT is a tetrazolium dye that can be monitored by the absorbance of its reduced
form. XTT can be reduced by the mitochondrial electron transport chain in the presence
of phenazine methosulfate (PMS, Acros, Morris Plains, NJ), which forms a water-soluble
formazan product, and is an indicator of cellular health (Scudiero et al., 1988).
XTT arrived as a yellow colored solid, which was divided into ~15 mg aliquots
and stored at -20 °C in 15 mL conical tubes. For an experiment, the solid in one aliquot
was resuspended under aseptic conditions in sterile RPMI-1640 medium without phenol
red at a concentration of 1 mg/mL. The 1 mg/mL XTT solution was then aliquotted into
0.5 mL aliquots and stored at -20 °C. The PMS was also dissolved in aseptic conditions
at a concentration of 5 mM in sterile water, and aliquots were stored at -20 °C. In both
BV-2 microglia and THP-1 macrophage experiments, the cells that were exposed to
treatment of any kind for 6 hours were further incubated with 0.33 mg/mL XTT diluted in
RPMI-1640 without phenol red and 8.3 μM PMS for 2 hours at 37 °C and 5% CO2. The
viability of the cells was measured by the extent of XTT reduction. The absorbance of
the reduced form of XTT was measured at 467 nm.
The viability of an Aβ solution can also be measured by XTT in a method known
as cell-free XTT assay. This technique was completed to make sure there was no
bacterial contamination within the Aβ solution. The cell free XTT was done in a similar
manner as the above cellular XTT, except the Aβ sample was incubated with a solution
containing 0.33 mg/mL XTT and 8.3 μM PMS without any cells at a final Aβ
concentration of 15 μM for 6 hours. After the incubation period, the reduced form of
XTT was again measured by absorbance at 467 nm.
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2.8.2 LDH Release Assay
An alternative to XTT of cell viability is the lactate dehydrogenase (LDH) release
assay. This assay was used with the BV-2 microglia to verify the XTT analysis. This
technique measures the amount of LDH released into the cellular medium to assess the
viability of the cells, because the release of LDH is an indicator of leakage from the
microglia due to disruption or damage to the cellular membrane (Tan et al., 2014). This
assay involves LDH-mediated reduction of nicotinamide adenine dinucleotide (NAD +),
and is coupled to XTT reduction to enhance the assay’s sensitivity. This procedure was
modified slightly from Korzeniewski et al., 1983 (Korzeniewski and Callewaert, 1983).
Following stimulation of the BV-2 microglia with LPS for 24 hours, the cellular
medium was removed and centrifuged to remove any of the detached microglia. The
sample medium (25 μL) was added to a 2:1 ratio of LDH reaction cocktail containing 150
mM CAPS buffer at pH 10.0 in water, 6 mM NAD+ in water, and 150 mM lactate in
water (all from Sigma Aldrich, St. Louis, MO), to XTT/PMS, containing 0.33 mg mL-1
XTT and 8.3 μM PMS. The amount of LDH release was measured by the change in
absorbance of reduced XTT at 467 nm over a linear time course of 5 minutes. These
samples were also compared to a positive control, where the BV-2 microglia were treated
with saponin, a known cellular toxin. Saponin causes significant LDH release from
microglia by removing cholesterol and disrupting the membrane integrity (Tan et al.,
2014).
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2.8.3 Cell Adhesion and Growth
Cell adhesion of adherent cells and cell proliferation are also ways to observe the
viability of a cellular culture. The cell adhesion and proliferation observations were
conducted in BV-2 microglia. The microglia were removed from the culture flask,
centrifuged, and resuspended in fresh growth medium as mentioned above in 2.5.
However, in these experiments, 300 μL of the microglia were plated at 5 x 105 cells mL-1
and incubated overnight at 37 °C and 5% CO2. The next day the microglia were
replenished with fresh growth medium and treated with LPS for 24 hours or longer.
After 24 hours the medium was removed and the cells in the medium were counted using
a Cellometer Auto T4 Plus SK-150 cell counter (Nexcelom Bioscience LLC, Lawrence,
MA, USA). The number of counted cells in the medium was then divided by the total
number of cells plated to determine the percentage of detached cells. The magnitude of
microglia proliferation was determined by directly counting the number of adherent
microglia over time (24, 48, and 72 hours). After each incubation time point, the cellular
medium was removed and the adherent cells were detached the same way as they were
detached from the culture flask, 0.25% trypsin. The number of adherent cells was then
counted using the same Cellometer, as mentioned above, along with the same calculation
to calculate the percent of attached cells.

2.9 ThT Measurements
Thioflavin-T Fluorescence (ThT) is a benzothiazole dye, which shows increased
fluorescence when bound to amyloid fibrils (Khurana et al., 2005) specifically binding to
the β-sheet secondary structure of aggregated Aβ. This dye has been extensively used
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for characterization of amyloid fibril presence and their rate of formation (Krebs et al.,
2005). Freshly purified Aβ(1-42), Aβ(1-40), and ratios of Aβ(1-42)/Aβ(1-40) monomer
and protofibrils solutions were monitored by ThT-fluorescence. For the experiment, the
Aβ solution was diluted to a final concentration of 5 μM in a final ThT concentration of 5
μM prepared in 50 mM Tris-HCl buffer (pH 8.0) to make a total volume of 100 μL.
Using a Cary Eclipse Fluorescence spectrophotometer, the ThT fluorescence emission
scans (460-520 nm) were carried out at an excitation wavelength of 450 nm. The actual
ThT fluorescence values were generated by integrating the emission scan between 470500 nm. The vehicle buffer control, aCSF, showed little to no ThT fluorescence when
used as a negative control in the absence of Aβ.

2.10 TEM
Transmission Electron Microscopy (TEM) was used to examine SEC-purified
Aβ(1-42), Aβ(1-40) and ratios of Aβ(1-42):Aβ(1-40) protofibrils and monomer after
aggregation. The samples were diluted to 20 μM in water and 10 μL were applied to a
200-mesh formvar-coated copper grid, the red side of the grid (Ted Pella Inc.). The
samples were allowed to incubate at room temperature for 10 minutes and then the excess
Aβ solution was removed by a Kimwipe. The grids were then washed three times by
being placed Aβ side down on a droplet of water. Heavy metal staining was performed
next by a 5 minute incubation of the grid, Aβ side down, on a droplet of 2 % uranyl
acetate (Electron Microscopy Sciences, Hatfield, PA). Lastly, the excess stain was
removed by a Kimwipe and the grid was allowed to air dry under a petri dish lid to avoid
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accumulation of dust particles. The affixed samples were visualized with a Philips EM
430 TEM at 300 kEv (courtesy of David C. Osborn).

2.11 DLS
Dynamic Light Scattering (DLS) was the technique used to assess the RH
measurements of Aβ(1-42):Aβ(1-40) ratios. The measurements were made at room
temperature with a DynaPro Titan instrument (Wyatt Technology, Santa Barbara, CA).
For each measurement, 30 μL of each sample was placed directly into a quartz cuvette
and light scattering intensity was collected at a 90° angle using a 10-second acquisition
time. Auto-corrected light intensity data was used to calculate particle diffusion
coefficients and converted to RH with the use of the Stokes-Einstein equation. Dynamics
software (version 6.7.1) was used to generate average RH values and to show histograms
of percent intensity vs. RH by data regulation and intensity-weighted mean RH values.
All DLS measurements were made and analyzed by Dr. Michael R. Nichols.
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CHAPTER 3

Aβ(1-42) PROTOFIBIRLS REGULATE IL-1β LEVELS AT MULTIPLE SITES IN
MICROGLIA

3.1 Introduction
AD is the most prevalent form of late-life dementia amidst the different
neurodegenerative disorders and has been defined by the presence of two pathological
hallmarks, NFTs and senile (amyloid) plaques. The NFTs are intracellular lesions of
insoluble, highly stable filamentous aggregates of the microtubule associated protein, tau,
whereas the senile plaques are extracellular lesions of insoluble, amyloid fibrils that are
polymers of the Aβ protein (Dickson, 2004, Selkoe, 2001). Recent data has shown that
the toxicity of Aβ actually lies within the soluble oligomeric intermediates found in the
AD brain and CSF, rather than the insoluble fibrils (Haass and Selkoe, 2007, Kayed et al.,
2003). These soluble oligomeric forms of Aβ have shown to contribute to the onset of
AD and induce neuronal and/or synaptic dysfunction (Haass and Selkoe, 2007, Lee et al.,
2006).
There has been an array of different aggregate morphologies of Aβ found within
the AD brain (Selkoe, 2004). The core of the Aβ plaques is primarily composed of the
42-amino acid Aβ fragment, Aβ(1-42). However, Aβ(1-40) has also been found
colocalized with the Aβ(1-42) (Selkoe, 2001). In vitro, the Aβ monomer undergoes the
self-assembly by non-covalent interactions to form polydisperse mixtures of soluble
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oligomers (Kayed et al., 2003) and protofibrils (Harper et al., 1997, Walsh et al., 1997).
These soluble aggregates go through a conformational transition from predominately
random coil to increasing amounts of β-sheet structure and ultimately produce insoluble
fibrils (Harper et al., 1999, Walsh et al., 1999). As a precursor to mature fibrils,
protofibrils have been characterized fairly well and have been shown to alter the normal
physiology of cultured neurons (Hartley et al., 1999), disrupt ion channels (Ye et al.,
2003), block LTP, inhibit synapse remodeling and impair memory consolidation
(O'Nuallain et al.).
A prominent component of AD pathology is the neuroinflammation found in the
affected areas of the AD brain. The evidence of inflammation, such as activated
microglia and proinflammatory cytokines, is most predominantly observed surrounding
the Aβ lesions within the AD brain (McGeer et al., 1987). The exact sequence of events
leading to AD is still unknown; however, it is thought that the accumulation of the Aβ
protein initiates a pathological cascade of events leading to neuronal dysfunction and
ultimately dementia. One downstream event of the pathological cascade is an
inflammatory response involving the activation and proliferation of microglia and
astrocytes which leads to an increase of inflammation associated proteins and markers of
oxidative stress (Golde, 2002). If the inflammation persists, it can lead to a chronic
inflammatory state, which has been suggested to be one of the underlying mechanism
causing progressive neurodegeneration (Golde, 2002, McGeer and McGeer, 1998).
The innate immune system protects the organism by recognizing invading
pathogens using PRRs. Both microglia and astrocytes express TLRs, which are a family
member of the PRRs and act by allowing the recognition of PAMPs of bacteria, fungi,
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and viruses. When activated, the TLR family, with the exception of TLR3, leads to the
recruitment of the adaptor protein myeloid differentiation protein 88 (MyD88), the
activation of the transcription factor nuclear factor-κB (NF-κB) and the expression of a
variety of genes involved in immune response, such as TNFα and pro-IL-1β (Kielian,
2006). However, the mechanism by which Aβ evokes a proinflammatory response is
very complex and many TLRs and accessory proteins have been shown to play a role in
the Aβ-induced proinflammatory response in monocytes/macrophages and microglia
including CD36, TLR4 and TLR6 (Stewart et al., 2010), and CD14, TLR2 and TLR4
(Fassbender et al., 2004, Reed-Geaghan et al., 2009, Udan et al., 2008). Studies have also
shown that a multireceptor complex comprised of SR class B (SR-B), CD36, α6β1integrin and the integrin associated protein CD47 interacts with Aβ and initiates an
inflammatory response (Bamberger et al., 2003).
Extracellular recognition of PAMPs by TLRs and downstream signaling events
can trigger oligomerization of cytoplasmic NLRs to form a multisubunit inflammasome
complex (Kersse et al., 2011). Different NLR family members vary in their N-terminal
protein-protein interaction region. For example, NLRP3 contains a pyrin domain, which
is responsible for complexation with ASC, the adaptor molecule containing CARD (Latz
et al., 2013). An important aspect of TLR signaling is the production of IL-1β mRNA and
the pro-form of IL-1β protein (pro-IL-1β). This event is considered “priming” of the
inflammasome and represents Signal 1 of a 2-stage process (Hanamsagar et al., 2012).
Many molecules, including the classical TLR4 agonist LPS, are known to stimulate
priming of the inflammasome (Signal 1) but not activation (Signal 2). Inflammasome
assembly via a CARD-CARD interaction brings caspase-1 to the complex and activation
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of the complex triggers caspase-1-catalyzed proteolytic cleavage of pro-IL-1β to mature
IL-1β (Schroder and Tschopp, 2010). A second signal is required for the inflammasome
activation step and subsequent production of mature IL-1β. Signal 2 may be provided by
a growing number of endogenous human molecules, referred to as DAMPs. These
molecules include certain pore-forming toxins, ATP, K+ efflux, and crystalline particles
such as silica and uric acid crystals (Hanamsagar et al., 2012).
Increasing data has demonstrated a significant role for the NLRP3 inflammasome
in AD (reviewed in (Tan et al., 2013)). Double transgenic mice that overexpress human
APP with familial AD mutations and have a deficiency in the NLRP3 inflammasome
showed a reduction in AD pathology and were protected from the ensuing cognitive
defects (Heneka et al., 2013). Earlier in vitro studies demonstrated that fibrillar Aβ
stimulated NLRP3 inflammasome activation and IL-1β production in microglia and this
process was shown to involve phagocytosis, lysosomal damage, and release of cathepsin
B (Halle et al., 2008). Another report confirmed fibrillar Aβ-stimulated inflammasome
activation but demonstrated that pre-priming of the inflammasome was required (Wu et
al., 2013). However, it was recently shown that Aβ may be able to provide both priming
and activation signals (Sheedy et al., 2013).

3.2 MyD88-Dependent Microglia Aβ(1-42) Protofibril-Induced Stimulation and
Priming of the NLRP3 Inflammasome
Aβ(1-42) protofibrils were prepared as mentioned in the methods and isolated by
SEC (Paranjape et al., 2013, Walsh et al., 1997). We have previously shown that this
protofibril preparation produces a Superdex 75 void-volume fraction containing Aβ
protofibrils characterized as curvilinear structures less than 100 nm in length with a RH
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range of 10-40 nm and an average RH of 21 nm (Paranjape et al., 2013). Our SECisolated soluble protofibrils have also shown to bind and enhance ThT fluorescence
emission at 480 nm compared to the SEC-isolated monomer, which elutes in the included
volume and did not show enhanced ThT fluorescence (Paranjape et al., 2012, Paranjape
et al., 2013). We have also previously demonstrated that Aβ(1-42) protofibrils, but not
Aβ(1-42) fibrils, are activators of microglia (Paranjape et al., 2012, Paranjape et al.,
2013) and that these soluble fibrillar precursors are able to trigger a proinflammatory
response via TLRs (Udan et al., 2008).
In this investigation, the role of MyD88 in Aβ(1-42) protofibril-induced cytokine
production, NLRP3 inflammasome activation and IL-1β production and secretion was
examined. During this investigation, I identified multiple points of regulation by Aβ
protofibrils including new insights into the IL-1β secretion process. The first observation
was of the mRNA levels of proinflammatory cytokines, TNFα and IL-1β. Primary
murine microglia were treated with SEC-isolated Aβ(1-42) protofibrils at different
incubation times and the mRNA levels were quantified. Protofibrils showed to
significantly increase the TNFα (Figure 3.1A) and IL-1β (Figure 3.1B) mRNA levels by
2 hours followed by a rapid drop of the transcript at the 4 and 6 hour time points.
Several TLRs have been demonstrated to recognize extracellular Aβ and initiate a
proinflammatory event in monocytes/macrophages and microglia (Fassbender et al.,
2004, Jana et al., 2008, Liu et al., 2012, Reed-Geaghan et al., 2009, Stewart et al., 2010,
Udan et al., 2008). One cytoplasmic mediator following signal transduction of TLR
stimulation and prior to NFκB activation is MyD88 (Kielian, 2006). Microglia isolated
from either WT or MyD88-/- mice were used to assess the contribution of TLR/MyD88
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Figure 3.1. Aβ(1-42) protofibrils formed and isolated in aCSF are significant
stimulators of TNFα and IL-1β transcription. SEC-isolated Aβ(1-42) protofibrils in
aCSF were incubated with WT primary microglia at a final concentration of 15 μM for 1,
2, 4, and 6 hours in serum-free medium. At each time point the cells were lysed for total
RNA extraction. TNFα (Panel A) and IL-1β (Panel A) mRNA levels were measured by
qPCR as described in Chapter 2, section 2.5.5.4. The term relative quantity is described
in Chapter 2, section 2.5.5.4 and represents the mRNA comparison between microglia
treated with Aβ(1-42) protofibrils and those treated with buffer control. β-actin was used
as an internal control in separate experiments and did not vary significantly between
samples. Data bars represent the mean ± standard error of n=8 qPCR trials. TNFα and
IL-1β mRNA levels at 2 hours were significantly different than any other time point
(*p<0.001).
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signaling in the Aβ protofibril-induced cytokine mRNA upregulation. WT microglia
again showed increase responsiveness at 2 hours in both TNFα and IL-1β mRNA to
Aβ(1-42) protofibrils (Figure 3.2). However, this responsiveness was significantly
diminished in MyD88-/- microglia compared to WT microglia. In the MyD88 -/microglia, the TNFα and IL-1β levels were comparative to the buffer controls (Figure
3.2). This data revealed that the transcriptional activation-induced by Aβ(1-42)
protofibrils is TLR/MyD88-dependent.
The next step along this pathway is the translation of the IL-1β mRNA to pro-IL1β, which was explored further by measuring the amount of intracellular pro-IL-1β using
an ELISA specific for the pro-form of IL-1β. The specificity of the pro-IL-1β ELISA
was confirmed by the observation that a mature IL-1β standard curve was not detected by
the pro-IL-1β specific antibodies, as seen in Chapter 2, Figure 2.4. After treatment of the
microglia with Aβ protofibrils, the conditioned medium was removed, the cells were
washed and lysed, the extract was analyzed and several observations were made. One
observation was the presence of existing stores of pro-IL-1β in the unstimulated WT and
MyD88-/- microglia after 6 hours (Figure 3.3). These stores indicate some level of
underlying basal NLRP3 inflammasome priming in the isolated primary microglia. This
may be unintentionally caused by the isolation and culturing process or intentionally
caused by the cells as an intracellular reservoir in order to induce a rapid microglial
response to potential stimuli. The second observation was the significant increase in the
pro-IL-1β levels in the WT microglia-induced by Aβ(1-42) protofibrils compared to the
control treatment after 4 (P<0.005, one-way ANOVA) and 6 hours (P<0.005) (Figure
3.3A). However, this same analysis did not show a significant difference in the MyD88 -/-

110

relative quantity

750000

0

A

40000

*

WT

0

KO

B

*

WT

KO

Figure 3.2. TNFα and IL-1β mRNA production is reduced in the MyD88−/−
microglia in response to protofibrils. SEC-isolated Aβ(1-42) protofibrils were
incubated with WT primary microglia and MyD88−/− (KO) microglia at a final
concentration of 15 μM for 2 hours in serum-free medium. After 2 hours the total RNA
was collected and TNFα (Panel A) and IL-1β (Panel B) mRNA levels were quantified by
qPCR as described in Figure 3.1 legend. Data bars represent the mean ± standard error of
n=8 qPCR trials. Absolute relative quantity values fluctuated between experiments (e.g.
TNFα mRNA Figure 3.1A and 3.2A) due to the exponential in the calculation which is
sensitive to small changes in raw data. Protofibril-treated microglia were compared to
aCSF-treated microglia to determine relative quantity. When comparing WT and
MyD88−/− microglia, experiments were always done on the same day. Statistical analysis
confirmed a significant difference (*p<0.001) between the WT and MyD88 −/− microglial
TNFα and IL-1β mRNA response.
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microglia (P>0.05) (Figure 3.3B). These data points were examined further by univariate
ANOVA considering both Aβ(1-42) protofibril-induced and vehicle control in both WT
and MyD88-/- microglia. This comparison showed a lesser, but still significant difference
(P<0.05) between the WT and MyD88-/- microglial response at the 6 hour time point.
The time-dependence production of pro-IL-1β was somewhat variable and difficult to
quantitate due to the observation that the protofibrils may have the ability to activate the
NLRP3 inflammasome, creating a dynamic pool of pro-IL-1β with a balance between
production and conversion to mature IL-1β.

3.3 Production of Intracellular Mature-IL-1β Induced by Aβ(1-42) Protofibrils in Primary
Microglia
Recent observations have demonstrated a role for Aβ in the activation of the
NLRP3 inflammasome (Halle et al., 2008, Heneka et al., 2013, Sheedy et al., 2013, Wu et
al., 2013). The activation of the NLRP3 inflammasome results in caspase-1 mediated
proteolytic cleavage of pro-IL-1β (31 kD) to the mature form of IL-1β (17 kD). When
studying the intracellular inflammasome processing of pro-IL-1β to mature IL-1β by
Aβ(1-42) protofibrils in WT microglia, both immunoblots and ELISA were used to
evaluate the intracellular pro- and mature IL-1β. Primary WT microglia were treated for
increasing times with SEC-isolated Aβ(1-42) protofibrils and the cells were lysed to
access intracellular IL-1β levels. Western blots were performed using 3ZD antibody,
which recognizes both pro- and mature IL-1β. The analysis showed a consistent pool of
pro-IL-1β throughout the time course of both the Aβ(1-42) protofibril induced and
vehicle control treated microglia (Figure 3.4A). In the same blot, significant levels of
intracellular mature IL-1β was observed after 4 and 6 hours of Aβ(1-42) protofibril
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Figure 3.3 Aβ(1-42) protofibrils stimulate intracellular pro-IL-1β production in
microglia. SEC-isolated Aβ(1-42) protofibrils in aCSF (gray bars) or aCSF buffer alone
(black bars) were incubated with WT (Panel A) and MyD88−/− (Panel B) primary
microglia at a final concentration of 15 μM for 1, 2, 4, and 6 hours in serum-free medium.
After each time point the conditioned medium was removed, the cells were lysed and the
extract was collected to measure intracellular pro-IL-1β protein by ELISA. Data bars
represent the average ± standard error of n=5 trials. One-way ANOVA looking at each
time point individually showed a significant difference between control and protofibrilstimulated WT microglia at 4 and 6 hours (both p<0.005) with no statistical difference at
1 and 2 hours in WT microglia and at any time point in MyD88−/− microglia. Univariate
ANOVA considering both treatment and the presence of MyD88 showed a lesser, but still
significant, difference (*p<0.05) between the WT and KO microglial response at only the
6 hour time point.
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treatment where no mature IL-1β was observed at 1 and 2 hours (Figure 3.4A). ELISAbased IL-1β measurements were also conducted on the same samples, showing the same
time-dependent production of intracellular mature IL-1β with significant increases at 4
and 6 hours (Figure 3.4C). It is possible that the IL-1β ELISA antibodies detect both the
pro- and mature IL-1β forms of the protein, however, the large increase in the IL-1β
levels measured by the ELISA (Figure 3.4C) corresponded with the increases observed in
the Western blot (Figure 3.4A). This suggests that the increase in the ELISA was mature
IL-1β protein. The intracellular mature IL-1β levels appear high due to the combination
of multiple wells (n=5) to prepare cell extracts in a small volume to increase detection
levels in the Western blot. A longer time course was also conducted at different
incubation times of the Aβ(1-42) protofibrils-induced primary microglia up to 24 hours
(Figure 3.4B and D). Both the Western blot and ELISA confirmed that the intracellular
mature IL-β levels continued to increase after the microglia were stimulated with Aβ(142) protofibrils.
So far, the time course data has shown that Aβ triggers the TLR/MyD88 pathway
leading to the transcription of IL-1β mRNA, synthesis of pro-IL-1β, and conversion of
pro- to mature IL-1β. Experiments were also completed to test this model by comparing
the intracellular mature IL-1β levels between WT and MyD88-/- microglia after treatment
with Aβ(1-42) protofibrils. WT microglia produced significant levels of intracellular IL1β while the MyD88-/- microglia were severely diminished in their ability to produce
intracellular mature IL-1β (Figure 3.4E). After a 6 hour incubation in the MyD88-/-,
microglia mature IL-1β levels were only 8% of the WT microglia, while no mature IL-1β
above the control was produced at 24 or 48 hours in the MyD88-/- microglia after with
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Figure 3.4. Aβ(1-42) protofibrils stimulate time- and MyD88-dependent
intracellular mature IL-1β accumulation in microglia. Panel A and C. WT primary
microglia were treated with SEC-isolated Aβ(1-42) protofibrils (15 μM) in aCSF (+) or
just aCSF buffer (−) and incubated for 0.5, 1, 2, 4, and 6 hours in serum-free medium at
37 °C. At each time point the cells were lysed and extracts prepared for intracellular IL1β Western blot (Panel A) and ELISA (Panel C) analysis. A separate, but similar
experiment was done over a longer time course with the same analysis (Panel B Western
blot, Panel D ELISA). Each cell extract sample for all panels was obtained from five
replicate wells in a 96-well plate and the band or data bar is representative of the 5-well
extract pool. Panel E. Intracellular mature IL-1β was measured by ELISA after
treatment of WT and MyD88−/− primary microglia (KO) with Aβ(1-42) protofibrils (15
μM) for 6 hours in serum-free medium. Extracts were prepared as above. Control
treatments with an equal volume of aCSF were subtracted from Aβ-stimulated samples
and averaged 10% for intracellular IL-1β.
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Aβ(1-42) protofibrils.

3.4 Time-Dependent Sequence of Aβ(1-42) Protofibril-Induced Microglia TNFα and IL1β Protein Secretion
Primary microglia were treated with SEC-isolated Aβ(1-42) protofibrils for
different lengths of time and the amount of secreted proinflammatory cytokines TNFα
and IL-1β were quantified from within the conditioned medium. The protofibrils were
able to induce a steady increase in the amount of secreted TNFα protein over a 6 hour
incubation (Figure 3.5A). The TNFα protein was in-line with the observed TNFα mRNA
seen in Figure 3.1A, where most of the protein was secreted after the majority of the
mRNA was transcribe. The Aβ(1-42) protofibril-induced IL-1β secretion time course
was significantly different than what was observed for TNFα. The maximal level of
secreted mature IL-1β was unexpectedly observed after a 1 hour incubation time and was
maintain at the same level through 6 hours (Figure 3.5B). This observation was
unexpected due to the maximal IL-1β protein secretion induced by Aβ(1-42) protofibrils
being observed prior to the induction of the maximal IL-1β mRNA transcription (Figure
3.1B). Additional experiments were performed and found that maximal levels of secreted
IL-1β protein were observed as early as 15 minutes, which was the earliest time point
tested. The amount of IL-1β produced by the microglia after overnight plating was also
observed and showed that there was no IL-1β secreted during overnight plating. This
data made it apparent that the microglia secrete a rapid quantum of mature IL-1β after
Aβ(1-42) protofibril stimulation and that the time point in which the conditioned medium
was collected was irrelevant. This rapid IL-1β secretion pattern was observed multiple
times. In fact, during the intracellular experiments presented in Figure 3.4A-D, secreted
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Figure 3.5. Aβ(1-42) protofibrils stimulate rapid IL-1β secretion but a slower timedependent TNFα secretion. SEC-isolated Aβ(1-42) protofibrils in aCSF were incubated
with WT primary microglia at a final concentration of 15 μM for 1, 2, 4, and 6 hours in
serum-free medium. At each time point the conditioned microglial medium was
collected for TNFα and IL-1β protein determination by ELISA. Panel A. TNFα protein
levels were determined from the supernatant of individually treated wells. Data bars
represent the mean ± standard error of n=5 trials at each time point. Control treatments
with an equal volume of aCSF produced very low TNFα levels compared to protofibrils
ranging from 36-290 pg/ml (<4%) at the different time points and were subtracted from
Aβ-stimulated samples. TNFα levels at each successive time point are statistically
different than the preceding time point (p<0.001). Panel B. IL-1β protein levels were
measured in the same manner as for TNFα. Control treatments with an equal volume of
aCSF produced IL-1β levels of 1 pg/ml and were subtracted from Aβ-stimulated samples.
The length of incubation time had no statistical difference on the amount of secreted IL1β (p>0.05).
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IL-1β was also measured in the conditioned medium, which was collected prior to the
cell lysate preparation. The samples collected at 0.25, 1, 2, 4, 6, or 24 hours had a similar
quantum of secreted mature IL-1β within the conditioned medium (Figure 3.6), again
showing the collection time point did not matter. Measuring both the secreted and
intracellular mature IL-1β from the same cells provided even stronger evidence that the
rapid IL-1β secretion stimulated by the Aβ(1-42) protofibrils was temporally distinct
from, and not entirely dependent on, the Aβ-triggered intracellular mature IL-1β
accumulation. The time-dependent studies presented have revealed several interesting
findings: (1) the presence of a small amount of pre-existing pro-IL-1β in the isolated
primary microglia, (2) that the activation of the NLRP3 inflammasome-induced by Aβ(142) protofibrils occurs much faster than the activation of the TLR/MyD88 pathway and
cytokine transcription/translation-induced by Aβ(1-42) protofibrils, and (3) the
intracellular build-up of mature IL-1β does not necessarily translate into an increase in
the IL-1β secretion. This data also again shows that Aβ(1-42) protofibrils are able to
produce mature IL-1β without an additional stimulus, as is the case with LPS and ATP
(Kielian, 2006).

3.5 The Impact of MyD88 on the Aβ(1-42) Protofibrils-Induced Microglial TNFα and IL1β Protein Secretion
Secretion of the TNFα protein was compared in the WT and MyD88 -/- microglia
after being stimulated with three known TLR ligands: LPS (TLR4), PAM3CSK4
(TLR2/1) and FSL-1 (TLR2/6). The levels of TNFα were significantly decreased in the
MyD88-/- microglia compared to the WT in response to LPS (93.5% reduction), due to
the MyD88-/- microglia response not being completely diminished confirms both MyD88118
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Figure 3.6. Correlation of IL-1β secretion with intracellular IL-1β production in
primary microglia after stimulation with Aβ(1-42) protofibrils. The conditioned
medium (Aβ protofibril-treated) from the samples presented in Figure 3.4 was removed
and secreted IL-1β was measured by ELISA. Data bars represent the average ± standard
error of n=5 trials. Secreted IL-1β in panels A and B was determined from the
conditioned medium collected from the same samples used for lysate preparation and
intracellular IL-1β measurement in Figure 3.4 C and D, respectively.
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dependent and independent pathways (Figure 3.7A). However, this was not the case for
PAM3CSK4 and FSL-1, where the absence of MyD88 completely eliminated the TNFα
secretion (Figure 3.7A). These results were obtained using a ligand concentration of 100
ng/mL; however, similar responses were seen in additional experiments using 10 ng/mL
(Figure 3.7B). The microglial TNFα response to Aβ(1-42) protofibrils was significantly
lowered in the absence of MyD88 (88% reduction), demonstrating a significant role for
the adaptor protein in mediating an Aβ(1-42) protofibril-induced TNFα secreted
response. The remaining response indicates the possibility of additional pathways for
mediating TNFα secretion that are independent of MyD88 (Figure 3.7A).
The levels of secreted mature IL-1β protein were also observed in the WT and
MyD88-/- microglia conditioned medium after treatment with the three different TLR
ligands and Aβ(1-42) protofibrils. Neither LPS, PAM3CSK4, nor FSL-1 alone were able
to induce the secretion of mature IL-1β protein in WT nor MyD88-/- microglia (Figure
3.8A), confirming that these TLR ligands do not activate the NLRP3 inflammasome
without the addition of a second stimulus. SEC-isolated Aβ(1-42) protofibrils, however,
induced similar levels of secreted IL-1β protein in both WT and MyD88-/- microglia
conditioned medium collected after 1, 2, 4, and 6 hours of stimulation (Figure 3.8B). The
observation that the absence of MyD88 did not decrease the Aβ(1-42) protofibril induced
IL-1β protein secretion, but does significantly decrease the IL-1β mRNA (Figure 3.2),
was the second piece of evidence suggesting a potential intracellular reservoir of pro- or
mature IL-1β within the cell that was produced prior to stimulation with Aβ(1-42)
protofibrils.
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Figure 3.7. Aβ(1-42) protofibril-induced TNFα secretion is dependent on MyD88.
Panel A. TLR4 ligand LPS, TLR1/2 ligand Pam3CSK4, TLR2/6 ligand FSL-1, and SECisolated Aβ(1-42) protofibrils were incubated with WT and MyD88−/− (KO) primary
microglia at a final concentration of 100 ng/ml for all TLR ligands and 15 μM for Aβ for
6 hours in serum-free medium. Secreted TNFα was measured by ELISA in the
conditioned medium. Data bars represent the average ± standard error of n=3 trials for
LPS, Pam3CSK4, and FSL-1, and n=6 trials for Aβ(1-42) protofibrils. Data is presented
as % WT response. Actual TNFα levels were 28467, 5480, 2556, and 12652 pg/ml were
LPS, Pam3CSK4, FSL-1, and Aβ(1-42) protofibrils, respectively. Panel B. TLR4 ligand
LPS, TLR1/2 ligand Pam3CSK4, and TLR2/6 ligand FSL-1 were incubated with WT and
MyD88−/− (KO) primary microglia at a final concentration of 10 ng/ml for all TLR
ligands in serum-free medium. Secreted TNFα was measured by ELISA in the
conditioned medium. Data bars represent the average ± standard error of n=9 trials for
WT and n=12 trials for MyD88-/-. Data is presented as % WT response. Actual TNFα
levels were 16112, 1098, and 3874 pg/ml were LPS, Pam3CSK4, and FSL-1, respectively.
Control treatments with an equal volume of H2O or aCSF were less than 3% of the TNFα
response and were subtracted from TLR ligand- or Aβ-stimulated samples. Statistical
analysis showed a significant difference (p<0.005) between the WT and MyD88 −/− results
for all treatments.
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Figure 3.8. Aβ(1-42) protofibril-induced rapid IL-1β secretion is not dependent on
MyD88. Panel A. TLR4 ligand LPS, TLR1/2 ligand Pam3CSK4, TLR2/6 ligand FSL-1,
and SEC-isolated Aβ(1-42) protofibrils were incubated with WT and MyD88−/− (KO)
primary microglia at a final concentration of 100 ng/ml for all TLR ligands and 15 μM
for Aβ for 6 hours in serum-free medium. Secreted IL-1β was measured by ELISA in the
conditioned medium. Data bars represent the average ± standard error of n=3 trials for
LPS, Pam3CSK4, FSL-1, and Aβ(1-42) protofibrils. Panel B. SEC-isolated Aβ(1-42)
protofibrils were incubated with WT primary microglia and MyD88 −/− (KO) microglia at
a final concentration of 15 μM for 1, 2, 4, and 6 hours in serum-free medium. Secreted
IL-1β was measured by ELISA in the conditioned medium. Data bars represent the
average ± standard error of n=5 trials. Control treatments with an equal volume of aCSF
produced 1 pg/ml IL-1β at all time points for both the WT microglia and the MyD88 −/−
microglia and were subtracted from Aβ-stimulated samples. Statistical analysis showed
no significant difference between the WT and MyD88−/− results at any time point
(p>0.05). Panel C. Secreted IL-1β was measured by ELISA after treatment of WT and
MyD88−/− primary microglia (KO) with Aβ(1-42) protofibrils (15 μM) for 6 hours in
serum-free medium. Conditioned medium was collected and secreted IL-1β was
measured by ELISA. The secreted data bars are the average ± standard error for n=5
trials. Control treatments with an equal volume of aCSF were subtracted from Aβstimulated samples and averaged 0.4%. No statistical difference was observed between
the WT and MyD88−/− response (p>0.05).
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3.6 Possible Mechanisms of Aβ(1-42) Protofibril-Induced IL-1β Secretion
There are two possible explanations for the disconnection between TLR/MyD88mediated IL-1β mRNA production and secretion of mature IL-1β. The probable options
are that the rapid Aβ(1-42) protofibril-induced microglia secretion is from an existing
mature IL-1β reservoirs, or that there is rapid activation of the NLRP3 inflammasome by
Aβ(1-42) protofibrils, activating caspase-1 which would then cleave an existing pool of
pro-IL-1β to mature IL-1β that can then be secreted. Both likely scenarios would
presumably occur prior to the TLR/MyD88-induced IL-1β transcription and translation to
pro-IL-1β protein. To explore these two potential hypotheses, we further examined the
rapid secretion process. First, the microglia were treated with a concentration range of
Aβ(1-42) protofibrils, which showed a dose-depended effect on the secreted mature IL1β levels; however, the secreted IL-1β levels were not affected by time (Figure 3.9A).
This indicated that the level of secreted mature IL-1β initially triggered by Aβ(1-42)
protofibrils correlated with the magnitude or concentration of the Aβ(1-42) protofibril
stimulus. Secondly, the amount of secreted IL-1β-mediated by Aβ(1-42) protofibrils was
reduced in a dose-dependent manner by a caspase-1 inhibitor z-YVAD-fmk (Figure
3.9B). The ability of a caspase-1 inhibitor to reduce the amount of secreted mature IL-1β
supports the second scenerio in which the rapid secretion of IL-1β originated from
existing reserviors of pro-IL-1β.
In all the previous experiments, and in most cases within the literature, the
microglia were treated once with the Aβ(1-42) protofibrils and then the secreted
cytokines were ananlyzed by collecting the conditioned medium after different incubation
times. This method is common, but it allows for the possiblity that the cytokine, or in
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Figure 3.9. Dose-dependent IL-1β secretion in primary microglia induced by Aβ(142) protofibrils. Panel A. Primary microglia were treated with SEC-isolated Aβ(1-42)
protofibrils (1, 5, 10, and 15 μM) and incubated for 2, 4, and 6 hours. Secreted IL-1β
levels were measured in the conditioned medium by ELISA. Data bars represent the
average ± standard error of n=3 trials for each condition. Statistical differences (p<0.05)
in secreted IL-1β elicited by each Aβ protofibril concentration are denoted with an
asterisk. No statistically significant differences were noted in the time dependence for
each Aβ(1-42) protofibril concentration. Panel B. Primary microglia were treated with
final concentrations of 0 μM, 5 μM, 10 μM, and 20 μM caspase-1 inhibition (Z-YVADFMK) for 30 minutes and then treated with SEC-isolated Aβ(1-42) protofibrils at a final
concentration of 15 μM and incubated for 6 hours. Secreted IL-1β levels were measured
in the conditioned medium by ELISA. Data bars represent the average ± standard error of
n=3 trials for each condition. Statistical differences (p<0.05) in secreted IL-1β elicited by
each Aβ protofibril concentration are denoted with an asterisk.
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this case IL-1β, was secreted early during the incubation and that the collection time does
not matter. In order to examine whether the microglia produced a sustained response to
the initial Aβ(1-42) protofibril stimulus, we conducted experiments where the microglia
were treated with Aβ(1-42) protofibrils and then the conditioned cellular medium was
collected, replaced, and collected again at increasing times. Using this methodology,
secreted IL-1β was only observed after the first collection of conditioned medium (Figure
3.10A), indicating that the Aβ(1-42) protofibril-induced secretion occurred shortly after
stimulation and was not sustained over time. Next, the same procedure was used but with
repeated stimulation of the same microglia with Aβ(1-42) protofibrils. This treatment
produced a similar quantum of secreted IL-1β with each subsequent treatment (Figure
3.10B). This data revealed that the microglial IL-1β secretion mechanism was not
desensitized nor depleted by the Aβ(1-42) protofibrils. These same findings were
obtained in the MyD88-/- microglia (Figure 3.11), again providing evidence of MyD88independent reservoirs of pro or mature IL-1β.
In Figures 3.4 and 3.6, it was observed that Aβ(1-42) protofibrils were able to
induce an accumulation of intracellular IL-1β at longer time points (6, 10 and 24 hours),
but that accumulation did not result in a corresponding increase of secreted mature IL-1β
protein. This observation, along with results from Figure 3.10, suggested that an
additional Aβ stimulus may be needed to trigger the release of the accumulated
intracellular mature IL-1β. To test this hypothesis, the primary microglia were treated
with Aβ(1-42) protofibrils for 6 hours to allow the accumulation of intracellular mature
IL-1β and then treated a second time with Aβ(1-42) protofibrils. However, this did not
result in a substantial increase in secreted mature IL-1β (Figure 3.12A), even though the
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Figure 3.10. Aβ protofibril-induced rapid IL-1β secretion is not sustained but is
repeatable. Panel A. Primary microglia were exposed to SEC-isolated Aβ(1-42)
protofibrils (15 μM) and allowed to incubate at 37 °C for 1 hour. The conditioned
medium was then removed, fresh medium applied, and collected at 2 hours. This process
was repeated again for the 4 hour analysis. No further IL-1β was secreted compared to
the 1 hour time point (p<0.001). Panel B. Experiments were conducted as described in
Panel A, although Aβ(1-42) protofibrils (15 μM) were added with the fresh medium at 1
and 2 hours. Data bars represent the average ± standard error of n=5 trials. No statistical
difference (NS) was noted in the amount of secreted IL-1β elicited by each successive
Aβ(1-42) profibril treatment (p>0.05).
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Figure 3.11. Aβ protofibril-induced rapid IL-1β secretion is not sustained but is
repeatable in MyD88−/− microglia. Experiments were conducted in the same manner as
described in Figure 3.10 legend but with the addition of a 6 hour time point. Panel A.
One initial treatment of primary microglia with Aβ(1-42) protofibrils (15 μM). A
statistically significant difference in secreted IL-1β was observed at 1 hour compared to
subsequent time points (p<0.001). Panel B. Repeated treatments with Aβ(1-42)
protofibrils did not significantly change the amount of secreted IL-1β (p>0.05). Data
bars represent the average ± standard error of n=3 trials.
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intracellular IL-1β was significantly increased during the initial 6 hour incubation with
Aβ(1-42) protofibrils (Figure 3.12B). The secreted results were similar to what was
observed in Figure 3.10 where the additional Aβ(1-42) protofibril treatments triggered the
same quantum of secreted mature IL-1β as the initial stimulus; however, this data shows
that the quantum was the same despite the substantial increase in the intracellular IL-1β.

3.7 Discussion
Aggregated Aβ has been recognized as a DAMP, which has similar qualities as
PAMPs, but are endogneous instead of external pathogens. As the Aβ monomer selfassembles into small, soluble oligomers and ultimately insoluble fibrils, their unique
structural character gives rise to proinflammatory properties. TLRs are the primary
recognition molecules in the innate immune system and a few of them, such as TLR4 and
TLR2 (Fassbender et al., 2004, Jana et al., 2008, Liu et al., 2012, Reed-Geaghan et al.,
2009, Udan et al., 2008) and TLR4 and TLR6 (Stewart et al., 2010) have been shown to
be major mediators of Aβ-triggered inflammation and cytokine production by
monocytes/macrophages and microglial cells. The adaptor protein, MyD88, has also
been implicated in an Aβ-induced inflammatory response within microglia (Lim et al.,
2012).
The TLRs and the NLRP3 inflammasome are connected through a well-accepted
2-signal model (Hanamsagar et al., 2012). The model is initiated in the first step, which
is “priming” of the immune cell, where the activation of the TLR causes MyD88
signaling and transcriptional activation resulting in mRNA and protein production. For
the protein production of IL-1β, the priming process results in the pro-form of the protein.
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Figure 3.12. A second stimulus of microglia with Aβ protofibrils secretion does not
release accumulated intracellular IL-1β. Primary microglia were exposed to SECisolated Aβ(1-42) protofibrils (15 μM) or aCSF buffer alone and allowed to incubate at
37 °C for 6 hrs. The conditioned medium was then removed and one cell extract was
prepared for each condition (combination of five wells in 20 μL of lysis buffer). For the
remaining cells, fresh medium was applied along with a second protofibril (n=5 wells or
replicates) or buffer treatment (n=5 replicates). After an additional 1 hr incubation, the
conditioned medium from each well was removed separately and one cell extract was
again prepared for each condition. Secreted (Panel A) and intracellular (panel B) IL-1β
was determined by ELISA. IL-1β data bars represent the average ± std error of n=5
replicates for secreted and one intracellular extract for each condition. Statistically
significant differences between treatments are denoted with an asterisk (p<0.001). No
statistical difference (NS) was found between the microglial IL-1β response when treated
with Aβ(1-42) protofibrils for 6 hr and again for 1 hr (p>0.05).
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The second step is signaled by endogneous molecules such as ATP and K+ efflux, which
triggers the activation of the inflammasome and cleavage of the pro-IL-1β into the mature
form of IL-1β. Over the last five years, Aβ has been observed in the stimulation of many
different innate immune pathways, including playing a role in the activation of the
inflammasome (Halle et al., 2008, Heneka et al., 2013, Sheedy et al., 2013, Wu et al.,
2013). Some of the reports studying Aβ and the NLRP3 inflammasome have used LPS
as TLR/MyD88 priming stimulus to produce the pro-IL-1β, therefore priming the
inflammasome (Halle et al., 2008). However, it has also been observed that Aβ alone is
able to stimulate both the priming (Stewart et al., 2010) and the activation of the
inflammasome. The studies shown in Chapter 3 clearly show that Aβ is able to provide
both signals needed to elicit the production and secretion of mature IL-1β; however, it is
likely that there are other mechanisms following the production of mature IL-1β in
microglia and its secretion. Recently, Savage and colleagues reported differences
between intracellular and secreted mature IL-1β in microglia stimulated with LPS
(Savage et al., 2012). The data presented here, along with others, have shown that LPS
alone does not induce IL-1β secretion; however, Savage et al., 2012 showed that LPS
alone did induce the production of intracellular mature IL-1β. This suggests the
possibility of additional sites for the regulation of IL-1β metablolism and/or trafficking.
While piecing together a representative model, the original 2-signal model of
linking TLRs to the NLRP3 inflammasome was applied, but specifically connected it to
Aβ(1-42) protofibrils and their ablility to effect multiple innate immune pathways (Figure
3.13). In the model (depicted from the analysis of the above data), the Aβ(1-42)
protofibrils are able to trigger two, possibly, three signals. The first signal is the
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Figure 3.13 Proposed model of Aβ(1-42) protofibril stimulation of the TLR/MyD88
and NLRP3 inflammasome pathways. This model fuses together the original two
signal model along with the new information obtained for the studies presented above.
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activation of the TLR/MyD88 pathway, representing Signal 1 of the original model.
During the first signal, the Aβ(1-42) protofibrils significantly upregulated IL-1β and
TNFα mRNA and pro-IL-1β protein, which were highly dependent on the TLR/MyD88
pathway. The Aβ(1-42) protofibrils were also able to provide Signal 2, which activated
the NLRP3 inflammasome resulting in the cleavage of pro-IL-1β to mature IL-1β. The
production of intracellular mature IL-1β induced by the Aβ(1-42) protofibrils was timedependent and signficantly reduced in the absecne of MyD88, likely due to the
diminished priming of the inflammasome. Fibrillar Aβ has previously been shown to
activate the inflammasome via a phagocytosis/lysosomal-leakage mechanism (Halle et
al., 2008, Sheedy et al., 2013, Wu et al., 2013), which was incorporated in this model
(Figure 3.13). In the original 2-signal model, the TLR/MyD88 engagement is accepted as
Signal 1; however, the first reponse that was observed through our analysis was the rapid
secretion of mature IL-1β (<15 minutes). This observed novel rapid secretion process is
not dependent on Aβ protofibril-induced, MyD88-mediated, priming of the microglia,
which occurred over longer periods of time. Throughout the investigation, low basallevels of pro-IL-1β were observed by Western blot and ELISA and very low basal-levels
of mature IL-1β detected only by ELISA. Existing pools of pro-IL-1β in primary
microglia cultures have been previosly observed by Western blot in several studies
(Takenouchi et al., 2011, Terada et al., 2010, Wu et al., 2013). The basal level of
inflammasome priming in unstimulated microglia may produce a pool of pro-IL-1β
poised for rapid caspase-1 cleavage or mature IL-1β pre-packaged in secretory vesicles
and available for rapid secretion. In vivo, these reserviors of pre- or mature IL-1β may
not be present unless
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primed by a separate event preparing the microglia for rapid IL-1β secretion in repsone to
Aβ.
The novel Aβ(1-42) protofibril-induced rapid IL-1β secretion was very
reproducible and appears to be secreted as a quantum of IL-1β. The quantum could be
repeatedly secreted by additional Aβ(1-42) protofibril treatments and the magnitude of
the IL-1β secretion was dependent on the concentration of the Aβ(1-42) protofibrils. A
recent review has suggested five different possible mechanisms for the secretion of IL1β: (1) exocytosis of the IL-1β-containing secretory lysosomes, (2) release of IL-1β from
shed plasma membrane microvesicles, (3) fusion of multivesicular bodies with the
plasma membrane and subsequent release of the IL-1β containing exosome, (4) export of
IL-1β through the plasma membrane using specific membrane transporters, and (5)
release of the IL-1β upon cell lysis (Lopez-Castejon and Brough, 2011). The last
mechanism is unlikely since we have previously shown that the Aβ(1-42) protofibrils are
not toxic to the microglia (Paranjape et al., 2012) and because the IL-1β secretion was not
sustained, and could be re-evoked by additional treatments of the same cells (Figures
3.10-3.12). A possible hypothesis is that the Aβ(1-42) protofibrils are able to trigger
rapid secretion of IL-1β from microglia that have previously attained a basal level of
activation and can either modulate the mature IL-1β secretion process or can rapidly
stimulate the NLRP3 inflammasome and mediate the cleavage of pro-IL-1β to mature IL1β, which can then be secreted.
From the above data, it was concluded that the Aβ(1-42) protofibrils are able to
stimulate both a time- and MyD88-dependent accumulation of intracellular mature IL-1β
and secretion of TNFα in the microglia. However, the Aβ(1-42) protofibril-induced pro-
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IL-1β and accumulation of intracellular mature IL-1β did not translate into increased
secreted IL-1β. Instead, the protofibrils secreted a rapid quantum of IL-1β that was seen
at earlier time points than the upregulation of the intracellular pathway. This secretion
was also limited or possibly highly regulated in its response. These findings allowed
further insight into the mechanisms by which Aβ(1-42) protofibrils are able to prime and
activate the NLRP3 inflammasome and highligthted differences between the Aβ(1-42)
protofibrils and other TLR ligands and NLRP3 inflammasome activators.
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CHAPTER 4

AGGREGATION PROPERTIES OF MIXED Aβ(1-42) AND Aβ(1-40) SOLUTIONS

4.1 Introduction
In the past it was thought that the insoluble fibrillar Aβ was the species which
caused the most damage in AD, including cytokine production (Meda et al., 1995, Yates
et al., 2000), interaction with proinflammatory receptors (Bamberger et al., 2003,
Fassbender et al., 2004, Stewart et al., 2010), and interaction with proinflammatory
pathways (Bianca et al., 1999, McDonald et al., 1998). However, more recent findings
have shown that the more diffuse soluble oligomeric Aβ intermediates found in the brain
and CSF are the more damage-causing species (Haass and Selkoe, 2007, Kayed et al.,
2003, Paranjape et al., 2012).
Within the brain of AD patients several different aggregate morphologies have
been identified (Selkoe, 2004). In normal physiological conditions the Aβ monomer
peptide is highly soluble, but through mechanisms that are not completely understood the
Aβ peptide aggregates to form Aβ plaques within the brain (Jarrett et al., 1993). In vitro
aggregation studies have shown that synthetic Aβ peptides are able to form fibrils which
are indistinguishable from fibrils isolated from AD patients’ brains (Halverson et al.,
1990, Hilbich et al., 1991, Kirschner et al., 1987). These studies show that the Aβ
monomer self-assembles through non-covalent interactions to form polydisperse soluble
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oligomers (Kayed et al., 2003) and protofibrils (Harper et al., 1997, Walsh et al., 1997)
and eventually produce insoluble fibrils (Harper et al., 1999, Walsh et al., 1999).
The Aβ peptide is formed by the proteolytic cleavage of APP by β- and γsecretase resulting in Aβ fragments that are 39-42 amino acids in length (Nixon, 2007,
Selkoe, 2001). The two fragments that are most commonly produced are Aβ(1-40) and
Aβ(1-42) (Selkoe, 2001). Even though these two isoforms have similar chemical
structures their structural and biophysical properties are very different. Aβ(1-42) is
widely known as the isoform that is more fibrillogenic and aggregation prone, compared
to Aβ(1-40) (Pauwels et al., 2012). Mutations in the APP gene surrounding the γsecretase cleavage site alter the production of Aβ(1-40) and Aβ(1-42) by increasing the
total Aβ amount within the AD brain and by increasing the ratio of Aβ(1-42):Aβ(1-40)
(Scheuner et al., 1996).
Initial characterization of the Aβ plaques led to the conclusion that the plaques
mostly consisted of the Aβ(1-40) peptide (Mori et al., 1992). However, more recent data
supports the predominance of Aβ(1-42) (Roher et al., 1993). Different ratios of Aβ(142):Aβ(1-40) were found when examining Aβ plaques from different regions of the
diseased brain. For example, Roher et al., 1993 showed that plaques within the
leptomeningeal vessels had an average ratio of 58:42 Aβ(1-42):Aβ(1-40), while plaques
within the parenchymal vessels had an average ratio of 75:25 Aβ(1-42):Aβ(1-40) (Roher
et al., 1993). In vivo mouse studies provided evidence that the ratio of Aβ(1-42):Aβ(140) plays a more significant role in the Aβ plaque load compared to the total amount of
Aβ (Yin et al., 2007). In an attempt to identify a biomarker for cognitively normal
patients who have an increased risk for developing AD, it was found that patients with
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low Aβ(1-42):Aβ(1-40) ratio levels in their plasma and CSF have a significantly greater
risk of developing AD. The reduction in the Aβ(1-42):Aβ(1-40) ratio within the plasma
and CSF is thought to be due to the aggregation and deposition of Aβ(1-42) in the brain
preceding the onset of AD symptoms (Fagan et al., 2000, Graff-Radford et al., 2007).
In vivo studies have established that the ratio of Aβ(1-42):Aβ(1-40) is an
important factor in the pathology of AD. The literature provides numerous studies
examining the aggregation and molecular mechanisms of the individual Aβ peptides, but
it is more physiologically relevant to understand the molecular basis and the
consequences associated with different ratios of Aβ(1-42):Aβ(1-40). In vitro studies
observing the aggregation, toxicity and influence of mixed Aβ in AD pathology have
identified many different effects Aβ(1-40) has on Aβ(1-42). Monomeric Aβ(1-40) was
shown to alter the kinetic stability, solubility, and morphological properties of Aβ(1-42)
aggregates. Equimolar ratios of Aβ(1-42):Aβ(1-40) (1:1) showed greater than 50%
inhibition of fibrillar formation by monomeric Aβ(1-42) (Jan et al., 2008) as well as the
formation of spherical oligomers (Chang and Chen, 2014). It was also found that
protofibrillar Aβ(1-42) fibrillogenesis was inhibited at even higher ratios of Aβ(142):Aβ(1-40) (10:1) (Jan et al., 2008). Aβ(1-40) was thought to inhibits Aβ(1-42)
aggregation by preferentially binding to the Aβ(1-42) protofibril (Pauwels et al., 2012,
Yin et al., 2007). Different levels of neurotoxicity were also found when observing
different ratios of Aβ(1-42):Aβ(1-40) (Chang and Chen, 2014, Kuperstein et al., 2010).
The current study was designed to learn more about the effect Aβ(1-40) has on
Aβ(1-42) aggregation. In order to be certain that the experiments started with
unaggregated dry Aβ peptides, individual Aβ peptides were treated with HFIP, mixed at
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the designed ratios and dried. Each ratio was separated by SEC and the amount of
protofibril formation and protofibril/monomer distributions were quantified. The data
showed that as the ratio of Aβ(1-42):Aβ(1-40) decreased in the original mixed Aβ
samples there was a corresponding decrease in the amount of protofibril formation and
increase in the monomer pool. The DLS and ThT fluorescence measurements of the
SEC-isolated protofibrils also decreased with a decrease in the Aβ ratio. Measurements
of ThT fluorescence of the SEC-isolated monomers were also observed over time
demonstrating a significant increase in the lag phase and aggregation time. Finally the
actual amounts of each peptide within the protofibril and monomer peaks were assessed,
by an Aβ C-terminal selective ELISA. These results suggested that Aβ(1-40) may have
very little interaction with Aβ(1-42) during protofibril formation.

4.2 Characterization of SEC-Isolated Aβ(1-42):Aβ(1-40) Protofibrils
Different ratios of Aβ(1-42):Aβ(1-40) have been observed in Aβ plaques
throughout different regions of the AD brain (Roher et al., 1993), indicating the
pathophysiological significance of both peptides. The majority of the biophysical studies
examining the molecular basis of Aβ peptide aggregation have been performed on the
individual isoforms, however, in vivo analysis has indicated that the ratio of Aβ(142):Aβ(1-40) is more physiologically relevant. The following study focuses on
examining the effect that the Aβ(1-40) isoform has on the protofibril formation and
aggregation of the Aβ(1-42) isoform. The different ratios were prepared from individual
lyophilized Aβ(1-42) and Aβ(1-40) peptides. The individual peptides were dissolved in
HFIP, then the Aβ/HFIP solutions were mixed at the selected molar ratios of 5:0, 4:1, 1:1,
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1:4, and 0:5 Aβ(1-42):Aβ(1-40) (Table 4.1 and Table 2.1), followed by evaporation and
vacuum-centrifugation to remove the residual HFIP. The molar ratios used were chosen
based on the desire to have a total Aβ concentration of 200 μM, suitable for SECinsolation (Table 4.1). The dry ratio peptides were brought into solution using the
protofibril preparation as described in Chapter 2, section 2.2.1 (Paranjape et al., 2013).
Reconstitution of the HFIP-treated and lyophilized Aβ(1-42):Aβ(1-40) ratios in NaOH
followed by dilution into aCSF at an overall Aβ concentration of 200 μM resulted in the
formation of protofibrils which were then isolated by SEC on a Superdex 75 column
(Figure 4.1A). This protofibril preparation and SEC-elution profile produced a voidvolume similar to what was previously observed by the Aβ(1-42) isoform alone
(Paranjape et al., 2013), however, the distribution of protofibrils to monomers decreased
as the ratio of Aβ(1-42):Aβ(1-40) decreased (Figure 4.1B and Table 4.1). The SECelution profile of 5:0 Aβ(1-42):Aβ(1-40) produced approximately equivalent amounts of
protofibrils and monomers, 56% and 44%, respectively (Figure 4.1A blue line, Figure
4.1B, and Table 4.1). As the ratio of Aβ(1-42):Aβ(1-40) increased, the distribution
shifted to a greater abundance of monomers, compared to protofibrils (Figure 4.1B and
Table 4.1).
DLS analysis was conducted on the Aβ(1-42):Aβ(1-40) ratio protofibril peaks
from Figure 4.1A and the RH was determined. A histogram (Figure 4.2 ratio 5:0, other
ratio histograms not shown) for each ratio was generated from the autocorrelation data
and the RH values were measured to be 21 nm for 5:0, 16 nm for 4:1, 15 nm for 1:1, and
14 nm for 1:1 (Table 4.2). The RH for 0:5 was undetermined. The DLS data showed that
the RH of the SEC-isolated Aβ(1-42):Aβ(1-40) protofibrils slightly decreases as the
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Table 4.1. Ratios of Aβ(1-42):Aβ(1-40).
Ratios

[Aβ1-40] μM

[Aβ1-42] μM

% Protofibril

% Monomer

5:0

200

0

56

44

4:1

160

40

39

61

1:1

100

100

31

69

1:4

40

160

11

89

0:5

0

200

10

90

This table gives the concentrations of each peptide for each ratio prior to SECpurification, along with the percentage of protofibrils and monomers formed for each
ratio.
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Figure 4.1. SEC-isolated Aβ(1-42):Aβ(1-40) protofibrils formed and isolated in
aCSF. Panel A. SEC-isolated Aβ(1-42):Aβ(1-40) protofibrils formed and isolated in
aCSF decreases as monomer increases when the ratio of Aβ(1-42):Aβ(1-40) decreases.
Lyophilized Aβ(1-42):Aβ(1-40) ratios were brought into solution with NaOH followed
by dilution into aCSF at a final concentration of 200 μM. The supernatant after
centrifugation was eluted from a Superdex 75 column and 0.5 ml fractions were
collected. UV absorbance at 280 nm was monitored during the elution. The protofibrils
eluted in the void volume while the monomer eluted in the included peak. The blue line
indicates Aβ(1-42) by itself and the red line indicates Aβ(1-40) by itself, while the black,
green and pink lines indicate the 4:1, 1:1, and the 1:4 Aβ(1-42):Aβ(1-40) ratios,
respectively. Panel B. Percent SEC recovery of Aβ(1-42)/Aβ(1-40) protofibril decreases
as the Aβ(1-42) concentration decreases. The graph indicates the percent of protofibril
and monomer from each SEC purified Aβ(1-42):Aβ(1-40) ratio. The black bars indicate
the percent of protofibril and the grey bars indicate the percent of monomer. Percent was
calculated by dividing the concentration of either the eluted protofibril or monomer by
the total eluted SEC-Aβ concentration and then multiplied by 100.
Aβ(1-42):Aβ(1-40) ratio decreases.
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Figure 4.2. DLS of SEC-isolated Aβ(1-42):Aβ(1-40) protofibrils. Aβ(1-42):Aβ(1-40)
protofibrils RH slightly decreased as the concentration of Aβ(1-42) decreased. Aβ(142):Aβ(1-40) protofibrils were analyzed immediately after SEC-isolation by DLS and a
representative regularized histogram of percent intensity versus R H is shown of the Aβ(142):Aβ(1-40) 5:0 ratio. Intensity-weighted mean RH values were derived from the
regularized histograms. The table indicates the RH for the other Aβ(1-42):Aβ(1-40)
ratios.
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Table 4.2. RH measurements of SEC-isolated Aβ(1-42):Aβ(1-40) protofibrils.
Ratio

[Aβ(1-42)] μM

[Aβ(1-40)] μM

RH (nm)

5:0

200

0

21

4:1

160

40

16

1:1

100

100

15

1:4

40

160

14

0:5

0

200

ND

143

original Aβ(1-42):Aβ(1-40) ratio decreased.
ThT is a benzothiazole dye, which shows increased fluorescence when bound to
amyloid fibrils (Khurana et al., 2005), specifically when bound to the β-sheet secondary
structure of aggregated Aβ (Krebs et al., 2005). The ThT technique has previously been
used as an indirect way to measure the extent of β-sheet structure within the soluble Aβ
protofibril species (Paranjape et al., 2013, Walsh et al., 1999). Here, ThT fluorescence
was used to characterize the SEC-isolated Aβ(1-42):Aβ(1-40) protofibrils from each of
the different Aβ(1-42):Aβ(1-40) ratios. For all ThT measurements, the SEC-isolated
Aβ(1-42):Aβ(1-40) protofibrils were diluted to 5 μM Aβ. Analysis of the SEC-peak of
the Aβ(1-42):Aβ(1-40) protofibril fractions after aggregation and elution in aCSF
revealed that the extent of ThT binding and fluorescence decreased as the ratio of Aβ(142):Aβ(1-40) decreased (Figure 4.3). These findings suggest that the amount of β-sheet
secondary structure decreased in the Aβ(1-42):Aβ(1-40) protofibrils as the ratio of Aβ(142):Aβ(1-40) decreased. However, the decreases observed in the amount of protofibrils
formed and in the protofibril RH and ThT fluorescence could be caused by the overall
decrease in the Aβ(1-42) concentration.

4.3 SEC-Purification of Aβ(1-42):Aβ(1-40) Ratios While Holding [Aβ(1-42)] Constant
In an attempt to identify whether or not the Aβ(1-40) peptide is intermingling
with the Aβ(1-42) peptide to form the SEC-isolated protofibrils, two Aβ(1-42):Aβ(1-40)
ratios where the Aβ(1-42) concentration was held constant while increasing Aβ(1-40)
were examined. The ratios were again prepared from individual lyophilized Aβ(1-42)
and Aβ(1-40) peptides, however this time the preferred molar ratios were 5:0 and 4:1
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Figure 4.3. ThT fluorescence of SEC-isolated Aβ(1-42):Aβ(1-40) protofibrils.
Freshly isolated Aβ(1-42):Aβ(1-40) protofibrils ThT fluorescence decreases as the
concentration of Aβ(1-42) decreases. Aβ(1-42):Aβ(1-40) protofibrils eluted from a
Superdex 75 SEC column in aCSF were diluted to 5 μM in aCSF containing 5 μM ThT
and the fluorescence emission was measured as described in the Chapter 2, section 2.9.
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with an Aβ(1-42) concentration of 200 μM in both ratios. The constant concentration of
the Aβ(1-42) peptide in this set of Aβ(1-42):Aβ(1-40) ratios caused the overall total Aβ
concentrations to be different for each ratio, 200 μM for the 5:0 and 250 μM for the 4:1.
The dry ratio peptides were again brought into solution using the protofibril preparation
as mentioned in Chapter 2, section 2.2.1, and then the aggregate species were isolated by
SEC. The SEC-elution profile for the 5:0 Aβ(1-42):Aβ(1-40) ratio was the same as seen
in Figure 4.1A. The SEC-elution profile of the 4:1 Aβ(1-42):Aβ(1-40) protofibril peak
was very similar to the protofibril peak of the 5:0 Aβ(1-42):Aβ(1-40) ratio, however the
monomer peak of the 4:1 Aβ(1-42):Aβ(1-40) indicates significantly more monomer
compared to the 5:0 Aβ(1-42):Aβ(1-40) monomer peak (Figure 4.4). Comparing the
SEC-profiles of the 5:0 and 4:1 Aβ(1-42):Aβ(1-40) ratios with constant Aβ(1-42)
concentrations suggested that the Aβ(1-40) peptide does not play a significant role in the
formation of the Aβ(1-42) protofibrils.

4.4 BV-2 Microglia Inflammatory Response Induced by Aβ(1-42):Aβ(1-40) Protofibrils
Aβ(1-42) protofibrils formed and isolated by SEC have previously been shown to
be effective stimulators of TNFα production in BV-2 microglia (Paranjape et al., 2013).
Similarly the SEC-isolated 5:0 Aβ(1-42):Aβ(1-40) protofibrils were able to stimulate the
BV-2 microglia at a final concentration of 15 μM. However when treating the BV-2
microglia with the same final concentration of both SEC-isolated 4:1 and 1:1 Aβ(142):Aβ(1-40) protofibrils their ability to stimulate the microglia decreased (Figure 4.5).
Treatment of the BV-2 microglia could not be completed for either the SEC-isolated 1:4
or 0:5 Aβ(1-42):Aβ(1-40) protofibrils due to the SEC in-line UV-determined
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Figure 4.4. SEC-purification profile of 5:0 and 4:1 Aβ(1-42):Aβ(1-40) ratios while
leaving the Aβ(1-42) concentration constant. SEC comparison of Aβ(1-42):Aβ(1-40)
ratios of 5:0 and 4:1 while leaving the Aβ(1-42) concentration constant shows an
equivalent amount of protofibrils and an increase in monomer. Lyophilized Aβ(142):Aβ(1-40) ratios were brought into solution with NaOH followed by dilution into
aCSF at a final concentration of 200 μM for Aβ(1-42) by itself and 250 μM for Aβ(142):Aβ(1-40) ratio at 4:1. The supernatant after centrifugation was eluted from a
Superdex 75 column and 0.5 ml fractions were collected. UV absorbance at 280 nm was
monitored during the elution. The blue line indicates Aβ(1-42) by itself and the red line
indicates Aβ(1-42):Aβ(1-40) ratio at 4:1.
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Figure 4.5. Stimulation of BV-2 microglia by SEC-isolated Aβ(1-42):Aβ(1-40)
protofibrils. Aβ(1-42):Aβ(1-40) protofibrils formed and isolated in aCSF decrease in
their ability to stimulate the microglia as the amount of Aβ(1-42) decreases. SEC-isolated
protofibrils from Aβ(1-42):Aβ(1-40) ratios of 5:0, 4:1, and 1:1 in aCSF were incubated
with BV-2 microglia at a final concentration of 15 μM (UV absorbance-determined) for 6
hours in serum-free medium. Secreted TNFα was measured by ELISA in the conditioned
medium. Control treatments with an equal volume of aCSF were subtracted from Aβstimulated samples. Due to the measurements being on separate days and the variability
of the cells the TNFα stimulated by the Aβ(1-42):Aβ(1-40) protofibrils is expressed as a
percentage of that day’s LPS TNFα response. 5:0 n=2 replicates, 4:1 n=5 replicates and
1:1 n=6 replicates. Statistics were compared to 5:0 SEC-isolated Aβ(1-42):Aβ(1-40)
protofibril treatment (* p < 0.005).
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concentrations being inadequate to obtain a final Aβ treatment concentration of 15 μM.
However, previous data from our lab has shown that SEC-isolated Aβ(1-40) protofibrils
are not able to stimulate microglia as well as SEC-isolated Aβ(1-42) protofibrils
(Paranjape et al., 2012). Due to the experiments being performed on separate days the
data was normalized to the % of the positive LPS control. This data shows that the
decrease in Aβ(1-42):Aβ(1-40) ratio resulted in a decrease in effective stimulation of
TNFα production in BV-2 microglia.

4.5 Aggregation of SEC-Isolated Aβ(1-42):Aβ(1-40) Monomer
A second set of the original Aβ(1-42):Aβ(1-40) ratios (Table 4.1) were SECisolated in order to study the aggregation of the SEC-isolated Aβ(1-42):Aβ(1-40)
monomer. These Aβ(1-42):Aβ(1-40) ratio preparations were incubated for 4 hours
before centrifugation and SEC-purification. Even though the incubation time was longer
for the second set of Aβ(1-42):Aβ(1-40) ratios, each ratio still produced similar SECprofiles as seen in Figure 4.1A.
ThT fluorescence was used to observe the increasing amount of β-sheet structure
within each Aβ(1-42):Aβ(1-40) ratio monomer fraction over time, which is an indirect
measure of aggregation. When measuring the ThT fluorescence of the SEC-isolated
Aβ(1-42):Aβ(1-40) monomers, each sample was diluted to 40 μM in aCSF with 0.05%
sodium azide, to prevent contamination, incubated at room temperature for 26 days and
measured for ThT fluorescence every 1-2 days. The SEC-isolated 5:0 and 4:1 Aβ(142):Aβ(1-40) monomers showed a very rapid initial aggregation with no lag phase,
whereas the SEC-isolated 1:1 Aβ(1-42):Aβ(1-40) monomer had a lag phase of 1 day,
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compared to the SEC-isolated 1:4 and 0:5 Aβ(1-42):Aβ(1-40) monomers whose
aggregation was much slower and had an obvious lag phase of 3 days. There was also an
observable difference in the intensity of the ThT fluorescence/binding of the SECisolated Aβ(1-42):Aβ(1-40) monomers over time. The SEC-isolated 5:0 Aβ(1-42):Aβ(140) monomer produced the greatest amount of ThT fluorescence/binding, followed by the
SEC-isolated 4:1 Aβ(1-42):Aβ(1-40) monomer and then the SEC-isolated 1:1 Aβ(142):Aβ(1-40) monomer. These three Aβ(1-42):Aβ(1-40) monomer ratios also showed a
similar trend in their aggregation profile; after aggregation into the species with the
greatest ThT binding, there was an observable decrease in the ThT fluorescence followed
by stabilization over a period of several days. The SEC-isolated 1:4 and 0:5 Aβ(142):Aβ(1-40) monomer both showed similar aggregation trends and ThT
fluorescence/binding intensities, eventually reaching a plateau that was lower than those
found for the 5:0, 4:1, and 1:1 Aβ(1-42):Aβ(1-40) (Figure 4.6). Together this data shows
that as the ratio of Aβ(1-42):Aβ(1-40) decreases the lag phase increases and the overall
ThT fluorescence/binding decreases. The observations of increased lag-phase and
reduced aggregation in these studies may be caused by either the combination of Aβ(140) monomer within the Aβ(1-42) monomer, or the overall reduction in Aβ(1-42) within
the SEC monomer peak.

4.6 Aβ C-Terminal Selective ELISA of the SEC-Isolated Aβ(1-42):Aβ(1-40) Protofibrils
and Monomers
Even though the original ratios contained a specific amount of Aβ(1-42) and
Aβ(1-40), it was not entirely clear how much of each peptide populated the SEC-isolated
protofibrils and monomers. In an attempt to observe how much Aβ(1-42) and Aβ(1-40)
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Figure 4.6. Aggregation of SEC freshly isolated Aβ(1-42):Aβ(1-40) monomer.
Freshly isolated Aβ(1-42):Aβ(1-40) monomer aggregates faster and with a higher ThT
fluorescence as the ratio of Aβ(1-42):Aβ(1-40) increases. The Aβ(1-42):Aβ(1-40)
monomer peak fractions were diluted to 40 μM in aCSF with 0.05% NaN3. The Aβ(142):Aβ(1-40) monomer samples were allowed to incubate at room temperature for 14-26
days. At different time points each Aβ(1-42):Aβ(1-40) monomer sample was diluted to 5
μM in aCSF containing 5 μM ThT and fluorescence emission was measured as described
in the Chapter 2, section 2.9.
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were incorporated into each SEC-isolated Aβ(1-42):Aβ(1-40) protofibril and monomer
peak, an Aβ C-terminal selective ELISA was designed. The Aβ ELISA was designed to
distinguish the difference between the C-terminus of Aβ(1-40) and Aβ(1-42), with the
difference being the addition of two amino acids, isoleucine and alanine, at the Cterminus of Aβ(1-42), within a single mixed Aβ sample. The ELISA was performed like
a standard sandwich ELISA, expect the capture antibodies were selective for either Aβ(142) or Aβ(1-40) and the detection antibody, Ab5, which recognizes all Aβ, was
conjugated to HRP.
SEC-peak fractions (monomer and protofibril) of the mixed Aβ samples were
analyzed by the C-terminal selective ELISA to directly measure the actual ratio of Aβ(142):Aβ(1-40) contained in each sample. Also both set of SEC-purified Aβ(1-42):Aβ(140) were examined and produced similar observations. As expected both the monomer
and the protofibril of the 5:0 Aβ(1-42):Aβ(1-40) ratio was only detected by the Aβ(1-42)
ELISA (Table 4.3). The 4:1 Aβ(1-42):Aβ(1-40) ratio showed that the SEC-protofibrils
only contained Aβ(1-42), while the monomer contained a lower ratio of Aβ(1-42):Aβ(140) (1.56) than the protofibrils, but still contain more Aβ(1-42) than Aβ(1-40) (Table
4.3). The 1:1 Aβ(1-42):Aβ(1-40) ratio displayed only trace amounts of Aβ(1-40)
compared to Aβ(1-42) in the SEC-isolated protofibrils, while the monomer had a much
lower ratio of Aβ(1-42):Aβ(1-40) (0.57) and actually contained more Aβ(1-40) than
Aβ(1-42) (Table 4.3). The SEC-isolated monomer of the 1:4 Aβ(1-42):Aβ(1-40) ratio
exhibited an even smaller ratio of Aβ(1-42):Aβ(1-40), again showing that the monomer
contained much more Aβ(1-40) than Aβ(1-42) (Table 4.3). While the protofibril of the
1:4 Aβ(1-42):Aβ(1-40) ratio and the 0:5 Aβ(1-42):Aβ(1-40) protofibril and monomer
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Table 4.3. Measured Aβ(1-42):Aβ(1-40) ratios in protofibril and monomer SEC
peaks.
Dry Aβ(1-42):Aβ(1-40)

Protofibril Peak

Monomer Peak

5:0

>10a

>10a

4:1

>10a

1.56

1:1

>10b

0.57

1:4

ND

0.18

0:5

ND

ND

a = no Aβ(1-40) detected

b = trace Aβ(1-42) detected

c = no Aβ(1-42) detected
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samples remain to be analyzed, the current C-terminal selective ELISA aids in explaining
some of the observed characteristics of the SEC-isolated protofibrils and monomers
displayed in Figures 4.1-4.6. This data also further suggests that the Aβ(1-40) does not
have a significant role in the formation of Aβ(1-42) protofibrils, due to the majority of the
Aβ(1-40) remaining in the monomer SEC-peak fractions.

4.7 Discussion

The current report examined different ratios of Aβ(1-42):Aβ(1-40) in order to
explore the effect of Aβ(1-40) on Aβ(1-42) aggregation. In vivo analysis has proven that
it is more physiologically relevant to fully understand the mechanistic details of Aβ(142):Aβ(1-40) ratios rather than one peptide by itself. The brain of AD patients contains
several different aggregate morphologies, including oligomers, protofibril and fibrils,
consisting of Aβ(1-40) co-localized with Aβ(1-42) (Harper and Lansbury, 1997, Harper
et al., 1999, Kayed et al., 2003, Selkoe, 2001, Selkoe, 2004, Walsh et al., 1997, Walsh et
al., 1999). Both peptides are commonly produced and are present in all individuals
(Selkoe, 1998, Selkoe, 2001) and their chemical structures are very similar, differing only
by two amino acids, isoleucine and alanine. However, Aβ(1-42) is known to be more
fibrillogenic and aggregation-prone, compared to Aβ(1-40) (Pauwels et al., 2012).
The studies presented here showed that reconstitution of dry Aβ(1-42):Aβ(1-40)
peptide mixtures at different ratios resulted in immediate protofibril formation. However,
SEC-purification of the mixed solutions indicated that as the ratio of Aβ(1-42):Aβ(1-40)
decreased, the amount of SEC-isolated protofibrils decreased and the monomer increased

154

(Figure 4. 1 and Table 4.1). Similar results were observed in previous studies, in our
laboratory, when observing the SEC-purification profiles of the individual peptides
(Paranjape et al., 2012). Subsequent SEC studies showed that if the Aβ(1-42)
concentration was held constant while increasing the Aβ(1-40) concentration, there was
no change in the amount of SEC-isolated protofibrils formed, while monomer increased
(Figure 4.4). Other than Jan et al., 2008, to my knowledge this report is one of the only
studies that observe the difference between Aβ(1-42):Aβ(1-40) ratios, where one peptide
was held constant while the other peptide and the total Aβ concentration were variable.
Jan and colleagues similarly suggested that Aβ(1-40) monomer does not interfere with
Aβ(1-42) ability to form higher order prefibrillar aggregates, however it does interfere
with Aβ(1-42) ability to form mature fibrils (Jan et al., 2008). In general, Aβ(1-40) has
been shown to effect Aβ(1-42) fibril formation, including kinetic stability, solubility, and
morphological properties and its induced neurotoxicity (Chang and Chen, 2014, Jan et al.,
2008). Even though some earlier studies show that Aβ(1-40) inhibits Aβ(1-42)
aggregation by preferentially binding to the Aβ(1-42) protofibril (Yin et al., 2007), the
protofibril formation and SEC-purification data in this report, suggests that Aβ(1-40) has
very little contact with Aβ(1-42) during protofibril formation, while others have
suggested that the two peptides interact, but prefer interactions with the same peptide
over interactions between different ones (Pauwels et al., 2012).
Other experiments were conducted during this study to examine the biophysical
properties of the formed and SEC-isolated Aβ(1-42):Aβ(1-40) ratio protofibrils. During
these biophysical studies, DLS and ThT fluorescence were used to observe the
protofibrils’ RH and β-sheet formation. The RH measurement for the SEC-isolated 5:0
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Aβ(1-42):Aβ(1-40) protofibrils (21 nm) was similar to that measured previously of the
Aβ(1-42) protofibrils (21.9 ± 4.0 std nm for n-5 SEC-purifications) (Paranjape et al.,
2013). However, the RH slightly decreased as the ratio of Aβ(1-42):Aβ(1-40) decreased
(Figure 4.2 and Table 4.2). A more distinct decrease was observed in the amount of ThT
fluorescence (Figure 4.3). Due to the conclusions drawn from the SEC-purification
profile comparisons and the C-terminal selective ELISA, it is likely that the slight
decrease observed by the DLS and the decrease in ThT fluorescence measurements are
caused by the overall decrease in the Aβ(1-42) concentration. However, Jan et al., 2008
attributed the decrease of ThT fluorescence to the Aβ(1-40) reducing the ability Aβ(1-42)
to form mature fibrils (Jan et al., 2008).
Early data examining cellular damage caused by Aβ indicated that the insoluble
fibrillar Aβ species caused the most damage, including cytokine production (Meda et al.,
1995, Yates et al., 2000) and interaction with proinflammatory receptors and pathways
(Bamberger et al., 2003, Bianca et al., 1999, Fassbender et al., 2004, McDonald et al.,
1998, Stewart et al., 2010). However, recently it has been found that the more diffuse
soluble oligomeric Aβ intermediates actually cause the most damage in AD by causing
neuronal and/or synaptic dysfunction (Haass and Selkoe, 2007, Kayed et al., 2003, Lee et
al., 2006). We have also recently confirmed that the Aβ(1-42) protofibrils, but not the
Aβ(1-42) fibrils, are robust activators of microglia (Paranjape et al., 2012). This present
study again shows that the Aβ protofibrils are able to significantly stimulate microglia,
however the extent of activation decreases as the ratio of Aβ(1-42):Aβ(1-40) decreases
(Figure 4.5).
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Several groups have used the technique of ThT fluorescence as a way to observe
Aβ aggregation, typically displaying a sigmoidal curve, which is characteristic for
aggregating proteins (Harper and Lansbury, 1997). Our lab has previously shown a ThT
fluorescent profile of SEC-isolated Aβ(1-42) monomer, which showed a lag phase of 14
days and aggregation over 3 days (Coalier et al., 2013). This technique has also been
used for comparing the aggregation properties of the different mixed Aβ(1-42):Aβ(1-40).
However my studies were constructed differently than other published studies by using
SEC-isolated Aβ(1-42):Aβ(1-40) monomer compared to freshly reconstituted Aβ(142):Aβ(1-40), which could contain a polydisperse mixture of Aβ spices. The studies
using freshly reconstituted Aβ(1-42):Aβ(1-40) concluded that equally mixing Aβ(1-42)
and Aβ(1-40) had the lowest ThT fluorescence even compared to an all Aβ(1-40)
preparation (Chang and Chen, 2014), while another study showed that lower ratios of
Aβ(1-42):Aβ(1-40) had longer lag phases, but increased elongation rates (Kuperstein et
al., 2010). However, the aggregation studies of SEC-isolated Aβ(1-42):Aβ(1-40)
monomer presented here indicate that as the ratio of Aβ(1-42):Aβ(1-40) decreased,
meaning the amount of Aβ(1-40) increases in the dry peptide ratio, the lag phase and
aggregation time increased (Figure 4.6). If the specific ratio of Aβ(1-42):Aβ(1-40)
dictates the amount of damage within the brains of AD patients then these observations
may have important implications toward a potential therapeutic target.
The Aβ C-terminal selective ELISA aided in explaining the results observed by
the SEC-purification, biophysical analysis and ThT aggregation of the monomer. The
ELISA indicated that the Aβ(1-40) may not have much interaction with the Aβ(1-42)
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during protofibril formation. This conclusion is suggested by a minimal amount of Aβ(140) observed in the SEC-purified protofibrils and a decrease in the
ratio of Aβ(1-42):Aβ(1-40) in the SEC-isolated monomers.
Overall, the data presented here has shown that the reconstitution of dry Aβ(142):Aβ(1-40) peptide mixtures at different ratios resulted in immediate protofibril
formation. However, SEC-purification of the mixed Aβ(1-42) and Aβ(1-40) peptides
showed that as the ratio of Aβ(1-42):Aβ(1-40) decreased, the amount of SEC-isolated
protofibrils decreased and monomer increased. While a second SEC comparison
experiment revealed that if the Aβ(1-42) concentration was held constant while
increasing the Aβ(1-40) concentration the amount of SEC-isolated protofibrils formed
would remain the same, while monomer increased. The Aβ C-terminal-selective ELISA
in combination with the SEC-profiles as well as other biological and biophysical studies
suggested that Aβ(1-40) may not significantly interact with Aβ(1-42) during protofibril
formation. The observations made from data presented here could assist in the
development of a more physiological relevant therapeutic target against mixed Aβ ratios.
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CHAPTER 5

THE EFFECT OF GOLD TEXTURED SURFACES AND AN LPS ANTAGONIST ON
CELLULAR PROCESSES

5.1 Introduction
Recently, significant efforts have focused on the development of new biomaterials
or biomembrane-mimicking substrates/interfaces, with the ability to monitor, investigate,
and modulate biological behavior. This effort may improve our ability to repair damaged
tissues due to trauma, disease, or congenital abnormalities. However, these interfaces
must be assessed for biocompatibility properties including in vivo stability, stimulation of
the host immune response and active interaction with living cells (Zhong and
Bellamkonda, 2008). Gold has been investigated for many years as a potential
biomaterial in biomedical devices and as a cell culture substrate. The advantages of gold
comes from its chemical stability, high conductivity (Shulga et al., 2007) and the
advances in gold-thiol chemistry for presenting ligands or immobilizing proteins for cell
adhesion studies (Mrksich, 2009, Mrksich and Whitesides, 1996, Tan et al., 2008, Tan et
al., 2011). Numerous examples of cellular studies on gold or chemically-modified gold
substrates have been reported and these studies demonstrate that cell adhesion is
influenced by the size and shape of the gold surface along with the chemical and protein
composition and the mechanical properties (Nikkhah et al., 2012, Park and Shuler, 2003)
of the nanoparticles (Hutter et al., 2010).
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Nanoporous gold is a member of the mesoporous metals that have pores and
ligaments ranging from tens to hundreds of nanometers in scale. These features are of
interest due to the potential applications of the nanoporous gold in biosensors (Pandey et
al., 2012, Shulga et al., 2007), catalysis (Wittstock et al., 2010) and cell culture platforms.
Due to nanoporous gold being resistant to corrosion and oxidation along with its porosity
makes it a unique material and a good candidate for being used as a potential platform for
cellular adhesion and drug delivery (Seker et al., 2012).
In the following studies, four substrates, including glass, ultra-flat gold (UF-Au),
ultra-thin nanoporous gold (UT np-Au) and nanoporous gold monolith (np-Au) (all
produced by Dr. Y.H. Tan), were evaluated for their ability to support microglial
survival, growth and functional cytokine production upon stimulation in the presence and
absence of LPS. LPS is a vital component of the outer membrane of gram-negative
bacteria (Kaeothip et al., 2011) and is a potent immune system stimulant commonly used
for inducing microglial activation (Hanisch and Kettenmann, 2007, Kloss et al., 2001,
Paranjape et al., 2012). During the duration of this project, Dr. Y.H. Tan produced all
surfaces necessary and performed all the imaging techniques, while I performed all
cellular plating and further biocompatibility studies.
Scanning electron microscopy (SEM), performed by Dr. Y.H. Tan, was also used
to evaluate whether microglia morphology is disturbed by the varied surfaces tested. UFAu substrate was generated using a well-known gold deposition technique, which results
in a 200 nm thick layer of gold on mica that can be subsequently glued to a glass
coverslip (Pandey et al., 2012). As a control, the glass coverslip was used in these
experiments. Since glass is a poor conductor, about 10 nm of gold was splattered on one
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side of the glass coverslip in order to enable SEM characterization. The porous metals,
UT np-Au and np-Au, were formed by dealloying to exhibit a completely irregular
morphology for both the ligaments and pore channels of the two metallic gold surfaces.
The average pore diameter and ligament dimension for UT np-Au was 54.3 ± 22 nm and
57.5 ± 20 nm, respectively; whereas the np-Au monolith plate had an average pore
diameter and ligament dimension of 35.3 ± 19 nm and 45.1 ± 26 nm, respectively.
Due to the fact that the nanoporous gold substrates were prepared by acid
dealloying allows for the possibility of residual less noble metals to form metal oxides
and disrupt normal cellular biology. This could cause toxicity to the cells by interfering
with metabolic processes or by causing oxidative stress via metal-induced ROS (Ercal et
al., 2001, Wataha et al., 1994). To rule out the presence of high amounts of residual
metals remaining after the acid dealloying process, energy dispersive X-ray spectroscopy
(EDS) analysis was performed by Dr. Y.H. Tan to determine the composition of metals,
such as gold, copper and silver on the gold or nanoporous gold substrates. Based on the
four EDS collected by Dr. Y.H. Tan, various small amounts of residual metals were
present on these substrate surfaces. The EDS peaks for copper (0.93 and 8.04 keV) and
silver (2.98 keV) were relatively insignificant compared to gold. Therefore, the potential
for silver or copper oxide toxicity or oxidative stress that may damage the cells is
minimal. The knowledge obtained by these studies may have implications for the
production of nanoelectronic devices to aid in the improvement of cell adhesion and drug
discovery.
Separate studies were also completed in an effort to explore molecules that
antagonize LPS signaling without activating an inflammatory cascade. This was
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accomplished by the design of simplified Lipid A analogs by the Demchenko laboratory.
The synthesis of these compounds enabled inhibition and toxicity studies to be completed
in order to test different methyl glucopyranoside-amino acid conjugates. This project
was a collaborative project among many different people. The Demchenko laboratory
produced all necessary compounds, while the Nichols laboratory performed all cellular
studies. Previous Nichols’ research assistants started all the cellular assays on the first
five compounds, while all my work was completed on the last compound (compound 24)
and the positive control (Table 5.1).

5.2 Adherence of Microglia to Gold Substrate Surfaces
The ability of BV-2 microglia to adhere to glass and the different gold substrates
was determined by quantifying the number of adherent microglia after plating of the cells
and overnight incubation at 37 °C in 5% CO2. Microglia adherence was exceptional for
UF-Au, and UT np-Au (>94% adherent cells), but slightly lower for np-Au (83%
adherent cells) compared to the control glass surface (Figure 5.1).

5.3 Viability of BV-2 Microglia Adhered to Different Gold Surfaces
In order to conclude whether or not the gold substrates were toxic to the BV-2
microglia, an XTT assay was performed to determine the cell viability. The standard
XTT assay relies on mitochondrial-mediated reduction of XTT by nicotinamide adenine
dinucleotide (NADH) (Berridge et al., 2005). This method generates a water-soluble,
orange-colored reduced formazan product. Since this conversion only occurs in viable
cells, the reduced orange formazan solution can be quantified spectrophotometrically at
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Figure 5.1. Ability of microglia to adhere to different substrates. BV-2 microglia (2
x 105 cells) were plated on different substrates (n=4 for each surface) and incubated
overnight at 37 °C and 5% CO2 to allow for cell adherence. The number of adherent cells
was determined as described in Chapter 2, section 2.8.3. Data and error bars represent
the mean and standard error for the 4 trials in one experiment. A statistically significant
difference, using a student t-test, was found in microglia adherence between glass and npAu (*p < 0.001).
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an absorbance of 467 nm. Microglia attached to glass, UF-Au, and UT np-AU produced
significant amounts of reduced XTT (Figure 5.2, black bars); meaning very little toxicity
was observed. However, the amount of reduced XTT produced by the cells incubated on
np-Au was significantly less compared to the other surfaces. Control wells, which were
cell-free, but contained each substrate and XTT, were also tested and showed very little
background levels of reduced XTT for each surface (Figure 5.2, gray bars). This was
expected, as the blank substrates used in this investigation are not known to react or cause
reduction of XTT. The low absorbance observed for the microglia on np-Au monolith
was rather unexpected since the np-Au monolith contains a similar porous morphology as
the UT np-Au substrate. The cell viability data indicated that the microglia on np-Au
monolith were metabolically compromised despite looking morphologically normal by
SEM and having similar adherence properties to the other substrates. A second
possibility was that the thickness of the np-Au monolith interfered with the production or
detection of reduced XTT. Although gold is known for its inertness, either flat or in the
presence of variable porosity, this scenario was possible due to the lower background
levels of reduced XTT observed for the np-Au control compared to the other substrates
(Figure 5.2).
Due to the potential interference of the np-Au monolith substrate with the XTT
assay, an alternative method of cell viability was used to test the viability of microglia on
the substrates. The alternative method was an LDH release assay, where the presence of
LDH in the medium indicates the leakage of intracellular LDH from the cells due to
disruption or damage of the membrane. Following incubation of microglia with the
various substrates, the cell culture media was collected and centrifuged and then the cell-
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Figure 5.2. Analysis of microglia viability by XTT assay. BV-2 microglia were plated
overnight to allow cell adherence followed by incubation for 24 hour at 37 °C in 5% CO2,
the medium was removed and cell viability was assessed using a XTT assay as described
in Chapter 2, section 2.8.1. Reduced XTT absorbance was measured at 467 nm. % cell
viability was determined by comparing metabolism of reduced XTT by microglia on URAu, UT np-Au, and np-Au to microglia on glass. Data and error bars represent the mean
and standard error for 12 measurements for each condition over two separate
experiments. A statistically significant difference was found in microglia viability
between glass and np-Au (*p < 0.001). The other data points were not statistically
different from each other.

165

free supernatant was examined for LDH activity (Figure 5.3). Minimal LDH activity was
observed in the microglia medium after incubation of all four substrates (Figure 5.3). In
particular, the np-Au monolith substrate did not elicit LDH release from the adherent
microglia indicating that the np-Au monolith was not toxic to microglia. Saponin, a
known cellular toxin via cholesterol removal and membrane disruption, caused
significant LDH release from the microglia cultured on glass and served as a positive
toxic control in these experiments (Figure 5.3).

5.4 Microglial Proliferation on Gold Substrate Surfaces
Cell survival and proliferation are important criteria for substrate
biocompatibility. In addition to morphology and toxicity, the four substrates used in this
investigation were evaluated for their ability to support cell growth and proliferation.
Time dependent studies of microglia seeded onto the four substrate surfaces were carried
out at 24, 48 and 72 hours (Figure 5.4). Quantification of cell density on these surfaces
over time indicated that the number of adherent microglia progressively increased on the
flat substrate surfaces, as observed by glass and UF-Au. Microglia density more than
doubled from the initial number of seeded cells on the flat surfaces (circles, triangles,
Figure 5.4). An increase in microglia density was also observed on the UT np-Au
substrate (squares, Figure 5.4) at the 48 hour time point; however, microglia density
leveled off after that. The density of microglia cultured on the np-Au monolith
(diamonds, Figure 5.4) after 24 hours of seeding was slightly less than the number of
cells plated and did not increase or decrease over time. The difference in microglia
growth was particularly striking at 48 hours between np-Au monolith and the other
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Figure 5.3. Cell cytotoxicity determined by LDH release assay. BV-2 microglia were
plated overnight on the four substrate surfaces to allow adherence and then incubated for
24 hours as described in Chapter 2, section 2.8.2. Conditioned medium was collected for
each sample and analyzed for LDH activity by measuring absorbance/min. The levels of
LDH activity in the conditioned medium from untreated or saponin-treated microglia on
glass were used as 100% or 0% viability controls, respectively. % cell viability for other
samples was determined by comparing LDH activity to the controls. Data and error bars
represent the mean and standard error for n=3 measurements in one experiment for all
conditions.
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Figure 5.4. Microglial proliferation on different substrate surfaces. BV-2 microglia
(2 x 105 cells, dashed line) were plated and allowed to grow at 37 °C and 5% CO2 on
glass (circles), UF-Au (triangles), UT np-Au (squares), and np-Au (diamonds) substrates.
Cell number was quantified as described in Chapter 2, section 2.8.3 at 24, 48, and 72
hours. Data points and error bars represent the mean and standard error for n=7
measurements for each condition and time point from two separate experiments.
Statistical analysis was performed using a student t-test and significant differences in
microglia density were observed between np-Au and the other samples at both 48 and 72
hours (*p < 0.001). The other data points were not statistically different from each other.
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substrates. The additional observation that continued growth on UT np-Au was also
hindered suggested that the texture had a negative effect on the process of cell division.
To ensure consistency in the given experiment, all microglial proliferation studies were
carried out simultaneously and similar observation were reached with repeated
experiments. The inability of the microglia to grow or proliferate on the texturized npAu surface helped to explain the contradiction between the earlier XTT and LDH release
toxicity results. Since the XTT assay was conducted after overnight plating along with
an additional 24 hour treatment incubation, the number of microglia at the analysis time
point showed to be significantly lower on the np-Au compared to the other substrates.
The difference in microglia cell number could explain the noticeably lower reduced XTT
absorbance values for np-Au in Figure 5.2.

5.5 Microglia Morphology upon LPS Stimulation
All of the above data has been in the absence of LPS to specifically show the
effect of the different gold surfaces on BV-2 microglia; however, at the same time as the
above experiments, samples in the presence of LPS were also observed. A timedependent morphological examination of LPS-stimulated microglia on glass and gold
surfaces was completed. The microglia were immobilized onto glass, UF-Au, UT np-Au,
and np-Au, stimulated with 10 ng/mL LPS or vehicle control and imaged using SEM by
Dr. Y.H. Tan at 0, 2, 6, 10 and 24 hour time points (Figure 5.5). Data for 2 and 10 hour
time points are not shown. Supported by numerous experimental trials, the morphology
of the microglia after LPS stimulation did not appear dramatically different compared to
unstimulated microglia under the same culture conditions. The shapes of the cells were
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observed by eye and it was found that the most frequently detected morphologies
included rounded, elongated, unipolar and bipolar shapes. Most of the microglia
contained many long and short processes (5 m to 30 m in length) projecting out of the
cell body. Additionally, some cells contained a major process extending from one end of
the microglial pole (unipolar), while other microglia had two major processes extending
or stretching from two opposite ends of the microglial poles (bipolar) (Figure 5.5). The
length of these major processes varied from cell to cell with some of the longest axes
extending 20 m or more. Another interesting observation observed during SEM
analysis was the direct interactions between extended major and minor processes of
neighboring microglia. These connecting microglia processes appeared to form
conjoining junctions.
Additional studies were done to assess the adherence and viability of LPSstimulated microglia on glass and gold substrate surfaces. These experiments were
conducted in a similar manner to those presented in Figures 5.1-5.3 using adherence,
XTT and LDH release assays. No differences were observed in microglia adherence or
viability on the glass and gold surfaces between unstimulated and LPS-stimulated
microglia (Figure 5.6).

5.6 Cytokine Release from Microglia Adhered to Substrate Surfaces
TNFα is a well-documented proinflammatory cytokine that is routinely monitored
to reflect microglial activation. Therefore, the level of microglial activation can be
assessed based on the amount of secreted TNFα (Paranjape et al., 2012, Syed et al.,
2007). In order to determine if microglia adherence to texturized gold surfaces has an
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Figure 5.5. Microglia morphology on different substrate surfaces with and without
challenge by LPS. BV-2 microglia were allowed to adhere to glass, UF-Au, UT np-Au
and np-Au monolith followed by LPS (10 ng/ml) exposure for 0, 2, 6, 10 and 24 hours.
At each time point the samples were prepared for SEM imaging. Images were captured
at an accelerating voltage of 5 kV. Data for 2 and 10 hour time points are not shown for
space reasons. All images are 58 m × 43 m in size. Scale bar equal to 10 m.
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Figure 5.6. Adherence and viability of LPS-stimulated microglia on glass and gold
substrate surfaces. BV-2 microglia (2 x 105 cells) were plated on different substrates,
incubated overnight at 37 °C and 5% CO2 to allow for cell adherence, treated with either
control-water (black bars) or LPS (red bars) incubated again for 24 hours. Substrates
alone were also tested in the absence of cells and treatment (green bars). Panel A. The
number of adherent cells were determined as described in Chapter 2, section 2.8.3. Data
and error bars represent the mean and standard error for n=3 and 2 for each surface
during two separate experiments. Panel B. Cellular viability was assessed by removing
the medium and preforming the XTT assay as described in Chapter 2, section 2.8.1.
Reduced XTT absorbance was measured at 467 nm. Data and error bars represent the
mean and standard error for 12 measurements (6 from two different experiments) for
each condition. Panel C. Conditioned medium was collected for each sample and
analyzed for LDH activity (absorbance/min) as described in Chapter 2, section 2.8.2.
Data and error bars represent the mean and standard error for n=4 measurements for glass
and n=3 for the other conditions.
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impact on microglia inflammatory pathways, the microglia were seeded and adhered to
glass, UF-Au, UT np-Au and np-Au substrates, stimulated with LPS (10 ng/mL) for 24
hours and then the levels of secreted TNFα were measured. This analysis revealed
comparable levels of TNFα production by microglia among the four studied substrate
surfaces (Figure 5.7). The findings indicated that these surfaces did not markedly alter
microglial cytokine production and were biocompatible with microglia proinflammatory
studies. There was only a small amount of TNFα production by the unstimulated
microglia demonstrating that the substrates alone do not elicit a microglial response
(Figure 5.7). Therefore, the TNFα production is solely caused by the LPS stimulation of
the microglia without any interference from the substrates themselves. The ability of
microglia to retain their normal specific response to LPS stimulation on glass and both
flat and texturized gold surfaces was a good indicator of biocompatibility for functional
microglial assays.

5.7 Biological Activity of LPS Antagonistic Compounds
One disease in which a drug delivery candidate has been studied in separate
experiments by our laboratory in conjunction with the Demchenko laboratory is
Septicemia. Septicemia is a world-wide health problem that is associated with mortality
rates of 40-60%. It has been well-established that septic shock is initiated by the
introduction of bacterial endotoxins, such as LPS, into the blood stream. In return, this
causes cardiovascular problems like myocardial dysfunction, vascular tone and
permeability abnormalities, as well as abnormal oxygen delivery and metabolism
resulting in brain, heart, kidney and liver failure (Kaeothip et al., 2011).
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Figure 5.7. Microglial inflammatory response upon LPS stimulation. BV-2
microglia were allowed to adhere to the substrate surfaces overnight, treated with 10
ng/mL final concentration of LPS or the same volume of sterile water and incubated for
24 hours at 37 °C and 5% CO2. The supernatant was then collected and analyzed for
secreted TNFα by ELISA. The black bars represent unstimulated control microglia and
the gray bars represent microglia stimulated with LPS. Values and error bars represent
the mean and standard error for n=6 measurements for each condition over two separate
experiments.
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LPS is comprised of three structural regions (Figure 5.8). One region is known as
the Lipid A region, which consist of a polyacrylated glucosamine disaccharide and is
largely responsible for the toxic activity (Kaeothip et al., 2011). The effects of LPS are
exerted through its interaction with LBP (LPS-binding protein). The LPS-LBP complex
then interacts with CD14, followed by additional interactions with TLR4 and MD-2. As
mention in Chapter 1, section 1.13.1, TLR4 is an integral membrane protein that
transmits the activation signal into the cell and initiates an immune response resulting in
the production of proinflammatory cytokines, such as TNFα (Kielian, 2006, Salminen et
al., 2009).
The driving force of the experiments with LPS antagonists was to investigate the
effect of the different synthetic manipulations within the LPS-antagonist compounds.
The inhibitory activity for these compounds on the LPS-induced TNFα production were
investigated by in vitro studies using THP-1 macrophages prepared as described in
Chapter 2, section 2.1.4. These compounds were also tested in the absence of LPS to
determine if the compounds alone showed any agonistic activity. Lastly, the compounds
were examined for their toxicity to the macrophages by the use of the XTT assay.
Together these measurements allowed for the explanation of whether the compounds are
actually inhibiting the LPS- induced activity or if the pseudo-inhibition was actually
caused by the toxicity of the compound to the cells.
The first compounds that were synthesized by the Demchenko lab and observed
for its antagonistic, toxicity, and agonistic properties were compounds 10, 12 and 13
(Table 5.1). These three initial compounds showed no LPS-induced TNFα production
inhibition, no toxicity and no agonistic activity in the concentration range of 0.1 nM to
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Figure 5.8. Structure of the Lipid A region of E. coli LPS (Kaeothip et al., 2011).
Possible structural elements responsible for the endotoxic activity of Lipid A are the
number and chain length of the fatty acid (lipids), the disaccharide core, and the 1, 4’diphosphate groups (Kaeothip et al., 2011).
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10 μM (Table 5.2). The key construct, compound 10, was slightly changed to obtain a
free carboxylic group (compound 11, Table 5.1) and was then able to significantly inhibit
the LPS-induced TNFα production at concentrations greater than 10 μM; however, the
compound showed toxic effects toward the macrophages at concentrations greater than
30 μM (Table 5.2), therefore it was suggested that most of the antagonistic activity was
related to the toxicity of the compound. After observing the antagonistic effects
compound 11, two new compounds were synthesized, which were lipidated (compound
19, Table 5.1) and alkylated (compound 24, Table 5.1) analogs of compound 11. In
addition to the above compounds, a standard positive control compound was also
synthesized (compound 4, Table 5.1), as described by Peri et al., 2007 (Peri et al., 2007).
For compound 19, the inhibition of the LPS-induced TNFα production was greatly
enhanced and began at 550 nM. At the concentration of 5 μM, the inhibition was ~80%
with no observed toxicity; however, the viability of the cells began to be compromised at
higher concentrations and small amounts of agonistic activity was observed in the 10-30
μM range. Compound 24, on the other hand, was found to be a very effective inhibitor of
the TNFα production induced by LPS (Figure 5.9). At 1 μM, the compound inhibited
70% of the LPS-induced TNFα production and eventually reached 90% inhibition by 40
μM. This particular compound also showed no toxicity towards the macrophages or
agonistic properties in the concentration range of 0.2 to 40 μM. After curve fitting, the
inhibition data it was observed that the IC50 of compound 24 was 470 nM. The results
observed by compound 24 were superior to the results observed by the positive control
(compound 4), which had an inhibition range of 3-10 μM, agonistic properties at
concentrations greater than 10 μM and caused toxicity to the macrophages at
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Table 5.1. Structure of Lipid A mimicking LPS antagonists.
Compound

Structure

Compound

10

12

13

11

19

24

4

Benzyl ring
-Bn

Fluorenylmethyloxycarbonyl
-Fmoc
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Figure 5.9. Compound 24 shows significant LPS-induced antagonistic activity
without inducing toxicity to the macrophage cells. THP-1 macrophages were treated
in 4 separate experiments, as described in Chapter 2, section 2.4, with increasing
concentrations of Compound 24. Secreted TNFα levels were determined in the presence
(circles, n=12) and absence (diamonds, n=8) of LPS. Cell viability (triangles, n=12) was
also observed as described in Chapter 2, section 2.8.1.
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concentrations greater than 30μM. Due to the inhibition qualities of compound 24 along
with its nontoxic effects this compound proves to be a potential therapeutic option (Table
5.2).
The knowledge gained from the monosaccharide-based compounds described in
these experiments adds to the work that has previously been published with disaccharidebased derivatives of Lipid A, however the monosaccharide-based compound, compound
24, is more potent than other published monosaccharide-based LPS inhibitors, but not
quite as potent as some of the best disaccharide compounds (Kaeothip et al., 2011) . The
noticeable increase in inhibition between compounds 19 and 24 compared to compounds
10, 12, 13, and 11 is likely caused by replacing the benzyl groups with acyl and alkyl
fatty acid chains. By removing the benzyl groups and adding the acyl and alkyl fatty
acids it may allow for less steric hindrance and more symmetrical similarities to the fatty
acid chains located on the Lipid A region of LPS. The lipid portions of compounds 19
and 24 likely makes them better inhibitors due to their similarities to the lipid chains on
Lipid A region of LPS and its known binding properties to CD14, where the lipid portion
of the LPS binds in the hydrophobic pocket of CD14 (Kim et al., 2005). The noticeable
increase in potency and decrease in toxicity by compound 24 with the alkyl chains (ether,
R-O-R) compared to compound 19 with the fatty acyl chains (ester, R-COO-R) is a little
less evident. The data suggests that the additional modifications further enhance the
activity of the compound (Kaeothip et al., 2011). Even though the structural differences
between compound 19 and 24 may be minimal, the differences in the activity/inhibition
could be due to polarity. The ester linkage of compound 19 is slightly more polar then
that of the ether linkage of compound 24. This additional element of hydrophobicity may
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Table 5.2. Summary of biological activity in human macrophage cells.

10, 12, 13

TNFα inhibition
(IC50)
None observed

11

46 μM

19

3 μM

>10 μM

10-30 μM

24

0.5 μM

None observed

None observed

4

6 μM

>30 μM

30-100 μM

Compound

Toxicity

Agonist activity

None observed

None observed

>10 μM
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None observed

explain the increased potency of compound 24.
We are currently investigating the potential therapeutic and mechanistic
properties of compound 24. In vivo inhibition studies of LPS-induced inflammation
(TNFα production) in mouse peritoneal cavities were conducted externally at Washington
Biotech. In preparation for these studies, the solubility and stability of compound 24 was
ascertained. In order to prepare compound 24 for these studies, the compound was
initially resuspended in 100% DMSO and then diluted further in PBS to make a final
concentration of 10% DMSO. The 10% DMSO was recommended by Washington
Biotech due to past observation of DMSO having anti-inflammatory properties (Repine et
al., 1979). Because all of the above studies for compound 24 were performed at 100%
DMSO until the addition into the cellular medium (0.67% DMSO), stability studies were
executed on compound 24 in 10% DMSO over a 14 day period (Figure 5.10). The
stability study provided evidence that compound 24 was stable in 10% DMSO by
remaining in solution. The compound was then able to be sent to Washington Biotech for
the in vivo studies (data not yet received). These studies will eventually be followed by
mechanistic studies observing the inhibition of Pam 3CSK4 and FSL-1, which are known
TLR2/TLR1 and TLR2/TLR6 ligands, respectively, in human THP-1 macrophages,
followed by mouse microglia.

5.8 Discussion
The above studies describe the general morphology of BV-2 murine microglia
cultured on different gold substrate surfaces, along with the inhibition of LPS-induced
TNFα production in THP-1 macrophages. The gold surface studies used UF-Au, UT np-
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Figure 5.10. Stability of Compound 24 in 10% DMSO. Compound 24 was
resuspended first in 100% DMSO and then further diluted by PBS for the final
Compound 24 concentrations in 10% DMSO. The absorbance of Compound 24 (Fmoc
group) at the indicated concentrations in 10% DMSO was measured at a wavelength of
301 nm three separate times over a 14 day time period.
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Au, and np-Au substrates to investigate their biocompatibility with microglia. SEM
provided high resolution images of microglia morphologies, while the in vitro studies
demonstrated that microglia were able to adhere to flat glass and gold surfaces as well as
texturized gold surfaces, although slightly less to the np-Au. The gold surfaces, even the
highly grooved UF np-Au and np-Au monolith, were not toxic to microglia and did not
interfere with LPS-induced TNFα production, suggesting good biocompatibility for
microglial functional and morphological studies.
The use of flat gold as a substrate platform for cell culture has been widely
reported in the literature due to its known biocompatibility (Voskerician et al., 2003,
Wegener et al., 2000) and ease of modification for controlling protein adsorption and cell
adhesion (Mrksich and Whitesides, 1996, Tan et al., 2008). Furthermore, a variety of
gold-based compounds have been investigated for their interaction with immune cells and
demonstrated the uptake of gold nanoparticles and microglial activation in vivo, via
bioluminescence imaging (Hutter et al., 2010). In 2012, Seker et al., 2012 presented the
first effort to utilize the high surface-to-volume ratio of np-Au compared to flat gold as a
potential platform for culturing adherent astrocytes and investigate its feasibility for
application as a drug delivery platform. Their results indicated that the porous surfaces
were only minimally effected by either the adherent astrocytes or the cell culture media,
making the porous surface a prospective material favorable for sustained drug delivery
(Seker et al., 2012).
Microglia are known to respond to many signals in their physical environment,
such as temperature, pressure and stiffness property of the substrate. Many of these
signals induce microglial migration towards site of damage or injury in the CNS. A
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recent study by Persheyev et al., 2011 indicated that BV-2 microglial morphology can be
greatly impacted upon interaction with nanoparticles that possess micro-protrusions in the
form of either sharp, homogeneous cones or spikes. The protrusions greatly impacted the
overall cell morphology and the actin cytoskeleton (Persheyev et al., 2011). Yarmush
and colleagues found that shorter processes were observed when astrocytes were cultured
on porous gold surfaces (Seker et al., 2012). They suggested that the presence of
“nanopits” in the nanoporous gold substrate may accommodate only a limited number of
focal adhesion sites compared to the non-porous gold substrates, thereby reducing
cellular spreading. The low impact of the flat and texturized gold surfaces on microglia
morphology in the studies above may be because the gold pores and ligaments are
significantly smaller than the reported dimensions in Persheyev et al., 2011; however, the
presence of pores and the discontinuous gold area may hinder the formation of the focal
adhesion sites needed for cell adhesion.
The use of SEM, performed by Dr. Y.H. Tan, at high resolution revealed very
little distinction in microglia morphology, whether they were cultured on UF-Au, UT npAu or np-Au. These observations may be due to minimal disruption of integrin
clustering. It has been reported that nanotopography can greatly impact the focal
adhesion of cells on the surface (Huang and Ding, 2010, Persheyev et al., 2011). The
ideal spacing of ~70 nm between the neighboring features or ligands can promote
integrin clustering, leading to an increase of focal adhesion complexes and an F-actin
network. Larger separation distances between neighboring features or ligands tend to
disrupt the integrin clustering and dramatically influence cell adhesion quality and
dynamic cell behaviors (Huang and Ding, 2010). In the case of the np-Au substrate, the
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ridged surface contains both irregular ligaments and pores; therefore, lacking a
continuous smooth surface along with the presence of gold surface features (pores and
ligaments) may not impact the exterior morphology of the microglia, but might directly
affect the quality of focal adhesion or the number of focal adhesion sites. However,
microglia adhesion to UT np-Au was not hampered and only slightly affected by np-Au
(~14%).
The UT np-Au and np-Au substrates were biocompatible with cultured microglia
in most of our assays except for cell growth or proliferation. UT np-Au was supportive
of microglia proliferation during the first 48 hours, but did not sustain growth at later
time points. Microglial growth was completely absent on the texturized np-Au surface,
which is consistent with a previous reports using antiserum against CD11b to label
endogenous microglia and macrophages from the retrieved implanted electrode from rats’
brains. The study resulted in a higher number of adherent microglia observed on the
smooth side of the electrode compared to the side which was composed of grooved
structures, along with a reduction of cells as the implantation time increased (Leung et
al., 2008).
The findings from these studies demonstrated that np-Au as a microglial cell
culture platform was metabolically non-toxic, non-disruptive to the cellular membranes
and compatible with microglia functional assays, but did not support microglial growth.
UT np-Au, however, did support microglia growth and matched the other characteristics
of np-Au. These materials may have potential as effective substrates for coating or
constructing nanoelectronic devices, biosensors and functional biomaterial coatings for
drug delivery.
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The studies involving the LPS-antagonists provided new information about the
structure-activity relationship of a novel class of compounds that mimic the Lipid A
portion of LPS, which will have an impact on the treatment of patients diagnosed with
septicemia. As a result, we have developed a plan to investigate the molecular
mechanisms underlying the antagonistic actions of the synthetic Lipid A analogs.
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